camptothecin has been researched along with Neoplasms in 956 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (0.94) | 18.7374 |
| 1990's | 147 (15.38) | 18.2507 |
| 2000's | 336 (35.15) | 29.6817 |
| 2010's | 370 (38.70) | 24.3611 |
| 2020's | 94 (9.83) | 2.80 |
| Authors | Studies |
|---|---|
| Choe, YH; Greenwald, RB; Wu, D | 1 |
| Fang, X; Shao, L; Wang, S; Zhang, H | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Basnet, A; Jahng, Y; Jeong, BS; Jeong, TC; Karki, R; Lee, CS; Lee, ES; Na, Y; Son, JK; Thapa, P; Zhao, LX | 1 |
| Cheng, L; Feng, W; LaVoie, EJ; Liu, AA; Liu, LF; Satyanarayana, M; Tsai, YC | 1 |
| Ferguson, DM; Flatten, KS; Gálvez-Peralta, M; Hackbarth, JS; Hiasa, H; Kaufmann, SH; Xing, C | 1 |
| Donadel, OJ; León, LG; Padrón, JM; Tonn, CE | 1 |
| Chen, XG; Chern, JW; Guo, QL; He, XG; Huang, CH; Li, TK; Li, ZY; Wang, XJ; Yang, Q; You, QD | 1 |
| Jahng, Y; Jung, MJ; Karki, R; Kwon, Y; Lee, ES; Na, Y; Nam, JM; Thapa, P; Thapa, U | 1 |
| Cho, HJ; Jung, MJ; Kim, J; Kwon, Y; Lee, ES; Na, Y; Woo, S | 1 |
| Chen, YL; Cheng, CM; Han, CH; Lin, SR; Peng, SI; Tseng, CH; Tzeng, CC; Yang, SH | 1 |
| Li, Z; Liu, L; Mu, L; Song, J; Wang, K; Wang, R; Xing, Y; Zhang, B; Zhang, W | 1 |
| Cho, WJ; Choi, JH; Ha, EM; Jahng, Y; Jeon, KH; Karki, R; Kwon, Y; Lee, E; Lee, ES; Na, Y; Thapa, P; Thapa, U; Yun, M | 1 |
| Agama, K; Cushman, M; DeGuire, S; Dexheimer, TS; Kiselev, E; Morrell, A; Pommier, Y | 1 |
| Chashoo, G; Chinthakindi, PK; Hamid, A; Koul, S; Majeed, R; Reddy, MV; Sangwan, PL; Saxena, AK | 1 |
| Cho, WJ; Choi, H; Jeon, KH; Kadayat, TM; Karki, R; Kwon, Y; Lee, E; Lee, ES; Na, Y; Park, PH; Thapa, P; Yoo, HY | 1 |
| Bose, DS; Idrees, M; Jakka, NM; Rao, JV; Todewale, IK | 1 |
| Imthiajali, S; Kamal, A; Lavanya, A; Mallareddy, A; Pal-Bhadra, M; Pushpavalli, SN; Ramaiah, MJ; Suresh, P | 1 |
| Cetin-Atalay, R; Durmaz, I; Herscovici, J; Onen-Bayram, FE; Scherman, D | 1 |
| Banerjee, UC; Baviskar, AT; Das, D; Guchhait, SK; Kandekar, S; Kashyap, M; Kundu, CN; Mohapatra, P; Preet, R; Satapathy, SR; Siddharth, S | 1 |
| Akula, B; Bharathi, EV; Billa, VK; Cosenza, SC; Gallo, JM; Lv, H; Mallireddigari, MR; Padgaonkar, A; Pallela, VR; Reddy, EP; Reddy, MV; Subbaiah, DR | 1 |
| Chen, L; Liu, Y; Wang, TT | 1 |
| Jee, JG; Jun, KY; Kadayat, TM; Karki, R; Kwon, Y; Lee, ES; Lee, JH; Park, C; Thapa, P | 1 |
| Atalay, R; Banoglu, E; Çalışkan, B; Cankara Pirol, Ş; Durmaz, I | 1 |
| Barraja, P; Carbone, A; Cirrincione, G; Diana, P; Montalbano, A; Muscarella, M; Parrino, B; Salvador, A; Spanò, V; Vedaldi, D | 1 |
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Lee, H; Srivastava, V | 1 |
| Dezhenkova, LG; Kalinina, AA; Kaluzhny, DN; Kubbutat, M; Luzikov, YN; Pommier, Y; Preobrazhenskaya, MN; Romanenko, VI; Schols, D; Shchekotikhin, AE; Shtil, AA; Tatarskiy, VV; Treshalin, MI; Treshalina, HM; Tsvetkov, VB; Volodina, YL | 1 |
| Fan, ZC; Gao, ML; Han, KL; Liu, H; Sun, H; Teng, YO; Wang, J; Yu, P; Zhang, YM; Zhao, HY; Zhou, Y | 1 |
| Apostolellis, H; Banuls, LM; Dahan-Farkas, N; Davids, H; Green, IR; Harmse, L; Kiss, R; Kornienko, A; Mathieu, V; Panayides, JL; Pelly, SC; Rey, ME; van Otterlo, WA | 1 |
| Fu, ZD; Huang, JT; Ji, TF; Li, DZ; Li, XY; Lin, JP; Liu, HY; Pan, XD; Song, HX; Wang, CY; Zhang, QZ; Zhang, YL | 1 |
| Chen, HL; Cheng, PL; Goto, M; Hsieh, KY; Lee, KH; Liu, YQ; Morris-Natschke, SL; Yang, GZ; Yang, QR; Zhang, N; Zhang, XS; Zhu, GX | 1 |
| Ding, J; Han, G; Liu, Y; Meng, C; Meng, LH; Qing, L; Shi, J; Wang, Q; Wang, Y; Wang, Z; Yang, Y | 1 |
| Dong, G; Fang, Y; Liu, N; Liu, Y; Sheng, C; Wu, S; Zhang, W | 1 |
| Bist, G; Kwon, Y; Lee, ES; Park, S; Shrestha, A; Song, C; Thapa Magar, TB | 1 |
| Ding, Q; Han, X; Li, S; Liu, Z; Qi, H; Qiao, X; Song, Y; Zhong, Y; Zhou, G | 1 |
| Bist, G; Kadayat, TM; Kwon, Y; Lee, ES; Lee, HJ; Park, S; Shrestha, A; Thapa Magar, TB | 1 |
| Chen, J; Hou, T; Huang, Y; Li, M; Li, X; Liu, F; Ni, J; Pan, P; Sun, H; Tian, S; Wang, X; Yu, H; Zhao, JJ; Zhu, F | 1 |
| Dmitriev, MV; Eroshenko, DV; Grishko, VV; Konysheva, AV; Krainova, GF | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Ilaš, J; Kikelj, D; Skok, Ž; Zidar, N | 1 |
| Chatterjee, DR; Contractor, D; Jain, A; Kumar, D; Nagpure, M; Rana, P; Satpute, DP; Vaidya, GN; Venkatesh, A | 1 |
| Chen, S; Dong, G; Huang, Y; Liu, D; Ma, Z; Sheng, C; Wan, K; Zhu, F | 1 |
| Agama, K; An, LK; Hu, DX; Pommier, Y; Tang, WL; Wang, W; Yang, H; Zhang, Y | 1 |
| Aubé, J; Baljinnyam, B; Bryant-Connah, M; Davis, D; De, S; Dextras, C; Dutta, D; Ferrer, M; Frankowski, KJ; Henderson, MJ; Huang, S; Jadhav, A; Kabir, M; Li, D; Lin, YH; Marugan, JJ; Mathews Griner, LA; Norton, J; Patnaik, S; Rudloff, U; Schoenen, FJ; Shah, P; Simeonov, A; Southall, N; Titus, S; Wachsmuth, LM; Wang, A; Wang, C; Wang, F; Williams, J; Xu, X; Zheng, W; Zhu, E | 1 |
| Bo, Y; Chen, X; Gong, J; Li, J; Shen, L; Yang, F; Zhan, Y; Zhang, Q; Zhang, Y; Zhong, D; Zhou, J | 1 |
| Gong, P; Li, C; Liu, J; Liu, Z; Peng, J; Shen, D; Song, S; Wu, Y; Yang, G | 1 |
| Chi, X; Gao, J; Lin, H; Lin, Y; Luo, X; Yang, Z | 1 |
| Chen, Y; Cheng, Z; Huang, Y; Lu, W; Wang, L; Yang, B; Yu, J | 1 |
| Cong, H; Hu, H; Jing, X; Meng, Q; Shen, Y; Sun, Y; Yu, B; Zhou, L; Zhu, Y | 1 |
| Mullard, A | 1 |
| Martorana, F; Motta, G; Motta, L; Pavone, G; Vigneri, P | 1 |
| Bauer, T; Dumbrava, EE; Enke, A; Giordano, H; Habeck, J; Hamilton, E; Hurley, S; Jeselsohn, R; Lin, KK; Shapiro, GI; Yap, TA | 1 |
| Chen, Y; Dong, C; Huang, B; Li, C; Lu, B; Ma, Q; Shen, Y; Sun, P; Xiang, H; Zhuang, F | 1 |
| Chen, J; Deng, B; Deng, X; Fang, Y; Li, L; Li, S; Mai, R; Zhao, H | 1 |
| Bai, B; Huang, F; Mao, Z; Qi, S; Yang, K; Yu, G; Yu, X; Zhang, X | 1 |
| Agama, KK; Arakawa, Y; Bindra, RS; Choi, WS; Gayle, S; Jo, U; Jones, K; Murai, Y; Paralkar, V; Pommier, Y; Saha, LK; Sun, Y; Sundaram, RK; Van Doorn, J; Vasquez, JC; Yang, X | 1 |
| Acharya, D; Arifullah, M; Gomez, LA; Isaq, M; Karua, CS; Lee, YR; Poojari, CC; Ramachandra, YL; Ravi, P; Rudraiah, SB; Somu, P; Thathapudi, JJ | 1 |
| Fu, T; Li, Y; Liu, Y; Long, W; Stang, PJ; Tan, W; Yan, Y; Zhang, P; Zhao, Z; Zhou, Z | 1 |
| Bai, L; Jin, Y; Lai, S; Shang, X; Shi, L; Zhou, R; Zhou, Y | 1 |
| Ding, Z; Fu, Q; Guo, Z; Liu, Z; Wang, Z; Zheng, Y | 1 |
| Erickson, SW; Gatto, G; Gill, JB; Gorlick, R; Harrison, DJ; Hingorani, P; Houghton, PJ; Kolb, EA; Kurmasheva, RT; Roth, ME; Smith, MA; Teicher, BA; Wang, WL; Wang, Y; Xu, Z; Zhang, W; Zhang, Z | 1 |
| Antunes, MV; Basso, J; Hahn, RZ; Ibaldi, MR; Linden, R; Pavei, CC; Schaefer, VD; Schwartsmann, G | 1 |
| Hu, JL; Hu, MS; Ke, ZC; Luo, LX; Song, J; Wang, Y; Wu, H; Xia, J; Zhou, HP | 1 |
| Rodriguez, JE; Végvári, Á; Zubarev, RA | 1 |
| Chen, D; Hu, H; Li, K; Qiao, M; Sun, X; Xu, M; Yang, C; Zhang, J; Zhao, F; Zhao, X | 1 |
| Basheer, B; Chakraborty, I; Kumar, P; Kumar, S; Patra, D; Shunmugam, R | 1 |
| Abe, I; Endo, Y; Kakizawa, N; Konishi, F; Miyakura, Y; Ohta, S; Rikiyama, T; Saito, M; Suzuki, K; Tago, K; Tamaki, S; Tsujinaka, S; Watanabe, F; Yanagisawa, K | 1 |
| Chen, M; Chen, X; Guo, Z; Liang, R; Tian, H; Wang, Z | 1 |
| Dong, C; Dong, W; Du, F; Gong, X; Hu, Q; Liu, Y; Shuang, S; Song, S; Wang, R; Wang, Z; Zhang, L | 1 |
| Fan, Q; Huang, W; Liu, J; Lu, F; Sang, R; Tang, Y; Wang, Q; Xia, H | 1 |
| Abutarif, M; He, L; Lee, M; Lu, Y; Sawamura, R; Shi, R; Shimizu, S; Tajima, N | 1 |
| Du, L; Lin, Z; Liu, JY; Lu, ZY; Luo, CM; Wen, LF; Yang, DC | 1 |
| Lin, Z; Liu, JY; Luo, CM; Wen, LF; Yang, DC; Yang, XZ | 1 |
| Badgett, T; Crimella, J; Fridley, BL; Gill, J; Gorlick, R; Llosa, N; Metts, JL; Reed, D; Sandler, E; Sansil, S; Smith, T; Thapa, R; Thompson, P; Trucco, M; Weiser, DA | 1 |
| Dai, Q; Fan, W; He, Q; Kong, L; Li, Z; Liao, Y; Long, S; Ren, Y; Wan, C; Yu, W; Zhang, Z; Zhu, R | 1 |
| Cao, L; Chen, J; Fang, M; Han, H; Li, X; Shang, K; Tang, D; Tian, H; Xiao, H; Xu, Z; Yin, J | 1 |
| Gao, Y; Han, H; Liu, C; Lu, Y; Shang, K; Tang, L; Xie, J; Yu, C; Zhang, L; Zhu, L | 1 |
| Abu, YF; Chen, C; Meng, J; Ramakrishnan, S; Roy, S; Tao, J; Xie, Y; Yan, Y; Zhang, Y; Zhou, Y | 1 |
| Feng, W; Huang, Z; Mu, X; Wang, Y; Zhai, M; Zhou, D; Zhou, X | 1 |
| Dai, L; Ding, Y; Li, X; Liu, M; Liu, Q; Meng, M; Pan, J; Xi, R; Yin, Y; Zhang, X | 1 |
| Gayle, S; Jones, K; Paradis, T; Paralkar, VM; Vasquez, J | 1 |
| Chen, M; Gao, S; Ma, Q; Qin, Z; Tian, R; Wang, G; Wen, Q; Xie, Q; Zhang, W; Zhu, L | 1 |
| Han Kim, S; Lip Jung, Y; Min Jung, J; Sung Lee, D; Thambi, T | 1 |
| Deng, D; Fang, L; Liang, B; Miao, Y; Zhao, L | 1 |
| Dai, QL; Jia, HJ; Rui Bai, S; Wang, XB; Xia, J; Yue He, S; Zhou, M | 1 |
| Aviyente, V; Bali, SK; Cifci, G; Haslak, ZP | 1 |
| Li, J; Qin, J; Sun, M; Wang, D; Zhen, Y | 1 |
| Alexandrov, IA; Gahramanov, V; Gerlitz, G; Kaczmarczyk, L; Kumar, S; Patel, S; Salmon-Divon, M; Sherman, MY; Yaglom, J | 1 |
| Ajani, JA; DiPeri, TP; Dumbrava, EE; Evans, KW; Fu, S; Kahle, M; Keyomarsi, K; Kirby, BP; Kong, K; Meric-Bernstam, F; Raso, MG; Rizvi, YQ; Wang, B; Yap, TA; Zhao, M; Zheng, X | 1 |
| Ding, YF; Kwong, CHT; Mok, GSP; Wang, R; Wang, Z; Yu, HZ; Zhao, Y | 1 |
| Ashley, GW; Carreras, CW; Fontaine, SD; Reid, RR; Santi, DV | 1 |
| Berg, SA; Choudhury, AD | 1 |
| Dai, Y; Li, Y; Qian, M | 1 |
| Deenen, MJ; Gelderblom, H; Guchelaar, HJ; Hulshof, EC; Mathijssen, RH; Peeters, SL; Swen, JJ; Thijs, AM | 1 |
| Dong, H; Huang, X; Wu, X | 1 |
| Dai, Z; Li, R; Liu, L; Liu, R; Qian, L; Sun, D; Xu, Y; Yang, P; Zhi, X | 1 |
| Del Re, M; Rolfo, C; Russo, A | 1 |
| Gao, YN; Liang, YX; Liu, R; Liu, Y; Lu, ZL; Sun, XY; Tang, Q; Zhang, X | 1 |
| Hu, Z; Jing, L; Sui, D; Wang, S; Wang, Y; Zhang, Q; Zheng, J; Zhu, M; Zou, P | 1 |
| Guo, Z; Jiang, H; Wang, C; Yu, J; Zhang, R | 1 |
| Hao, L; Piao, Y; Shen, Y; Wang, G; Zhou, Z | 1 |
| Abe, M; Abe, Y; Agatsuma, T; Hashimoto, Y; Hayakawa, I; Hirotani, K; Iguchi, T; Ishizaka, T; Kagari, T; Kamai, Y; Kaneda, Y; Karibe, T; Koyama, K; Maeda, N; Morita, K; Murakami, M; Nakada, T; Nomura, T; Ogitani, Y; Shiose, Y; Ueno, S; Wakita, K; Zembutsu, A | 1 |
| Cai, J; Deng, Y; Huang, H; Li, G; Luo, S; Lv, X; Zhang, Q; Zhao, B | 1 |
| Huang, Y; Li, B; Wang, J; Wu, S; Xie, X; Zeng, F; Zhan, C | 1 |
| Fan, G; Jia, S; Lin, K; Shi, J; Yu, S; Yuan, J; Zhang, Y; Zhou, Q | 1 |
| Císař, J; Guo, L; Guo, Y; Kuřitka, I; Li, C; Liu, H; Liu, Y; Sedlařík, V; Škoda, D; Wang, Y; Xiao, H | 1 |
| Chen, M; Chen, X; Guo, Z; Hao, K; Lin, L; Liu, F; Sun, P; Tang, Z; Tian, H; Wang, D; Yu, H | 1 |
| Cao, J; Fu, X; Han, S; Hao, N; He, B; Liang, Y; Ma, Q; Sun, Y; Xu, W | 1 |
| Agatsuma, T; Soria, JC; Yver, A | 1 |
| Keam, SJ | 1 |
| He, G; Ma, Y; Miao, Z; Qian, H; Sun, S; Wang, X; Xu, Y; Zha, Z; Zhou, H | 1 |
| Chen, M; Chen, Z; Li, X; Wang, T; Xie, S; Zhang, Z | 1 |
| Goldenberg, DM; Sharkey, RM | 1 |
| Li, T; Liu, B; Liu, Y; Muhammad, N; Wang, H; Wang, J; Zhan, H | 1 |
| Guan, H; Jiang, T; Liu, J; Liu, X; Wang, X; Wu, G; Yin, R; Yu, M; Yu, R; Zhang, Y | 1 |
| Cookson, E | 1 |
| Bešlija, S; Gatalica, Z; Vranić, S | 1 |
| Jain, A; Jain, SK; Saraf, S; Tiwari, A; Verma, A | 1 |
| Ci, Y; Dou, P; Han, F; Li, Y; Nie, H; Qiao, S; Sun, H; Xie, W; Zhang, D; Zhang, X | 1 |
| Chen, P; Jian, S; Li, F; Li, H; Li, J; Liang, S; Liu, Z; Sun, X; Zeng, Y; Zhang, P; Zhang, Q | 1 |
| Cordes, LM; Dorlo, TPC; Figg, WD; Huitema, ADR; Madan, RA; Peer, CJ; Pommier, Y; Schmidt, KT; Sciuto, L; Thomas, A; Wroblewski, S | 1 |
| Dai, X; Liu, Y; Zhang, B; Zhou, W | 1 |
| Hao, L; Piao, Y; Shen, Y; Tang, J; Zhou, Q; Zhou, Z | 1 |
| Gu, L; Guo, Z; He, L; Hu, Z; Jia, S; Jiang, L; Mu, D; Pan, FY; Sun, Y; Wu, C; Wu, T; Yang, Y; Zhang, J; Zhang, M; Zhang, Y; Zhu, H | 1 |
| Jin, X; Li, Y; Su, Y; Xu, Q; Ying, X; Zheng, Y | 1 |
| Brooks, T; Massey, AJ; Wayne, J | 1 |
| Chen, Y; He, Z; Li, S; Sun, B; Sun, J; Sun, Y; Tao, W; Zhao, D | 1 |
| Grossi, F; Indini, A; Rijavec, E | 1 |
| Chen, J; Guan, Z; Huang, Y; Huang, Z; Lai, H; Xiao, Z; Xu, C; Xu, X; Yang, H; Zhang, T; Zhao, C | 1 |
| Hamada, A; Hasegawa, K; Jikoh, T; Nishikawa, T; Ogitani, Y; Ohuchi, M; Sugihara, K; Suzuki, M; Tamura, K; Teishikata, T; Yagishita, S; Yatabe, Y; Yonemori, K | 1 |
| He, W; Hu, X; Li, Q; Li, T; Li, Y; Wang, Q; Xu, Q; Zheng, Y | 1 |
| Al-Tel, TH; Alhamad, DWM; Darwish, MH; Hamad, M; Khaiwa, N; Maarouf, NR; Omar, HA; Orive, G; Sebastian, A | 1 |
| Fan, Z; Fu, X; Hai, J; He, S; Hou, Z; Shi, D; Yang, Y; Yin, W; Zhang, D | 1 |
| Jia, D; Wang, Y; Wen, F; Zhang, X | 1 |
| Hu, XY; Niu, P; Tian, X; Velmurugan, K; Wang, K; Wang, L; Zhao, Y; Zuo, M | 1 |
| Ghaedi, K; Majd, A; Miralaei, N; Peymani, M; Safaei, M | 1 |
| Fioretzaki, R; Kosmas, C; Papageorgiou, G; Tsakatikas, S | 1 |
| Dhanasekaran, DN; Han, Y; Jo, H; Kim, H; Kim, S; Kim, SJ; Lee, J; Song, YS; Wang, W; Yang, KM | 1 |
| Fan, R; Guo, X; Li, D; Li, Z; Liu, Y; Song, C; Tang, X; Xu, H; Zhang, Y; Zhang, Z | 1 |
| Du, Y; Fu, Z; He, R; Ismail, M; Li, X; Ling, L; Yao, C; Zhang, W | 1 |
| Sahota, S; Vahdat, LT | 1 |
| Bardia, A; Goldenberg, DM; Govindan, SV; Guarino, M; Isakoff, SJ; Maliakal, P; Mayer, IA; Messersmith, WA; Ocean, AJ; Picozzi, VJ; Sharkey, RM; Starodub, AN; Vahdat, LT; Wegener, WA | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Bao, Y; Guo, L; Ji, F; Li, Y; Tang, Q; Wang, J | 1 |
| Bahrami, A; Blankenship, K; Bradley, C; Chen, X; Clay, MR; Dapper, J; Downing, J; Dyer, MA; Easton, J; Federico, SM; Freeman, BB; Gordon, B; Honnell, V; Karlstrom, A; Mardis, ER; Ocarz, M; Pappo, A; Shelat, AA; Stewart, E; Twarog, NR; Wilson, RK; Wu, J; Xu, B; Zhang, J; Zhou, X | 1 |
| Chen, K; Chen, X; Fan, J; Fu, X; Jacobson, O; Liu, Y; Ma, Y; Ni, Q; Niu, G; Wang, Z; Xu, F; Yang, Z; Yu, G; Zhang, F; Zhao, X; Zhu, G | 1 |
| Chen, M; Chen, Z; He, N; Li, X; Wang, T; Yuan, J; Zhao, L | 1 |
| Duan, Z; Pan, D; Peng, H; Wei, X; Wen, J | 1 |
| Chen, W; Ge, Z; Ke, W; Li, J; Li, Y; Wang, W; Wang, Y | 1 |
| Hawkins, CJ; Miles, MA | 1 |
| Bohrer, LR; He, Y; Huang, H; Pan, Y; Wang, L; Zhao, Y | 1 |
| Alsina, M; Braña, I; Britten, CD; Del Conte, G; Ezeh, P; Houk, B; Kern, KA; Leong, S; Pathan, N; Pierce, KJ; Siu, LL; Soares, HP; Tabernero, J; Vermette, J; Wainberg, ZA | 1 |
| Gao, S; Li, L; Liu, T; Ma, Q; Miller-Kleinhenz, J; Qin, Z; Tian, R; Wang, G; Zhang, F; Zhu, L | 1 |
| Chen, M; Chen, X; Guo, Z; Tian, H; Xu, M; Zhou, X | 1 |
| Go, Y; Hong, E; Jung, E; Khang, G; Lee, D; Singh, SVB; Yoo, D; Yoo, W | 1 |
| Baryshok, VP; Lazarev, IM; Lazareva, NF | 1 |
| Bao, WG; Li, YQ; Shi, WG; Tu, ZK; Wu, D; Yin, QL; Yu, H; Yu, YY; Zhao, DW; Zhong, BH | 1 |
| Cheng, A; Hou, Z; Jin, X; Wu, S; Xie, W; Yang, L; Yang, X | 1 |
| Ahmed, KM; Chakraborty, S; Charaka, V; Hambarde, S; Hunt, CR; Pandita, RK; Pandita, TK; Ramnarain, D; Singh, DK; Singh, M | 1 |
| Dai, Z; Gao, C; Liang, X; Mo, S; Sun, D; Zhang, N | 1 |
| He, J; Lei, J; Li, C; Li, X; Liu, J; Liu, K; Liu, Y; Wang, L; Xiao, S; Zheng, D; Zhu, P | 1 |
| Chia, YL; Eldon, MA; Gordi, T; Hoch, U; Sy, SKB | 1 |
| Ando, K; Bharti, AK; Brahmandam, M; Harrington, Y; Oki, E; Shah, AK; Srinivasiah, A; Taylor-Parker, J; Tohme, YH | 1 |
| Adhikari, N; Amin, SA; Gayen, S; Jha, T | 1 |
| Huang, W; Jin, H; Shi, L; Sun, M; Yan, D; Zhu, X | 1 |
| Chen, X; Cheng, S; He, Z; Jacobson, O; Liao, A; Ma, Y; Ni, Q; Niu, G; Song, J; Wang, Z; Yu, G; Zhang, F; Zhang, L; Zhu, G | 1 |
| Hu, X; Liang, H; Liu, G; Liu, S; Xing, D; Zhai, S | 1 |
| Aluri, R; Jayakannan, M; Joshi, DC; Saxena, S | 1 |
| Aldaz Pastor, A; Garcia-Del-Barrio, MA; Martin-Algarra, S | 1 |
| Ayyanaar, S; Kesavan, MP; Kotla, NG; Kumar, GGV; Rajagopal, G; Rajesh, J; Sivaraman, G; Webster, TJ | 1 |
| Hosokawa, T; Ishikawa, T; Kanazawa, M; Kanbayashi, Y; Kawano, R; Nakajima, Y; Tabuchi, Y; Taguchi, T; Takayama, K; Yoshida, N; Yoshioka, T | 1 |
| Cao, Y; Huang, T; Jiang, H; Li, W; Liu, Y; Pan, X; Shi, M; Wu, Q; Zhang, J | 1 |
| Cai, Z; Cang, H; Huang, R; Sun, B; Sun, Y; Zhang, H | 1 |
| Dong, Z; Guo, Y; Han, M; Wang, T; Wang, X; Wang, Y; Zhao, S | 1 |
| Hu, X; Qin, H; Xing, D; Yan, H; Yang, J; Zhai, S | 1 |
| Ahmad, I; Eltahan, AS; Kaleem, QM; Li, C; Liang, XJ; Mozhi, A; Tuguntaev, RG; Wang, C; Yang, R | 1 |
| Chan, L; Chen, T; Feng, P; Huang, W; Huang, X; Liang, Y; Mei, C; Tan, CH; Zeng, D | 1 |
| Ahmad, N; Ahmad, R; Alam, MA; Jalees Ahmad, F; Umar, S | 1 |
| Chen, X; Gao, C; He, Z; Hua, B; Huang, F; Huang, X; Jacobson, O; Liu, Y; Mao, Z; Wang, W; Wang, Z; Yu, C; Yu, G; Zhang, F; Zhao, X; Zhou, J; Zhu, X | 1 |
| Deng, B; Jia, L; Li, X; Li, Y; Lou, Y; Tan, H; Yu, L | 1 |
| Bai, S; Gao, YE; Hou, M; Kang, Y; Li, B; Ma, X; Shi, X; Xiao, B; Xu, Z; Xue, P | 1 |
| Chen, M; Cheng, Y; Feng, Q; Huang, L; Liang, F; Liu, S; Xu, C; Xu, P; Yang, X | 1 |
| Ishikura, K; Mizukami, Y; Okuyama, H; Tamura, K | 1 |
| Du, Y; He, W; Ismail, M; Li, X; Ling, L; Xia, Q; Yao, C; Zhou, W | 1 |
| Huang, Y; Liu, S; Lu, W; Xu, Y; Yu, J; Zhang, X | 1 |
| Ding, HF; Huang, YQ; Ji, M; Qian, G; Song, YS; Wang, JL; Yuan, JD; Zhang, Y | 1 |
| Fujita, KI; Ishida, H; Iwai, S; Kamei, D; Kubota, Y; Sasaki, Y; Taki-Takemoto, I; Tsuboya, A | 1 |
| Akahori, D; Amano, T; Hasegawa, H; Kakutani, T; Koda, K; Kunimoto, Y; Matsui, T; Niwa, H; Ozawa, Y; Suda, T; Tanahashi, M; Yamada, K; Yokomura, K | 1 |
| Artali, R; Cardile, F; Cincinelli, R; Colelli, F; Dallavalle, S; Frusciante, M; Fucci, A; Guglielmi, MB; La Porta, I; Melito, C; Musso, L; Pisano, C; Signorino, G | 1 |
| Bi, Y; Lee, RJ; Li, C; Li, L; Sun, Y; Teng, L; Wang, M; Wang, X; Xie, J | 1 |
| Cai, K; Chen, Q; Chen, X; Cheng, J; Guo, Q; He, X; Jiang, C; Li, C; Liu, L; Lu, Y; Ruan, C; Sun, T; Zhang, Y | 1 |
| Du, Y; He, W; Ismail, M; Li, X; Ling, L; Xia, Q; Yao, C | 1 |
| Dong, Z; Guo, Y; Han, M; Qiu, H; Wang, T; Wang, X; Wang, Y | 1 |
| Bunyan, E; Krishnan, V; Lensch, V; Menegatti, S; Mitragotri, S; Pusuluri, A; Sarode, A; Soh, HT; Vogus, DR | 1 |
| Barreto, R; Bonetto, A; Couch, ME; O'Connell, TM; Pin, F | 1 |
| Gao, Z; He, Z; Liu, T; Liu, Y; Luo, C; Sun, J; Sun, M; Wang, J; Zhang, X; Zhao, Y | 1 |
| Hemler, ME; Hwang, S; Takimoto, T | 1 |
| Abe, Y; Agatsuma, T; Jikoh, T; Nakada, T; Sugihara, K | 1 |
| Chen, H; Hao, P; Huang, W; Luo, S; Peng, B; Qin, J; Zan, X; Zhang, T | 1 |
| Fan, Z; Hou, Z; Jiang, B; Li, Y; Su, G; Tian, H; Wang, F; Ye, S; Zhang, Y; Zhu, Q | 1 |
| Hu, X; Shen, Q; Xing, D; Zhang, W | 1 |
| Chen, W; Ge, Z; Japir, AAMM; Ke, W; Mukerabigwi, JF; Wang, Y; Yin, W; Zha, Z | 1 |
| Li, F; Li, Q; Weng, Q; Xia, L; Zhang, X; Zheng, Y; Zhou, L | 1 |
| Qing, L; Qing, W | 1 |
| Gan, Z; Gu, Z; Liu, X; Mo, R; Piao, Y; Shao, S; Shen, Y; Tang, J; Wang, J; Xiang, J; Xu, C; Yu, Q; Zhou, Q; Zhou, Z | 1 |
| Jia, L; Li, B; Li, F; Liu, J; Zhang, D; Zheng, J | 1 |
| Ding, F; Guo, Y; Pan, G; Zhang, C; Zhang, J; Zhu, X | 1 |
| Cardillo, TM; Gold, DV; Goldenberg, DM; Govindan, SV; Sharkey, RM; Tat, F | 1 |
| Beretta, GL; Gatti, L; Perego, P; Zaffaroni, N | 1 |
| Batey, MA; Curtin, NJ; Kyle, S; Lau, A; Martin, NM; Newell, DR; Richardson, C; Slade, A; Zhao, Y | 1 |
| Boku, N; Fujiki, T; Fujino, K; Gemma, A; Kakihata, K; Masatani, S; Morita, S; Shiozawa, T; Tadokoro, J | 1 |
| Beeram, M; Bekaii-Saab, T; Buchbinder, A; Lokiec, FM; Papadopoulos, KP; Patnaik, A; Rezaï, K; Schaaf, LJ; Tahiri, S; Tolcher, AW; Urien, S | 1 |
| Matsuzaki, T; Nagaoka, M; Shishido, Y; Ueno, S; Yamazaki, R | 1 |
| Boxberger, F; Dörje, F; Harich, HD; Hohenberger, W; Koch, S; Neurath, MF; Siebler, J; Wein, A | 1 |
| Jin, E; Ma, X; Murdoch, WJ; Radosz, M; Shen, Y; Sui, M; Tang, J; Van Kirk, EA; Zhou, Z | 1 |
| Yang, ZZ; Zhao, DX; Zou, HY | 1 |
| Gu, Z; Mao, W; Shen, Y; Sui, M; Sun, W; Sun, X; Tang, J; Wang, J | 1 |
| Brown, GW; Giaever, G; Lee, AY; Nislow, C; Torres, NP | 1 |
| Ding, SJ; Ho, CC | 1 |
| Dong, K; Li, Z; Liu, Z; Qu, X; Ren, J | 1 |
| Bleul, R; Häfeli, UO; House, MJ; Marten, GU; Maskos, M; St Pierre, TG; Thiermann, R | 1 |
| Fujiwara, K; Katakami, N; Kitao, A; Matsumoto, K; Minami, H; Morita, S; Negoro, S; Shibata, N; Tanioka, M; Yamaguchi, S | 1 |
| Caron, WP; Ramanathan, RK; Schell, RF; Sidone, BJ; Walsh, MD; White, TF; Zamboni, BA; Zamboni, WC | 1 |
| Davidson, TB; Malogolowkin, M; Mascarenhas, L; May, W; Sposto, R; Venkatramani, R | 1 |
| Guo, Y; Han, M; Liu, X; Wang, X; Wang, Y | 1 |
| Bala, V; Boyd, BJ; Prestidge, CA; Rao, S | 1 |
| Jie, J; Liu, Z; Tian, B; Yang, Y; Zhang, X; Zhou, M | 1 |
| Lopes, Gde L | 1 |
| Bendell, JC; Burris, HA; Chan, E; Ikeda, S; Infante, JR; Jones, SF; Keedy, VL; Kodaira, H; Lee, W; Rothenberg, ML; Wu, H; Zamboni, BA; Zamboni, WC | 1 |
| Fujisaki, H; Hara, J; Okada, K; Osugi, Y; Tanaka, C; Yamasaki, K | 1 |
| Blackwood, E; Del Nagro, C; Evangelista, M; Jackson, PK; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Xiao, Y | 1 |
| Carron, JD; Hakenjos, J; Henne, KL; Henne, WA; Kularatne, SA | 1 |
| Ames, MM; Erlichman, C; Goetz, MP; Goldberg, RM; Grothey, AA; Kuffel, MA; Mandrekar, SJ; McGovern, RM; McKean, HA; McWilliams, R; Reid, JM; Safgren, SL; Tan, AD | 1 |
| Hao, X; Jie, J; Li, W; Tian, B; Zhang, X | 1 |
| Bekaii-Saab, T; Clinton, SK; Grever, MR; Kraut, EH; Martin, LK; Monk, P; Serna, D | 1 |
| Chen, A; Choyke, P; Doroshow, JH; Fer, N; Jeong, W; Kinders, RJ; Kummar, S; Melillo, G; Park, SR; Rapisarda, A; Steinberg, SM; Turkbey, B | 1 |
| Adamson, PC; Ahern, C; Bagatell, R; Blaney, S; Fox, E; Ingle, AM; Little, AR; Norris, R; Voss, S; Weigel, BJ | 1 |
| Gopalakrishnan, R; Shankar, B | 1 |
| Bertozzi, D; Capranico, G; Fornari, F; Gramantieri, L; Manzo, SG; Marinello, J | 1 |
| Fujita, K; Sasaki, Y | 1 |
| Cheng, AL; Cho, DC; Chuadhary, I; Coleman, T; Ghalib, MH; Ghamande, S; Goel, S; Hsu, SC; Kuo, MW; Kwak, EL; Lin, CC; Mach, WB; Shapiro, GI; Silverman, MH; Tseng, Y; Yang, JC | 1 |
| Chu, YF; Feng, J; Jia, HZ; Wang, HF; Zhang, XZ; Zhuo, RX | 1 |
| Ho, YP; Stougaard, M | 1 |
| Boren, J; Brindle, KM; Mahajan, S; Patel, II; Reichelt, S; Schreiner, A; Steuwe, C; Ul-Hasan, M | 1 |
| Hao, X; Jie, J; Yang, Y; Yu, C; Zhang, X; Zhou, M | 1 |
| Xu, Z; Yin, Z; Zheng, W | 1 |
| Bloomfield, A; Dorton, R; Guan, J; Leamon, CP; Nelson, M; Reddy, JA; Vetzel, M | 1 |
| Cheng, L; Dong, XL; Hu, J; Li, M; Liu, BR; Qian, XP; Ren, W; Sun, ZP; Xie, L; Xu, GX | 1 |
| Chen, X; Gan, Y; Guo, S; Li, F; Li, J; Wang, X; Zhang, X | 1 |
| Beau, J; Innominato, PF; Iurisci, I; Karaboue, A; Lévi, F; Madrid, JA; Moreau, T; Ortiz-Tudela, E; Rol, MA | 1 |
| An, GY; Gong, LL; Guo, CL; Han, FF; Li, GR; Liu, H; Liu, LH; Lv, YL; Yu, D; Zhu, J | 1 |
| Chen, X; Yu, Y; Zhan, Y; Zhang, Y; Zhong, D | 1 |
| Cao, S; Durrani, FA; Rustum, YM; Tóth, K | 1 |
| Chu, L; Ding, D; Kong, D; Liu, J; Xu, H; Yang, C; Yang, Z; Zhang, Y | 1 |
| Boige, V; Dias, MM; Glimelius, B; Karapetis, CS; Kweekel, DM; Lara, PN; Laurent-Puig, P; Martinez-Balibrea, E; McKinnon, RA; Páez, D; Pignon, JP; Punt, CJ; Redman, MW; Sorich, MJ; Toffoli, G; Wadelius, M | 1 |
| Chen, L; Davis, M; Gaur, S; Kretzner, L; Wang, Y; Wu, X; Yen, T; Yen, Y; Yuan, YC | 1 |
| Ahmad, S; Kong, R; Liu, T; Phan, AT; Scott, JE; Williams, AL; Wong, ST; Yeh, LA; Zhao, H; Zhu, X | 1 |
| Adane, ED; Arnold, SM; Leggas, M; Liang, Y; Tsakalozou, E | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wang, L; Wu, XY; Xiang, J | 1 |
| Amini, M; Dinarvand, R; Ghahremani, MH; Ghanbarpour, AR; Gharghabi, M; Ostad, SN; Rouhani, H; Sepehri, N; Tavassolian, F | 1 |
| Cho, AR; Heo, JH; Hwhang, TH; Kim, WM; Lee, DH; Park, DJ; Won, JH; Yun, HJ | 1 |
| Phelps, MA; Sparreboom, A | 1 |
| Das, S; House, LK; Innocenti, F; Janisch, L; Karrison, T; Maitland, ML; Marsh, R; Ramírez, J; Ratain, MJ; Salgia, R; Schilsky, RL; Turcich, M; Undevia, S; Wu, K | 1 |
| Bagatell, R; Berkowitz, N; Buchbinder, A; Fox, E; Gore, L; Macy, ME; Muscal, JA; Norris, RE; Shusterman, S | 1 |
| Tadje, M | 1 |
| Cabral, H; Kataoka, K | 1 |
| Cai, P; Gao, F; Gao, L; Gao, X; Huang, G; Liang, J; Liu, R; Wang, Y; Wei, Y; Yuan, Q; Zhu, H | 1 |
| Deng, Y; Ediriwickrema, A; Saltzman, WM; Zhou, J | 1 |
| Doi, A; Doi, T; Hamaguchi, T; Ichinohe, R; Kaniwa, N; Matsumura, Y; Odaka, Y; Ohtsu, A; Okuda, H; Okuyama, M; Sai, K; Saijo, N; Saito, Y; Sakamoto, H; Sawada, J; Shimada, Y; Takahashi, A; Takahashi, H; Yoshida, T; Yoshino, T | 1 |
| Guo, M; Guo, Y; Muhammad, F; Qi, W; Wang, A; Zhao, J; Zhu, G | 1 |
| Jin, E; Ma, X; Murdoch, WJ; Murphy, CJ; Shen, Y; Sun, Q; Van Kirk, EA; Zhou, Z | 1 |
| Balasubramanian, N; Chaphekar, S; Jayakannan, M; Pramod, PS; Shah, R | 1 |
| Li, Y; Liu, R; Ma, G; Yang, J; Zhang, X; Zhang, Z | 1 |
| Brennan, RC; Furman, W; Mao, S; McGregor, LM; Santana, V; Stewart, CF; Turner, DC; Wu, J | 1 |
| Chazin, Ede L; Junior, WT; Moor, LF; Reis, Rda R; Vasconcelos, TR | 1 |
| Azuma, S; Kawato, N; Makihara, K; Nakata, I; Ueno, H | 1 |
| Alvarez-Cuesta, E; Angel-Pereira, D; Berges-Gimeno, MP; Madrigal-Burgaleta, R; Ureña-Tavera, A; Zamora-Verduga, M | 1 |
| Ahn, JS; Hong, YS; Kim, JE; Kim, KP; Kim, TW; Lee, J; Lee, JL; Park, SJ; Park, YS; Shin, DB; Sym, SJ | 1 |
| Cho, HJ; Choi, HG; Choi, JY; Kim, JO; Ramasamy, T; Shin, BS; Umadevi, SK; Yong, CS | 1 |
| Hu, J; Liu, G; Liu, S; Zhang, G | 1 |
| Chang, YJ; Fan, NC; Ho, JA; Lai, NC; Lu, HY; Wang, LS; Wu, LC; Yang, CM | 1 |
| Chang, JY; Chang, TC; Chen, LT; Cheng, AL; Chiang, NJ; Shen, BN; Shiah, HS; Wang, YW; Yang, CH; Yeh, CG; Yeh, KH | 1 |
| Tian, B; Yu, C; Zhang, X; Zhou, M | 1 |
| Magdy, T; Nies, AT; Schwab, M; Zanger, UM | 1 |
| Chan, MH; Lin, HM | 1 |
| Barbieri, P; Delmonte, A; Gallerani, E; Hess, D; Joerger, M; Pace, S; Sessa, C | 1 |
| Bendell, JC; Burris, HA; Chan, E; Ikeda, S; Infante, JR; Jones, SF; Keedy, VL; Kirschbrown, WP; Kodaira, H; Lee, W; Rothenberg, ML; Wu, H; Zamboni, BA; Zamboni, WC | 1 |
| Arakawa, Y | 1 |
| Kaku, Y; Kanno, T; Nishizaki, T; Tsuchiya, A | 1 |
| Crona, DJ; de Graan, AJ; Innocenti, F; Mathijssen, RH; Qiao, W; Ramirez, J; Ratain, MJ; Rosner, GL; van Schaik, RH | 1 |
| Eto, K; Fukushima, H; Furuhata, T; Isobe, H; Iwanaga, I; Kawamoto, Y; Komatsu, Y; Kudo, M; Masuko, H; Minami, S; Miyagishima, T; Nakajima, J; Nakamura, M; Oba, K; Ohsaki, Y; Okita, K; Sasaki, K; Shibuya, H; Takahashi, Y; Tateyama, M; Yokoyama, R; Yuki, S | 1 |
| Chen, RC; Chen, WT; Kang, ST; Lin, JL; Wang, CH; Yeh, CK | 1 |
| Anselmo, AC; Camacho, KM; Kumar, S; Menegatti, S; Mitragotri, S; Vogus, DR | 1 |
| Alam, S; Alves, DS; Barrera, FN; Bayer, AM; Best, MD; McNitt, CD; Popik, VV; Whitehead, SA | 1 |
| Goldenberg, DM; Govindan, SV; Guarino, MJ; Hamburger, SA; Maliakal, PP; Ocean, AJ; Picozzi, VJ; Shah, MA; Sharkey, RM; Starodub, AN; Thomas, SS; Vahdat, LT; Wegener, WA | 1 |
| Buil-Bruna, N; Garrido, MJ; Mangas-Sanjuan, V; Soto, E; Trocóniz, IF | 1 |
| Amzerin, M; Errihani, H; Mokrim, M; Piccart, MJ | 1 |
| Chen, J; Dong, J; Gu, W; Lu, S; Peng, P; Xiong, Z; Xu, F; Yang, X | 1 |
| Guo, N; Jiang, D; Teng, YO; Wang, L; You, X; Yu, P | 1 |
| Her, C; Wu, X; Xu, Y | 1 |
| Alba, M; Delalat, B; Formentín, P; Marsal, LF; Rogers, ML; Voelcker, NH | 1 |
| Ballesta, A; Dulong, S; Lévi, F; Okyar, A | 1 |
| Cirkel, GA; Daenen, LG; Gerrits, J; Houthuijzen, JM; Huitema, AD; Ishihara, K; Oosterom, I; Roodhart, JM; van Tinteren, H; Verhoeven-Duif, NM; Voest, EE | 1 |
| Palakurthi, S | 1 |
| Gjerset, RA; Zhao, M | 1 |
| Acquaviva, J; Astsaturov, I; Bates, RC; Chimmanamada, D; He, S; Inoue, T; Jimenez, JP; Khazak, V; Ogawa, LS; Osman, S; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Tatsuta, N; Ying, W; Zhang, C; Zhang, J | 1 |
| Akiyama, Y; Fujita, K; Kato, Y; Kawara, K; Kitamura, M; Kunishima, M; Masuo, Y; Okumura, H; Sasaki, Y; Shimada, K; Sunakawa, Y; Suzuki, H; Watanabe, Y | 1 |
| Arzt, J; Busman, TA; Holen, KD; Lian, G; LoRusso, P; Rosen, LS; Rudersdorf, NS; Tolcher, AW; Vanderwal, CA; Waring, JF; Yang, J | 1 |
| Bawa, O; Bosq, J; Daudigeos-Dubus, E; Geoerger, B; Lanvers-Kaminsky, C; Le Dret, L; Opolon, P; Pagès, M; Vassal, G; Vievard, A; Villa, I; Zopf, D | 1 |
| Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M | 1 |
| Dai, Z; Jing, L; Shao, S; Wang, Y; Yang, Y; Yue, X | 1 |
| Cheng, Y; Wang, C; Wang, X; Wang, Y; Xiao, J; Zhang, J; Zhang, Q | 1 |
| Chen, B; Feng, J; Jiang, Y; Liu, G; Wang, H; Xie, Q | 1 |
| Chen, Q; Ge, Z; Huang, M; Ke, W; Li, J; Wang, L; Yin, W; Zhang, P | 1 |
| Beretta, GL; Varchi, G; Zaffaroni, N | 1 |
| Li, J; Lin, G; Wang, L; Xie, J; Yi, L; Zhang, K; Zhang, R | 1 |
| Li, G; Zhao, L; Zhao, M | 1 |
| Bell, T; Boerner, JL; Boerner, SA; Bowditch, A; Burger, A; Cai, D; Chen, AP; Cleary, JM; Ferry-Galow, K; Heilbrun, LK; Ji, J; Kinders, RJ; Li, J; LoRusso, PM; Marrero, AM; Parchment, RE; Pilat, MJ; Rubinstein, L; Sausville, EA; Shapiro, GI; Smith, D; Tolaney, SM; Wolanski, A; Zhang, J; Zhang, Y | 1 |
| Liu, JY; Nie, YL; Wang, XF; Wei, LM; Yan, L; Zhang, LR | 1 |
| Clark, DW; Mani, C; Palle, K; Tripathi, K | 1 |
| Kumar, S; Manjunatha, BL; Nataraja, KN; Ravikanth, G; Shaanker, RU; Shankar, R; Singh, HR | 1 |
| Anthony Greco, F; Barton, JH; Bendell, JC; Burris, HA; Infante, JR; Jones, SF; Nambu, Y; Thompson, DS; Watanabe, N | 1 |
| Camacho, KM; Menegatti, S; Mitragotri, S | 1 |
| Chen, M; Li, X; Luo, X; Wei, J; Xu, G; Zhang, H | 1 |
| Alzghari, SK; Chee, W; La-Beck, NM; Petersen, GH; Sankari, SS | 1 |
| Jang, DJ; Moon, C; Oh, E | 1 |
| Gokduman, K | 1 |
| Agatsuma, T; Hagihara, K; Naito, H; Ogitani, Y; Oitate, M | 1 |
| Campbell, JL; Dai, H; Karanja, KK; Li, H; Li, Z; Liu, C; Liu, W; Polaczek, P; Popuri, V; Schlacher, K; Shan, SO; Shen, B; Wu, Q; Zheng, L; Zhou, M | 1 |
| Lee, RJ; Teng, L; Teng, M; Xie, J; Yang, S; Yu, B; Zhang, X | 1 |
| Spindler, A; Stefan, K; Wiese, M | 1 |
| Chen, M; Chen, Z; He, N; Li, X; Zhao, L | 1 |
| Durmus, S; Schinkel, AH; van Hoppe, S | 1 |
| Guo, B; Qian, SY; Sun, M; Yang, X; Zhang, Q | 1 |
| Asakiewicz, C; Braiteh, F; Chaudhary, A; Denlinger, CS; Gao, L; Lee, JJ; Lin, Y; LoRusso, P; Nasroulah, F; Shepard, DR; Wang, D | 1 |
| Byrne, A; Dean, A; Hayden, I; Marinova, M | 1 |
| Chen, S; Chowbay, B; Khor, CC; Lam, S; Sutiman, N; Yu, Y; Zhang, CZ | 1 |
| Cheung, YK; Mao, X | 1 |
| Balasubramanian, P; Chen, AP; Evrard, YA; Kinders, RJ; Kummar, S; Wang, L | 1 |
| Ci, T; Cui, S; Ding, J; Liu, R; Shen, Y; Yu, L | 1 |
| Terada, T | 1 |
| Bao, Y; Guo, J; Guo, L; Ji, F; Li, Y; Sun, W; Tang, Q; Wang, J | 1 |
| Ju, H; Lei, J; Liu, J; Shen, H; Zhang, L | 1 |
| Gao, YE; Hou, M; Kang, Y; Liu, S; Shi, X; Xu, Z; Xue, P | 1 |
| Huang, Y; Li, L; Wu, L; Yang, Q; Zhou, Z | 1 |
| Benetti, E; Centamore, A; Collina, S; Della Volpe, S; Martino, E; Sakaj, M; Sala, A; Terribile, E | 1 |
| Cai, Y; Dai, L; Gao, J; Lin, M; Liu, J; Ren, C; Shen, H; Shi, Y; Yang, Z; Zhan, J | 1 |
| Fang, JY; Hua, SC; Hung, CF; Hwang, TL | 1 |
| Gelderblom, H; Guchelaar, HJ; Kweekel, D | 1 |
| Gounder, M; Gu, Z; Kudelka, AP; Lee, SJ; Li, JM; Loyer, E; Rubin, EH; Thalasila, A; Verschraegen, CF | 1 |
| Burden, RE; Fay, F; Marouf, WM; McCarron, PA; Olwill, SA; Quinn, DJ; Scott, CJ | 1 |
| Inui, K; Onoue, M | 1 |
| Cendros, JM; Evans, TR; Falk, S; Graham, JS; Samuel, LM | 1 |
| Stebbing, J | 1 |
| Eberhardt, S; Lee, F; Lee, SJ; Lu, H; Maestas, A; Rabinowitz, I; Royce, M; Sayar, H; Shen, Z; Smith, H; Verschraegen, C | 1 |
| Drengler, R; Duan, W; Kolesar, JM; Kuhn, J; Otterson, G; Schaaf, LJ; Shapiro, C; Villalona-Calero, MA; Xu, Y | 1 |
| Cai, XM; Liu, MZ; Xie, HL; Zha, XL | 1 |
| Berlin, JD; Chan, E; Goff, LW; Lockhart, AC; Roth, BJ; Rothenberg, ML; VerMeulen, WL | 1 |
| Hong, M; Jiang, Y; Pei, Y; Tang, G; Zhu, S | 1 |
| Brown, K; Carvajal, R; Chung, K; Egorin, MJ; Gonen, M; Kelsen, D; Klimstra, DS; Lefkowitz, R; Maki, R; Manova-Todorova, K; Mui, J; O'Reilly, E; Schwartz, GK; Shah, M; Sheikh, T; Sikorski, R; Tipian, C; Tse, AN; Wu, N | 1 |
| Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Sasaki, Y; Sugiyama, M; Sunakawa, Y; Yamamoto, W; Yamashita, K | 1 |
| Aono, T; Fujii, M; Hasegawa, J; Hirota, M; Iwase, K; Kimura, T; Matsuda, C; Nakai, S; Nasu, S; Nishikawa, K; Shimada, K; Tanaka, Y; Wada, D | 1 |
| Fujimitsu, Y; Kojima, H; Kojima, T; Kure, N; Matsui, T; Mochizuki, Y; Uemura, T | 1 |
| Diao, YY; Fang, QL; Gao, JQ; Han, M; He, CX; He, QJ; Hu, YZ; Liang, WQ; Xu, DH; Yang, B; Yang, XC | 1 |
| Gelderblom, H; Kroep, JR | 1 |
| Baki, M | 1 |
| Angiolillo, A; Cohen, MB; Gorlick, R; Jakacki, R; Levy, AS; Meyers, PA; Ringuette, SN; Wexler, LH | 1 |
| Amato, A; Clark, JW; He, X; Lynch, TJ; Pace, S; Ready, N; Ryan, DP; Safran, H; Salem, N; Supko, JG; Zhu, AX; Zvereva, N | 1 |
| Batist, G; Chi, KN; Chia, SK; Gelmon, KA; Janoff, AS; Louie, AC; Mayer, LD; Miller, WH; Swenson, CE | 1 |
| Feng, L; Gu, B; Han, X; Liu, J; Liu, M; Liu, Y; Lu, W; Xie, C; Zhan, C | 1 |
| Adamson, PC; Blaney, SM; Furman, WL; Ivy, P; Krailo, MD; McGregor, LM; Schaiquevich, P; Speights, R; Spunt, SL; Stewart, CF | 1 |
| Belani, CP; Edwards, RP; Friedland, DM; Maruca, L; Ramalingam, S; Ramanathan, RK; Stoller, RG; Strychor, S; Zamboni, BA; Zamboni, WC | 1 |
| Aoun, N; Baz, W; Burton, J; El-Soueidi, R; Forte, F; Lowry, J; Nakhl, F | 1 |
| Cushman, M; Pommier, Y | 1 |
| Fukushima, M; Inui, K; Kanai, M; Katsura, T; Kobayashi, M; Matsumoto, S; Nishimura, T; Onoue, M; Shimizu, A; Terada, T; Teramukai, S; Yanagihara, K | 1 |
| Berg, DJ; Bernaards, C; Blanchard, R; Denlinger, CS; Dorr, A; Hambleton, J; Holden, S; Kearns, A; Kenkare-Mitra, S; Litwin, S; Lum, B; McLaughlin, S; Meropol, NJ; O'Dwyer, PJ; Redlinger, M; Spittle, C; Xu, L | 1 |
| Basili, S; Moro, S | 1 |
| Cao, Z; Giovanella, B; Kozielski, A; Liu, X; Vardeman, D; Wang, Y | 1 |
| Pommier, Y | 3 |
| Green, IR; Sagar, S | 1 |
| Cuong, NV; Hsieh, MF; Huang, CM | 1 |
| Alabi, CA; Choi, CH; Czernin, J; Davis, ME; Hildebrandt, IJ; Hwang, J; Mack, BC; Schluep, T | 1 |
| Cha, TL; Chen, KC; Hou, HS; Huang, SM; Juan, TY; Leu, YL; Prijovich, ZM; Roffler, SR; Sun, GH; Wu, CC; Yu, CP | 1 |
| Hoskins, JM; Innocenti, F; McLeod, HL; Ratain, MJ; Rosner, GL | 1 |
| Bussom, S; Chang, HM; Cheng, YC; Lam, W; Wang, CJ | 1 |
| Chang, CM; Chang, CY; Chang, JY; Chao, YS; Chen, CP; Chen, CT; Chuu, JJ; Huang, CL; Lee, TY; Li, CM; Lin, CT; Shen, CC; Wang, HS; Yeh, TK | 1 |
| Axelrod, F; Basi, J; Clarke, MF; Donigian, L; Dylla, S; Fitch-Bruhns, M; Gurney, A; Hoey, T; Lazetic, S; Lewicki, J; Park, IK; Sato, A; Satyal, S; Wang, X; Yen, WC | 1 |
| Belani, CP; Edwards, RP; Friedland, DM; Maruca, L; Ramalingam, S; Ramanathan, RK; Stoller, RG; Strychor, S; Wu, H; Zamboni, BA; Zamboni, WC | 1 |
| Davis, ME | 1 |
| Fram, RJ; Yurkovetskiy, AV | 1 |
| Crews, KR; Daw, NC; Furman, WL; Gajjar, AJ; Houghton, PJ; McCarville, MB; McGregor, LM; Navid, F; Panetta, JC; Rodriguez-Galindo, C; Santana, VM; Spunt, SL; Stewart, CF; Wu, J | 1 |
| Cha, PC; Furuhata, T; Harada, H; Hirata, K; Kawamoto, S; Mushiroda, T; Nakamura, Y; Nishidate, T; Sasaki, K; Shimoyama, R; Shinoda, N; Zembutsu, H | 1 |
| Ehrnrooth, E; Frederiksen, KS; Skak, K; Søndergaard, H | 1 |
| Abraham, RT; Aslanian, A; Brognard, J; Coughlin, C; Dolled-Filhart, M; Hunter, T; Manning, G; You, Z; Zhang, YW | 1 |
| Bhonde, MR; Fechner, H; Hanski, C; Hanski, ML; Jebautzke, B; Lin, WC; Peiró-Jordán, R; Stehr, J; Yokoyama, KK; Zeitz, M | 1 |
| Arceci, RJ; Bagatell, R; Boklan, J; Gore, L; Harbison, C; Herzog, C; Hunger, SP; Katzenstein, HM; Kuttesch, J; Langer, C; Lu, H; Smith, AA; Trippett, TM; Weber, M; Whitlock, JA; Wolff, J; Zhou, X | 1 |
| Hamaguchi, T; Kaniwa, N; Kim, SR; Kunitoh, H; Maekawa, K; Matsumura, Y; Minami, H; Nishimaki-Mogami, T; Ohe, Y; Ohtsu, A; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Tamura, T; Yamada, Y; Yamamoto, N; Yoshida, T | 1 |
| Higashihara, M; Horie, R; Nakashima, M; Sasaki, M; Togano, T; Tsuruo, T; Umezawa, K; Watanabe, M; Watanabe, T | 1 |
| Baggstrom, MQ; Fracasso, P; Govindan, R; Morgensztern, D; Pillot, G; Suresh, R; Tan, B; Wildi, J | 1 |
| Chen, GQ; Cheng, JK; Shen, SM; Wang, LS; Wu, YL; Yu, Y | 1 |
| Blobe, GC; Dugan, E; Fernando, NH; Gockerman, JP; Hurwitz, HI; Meadows, KL; Morse, MA; Petros, WP; Truax, R | 1 |
| Adamson, PC; Ames, MM; Blaney, SM; Ingle, AM; Nelson, MD; Perentesis, JP; Reid, JM; Safgren, SL; Wagner, LM | 1 |
| Innocenti, F; Ratain, MJ | 2 |
| Arnold, SM; DeSimone, PA; Eckardt, JR; Fields, SZ; Kee, BK; Leggas, M; Moscow, JA; Rinehart, JJ; Shelton, BJ; Tsakalozou, E | 1 |
| Simanek, EE; Venditto, VJ | 1 |
| Alberti, DB; Choi, BS; Eickhoff, JC; Holen, KD; Ivy, SP; Kolesar, JM; Marnocha, R; Schelman, WR; Thomas, JP; Wilding, G | 1 |
| Furuya, K; Goto, T; Kato, M; Kikuchi, Y; Takano, M; Yoshikawa, T | 1 |
| Bae, SM; Jeong, SY; Kim, IS; Kim, JH; Kim, K; Kim, MS; Kwon, IC; Lee, DS; Lee, H; Min, KH; Park, RW; Park, S; Shin, H | 1 |
| Efferth, T; Konkimalla, VB | 1 |
| Brendel, E; Laferriere, N; Langenberg, MH; Mergui-Roelvink, M; Roodhart, JM; Schellens, JH; van der Sar, J; Verheul, HM; Voest, EE; Witteveen, PO | 1 |
| Hu, ZY; Yu, Q; Zhao, YS | 1 |
| Heideman, RL; McNall-Knapp, RY; Meyer, WH; Reeves, EN; Williams, CN | 1 |
| Barrett, JS; Ida, K; Ishida, Y; Kaneko, M; Kashiwase, S; Kimura, T; Kumagai, M; Makimoto, A; Mugishima, H; Nagatoshi, Y; Taga, T | 1 |
| Matsumura, Y | 1 |
| Bathula, SR; Conwell, C; Huang, L; Liu, F; Liu, Y; Park, JY; Zhang, Y | 1 |
| Adams, DJ; Driscoll, TA; Flowers, JL; Manikumar, G; Morgan, LR; Wani, MC; Waud, WR | 1 |
| Hatch, H; Hirai, H; Kotani, H; Majumder, PK; Miyama, K; Nakatsuru, Y; Pan, BS; Sootome, H; Taguchi, S; Tsujioka, K; Ueno, Y | 1 |
| Bang, Y; Belani, CP; Edwards, RP; Friedland, DM; Kim, J; Lee, H; Maruca, LJ; Ramalingam, S; Ramanathan, RK; Stoller, RG; Strychor, S; Zamboni, BA; Zamboni, WC | 1 |
| Briasoulis, E; Fountzilas, G; Golfinopoulos, V; Karina, M; Papakostas, P; Pavlidis, N | 1 |
| Hamaguchi, T; Hosokawa, M; Kaniwa, N; Kunitoh, H; Matsumura, Y; Minami, H; Naito, M; Nishimaki-Mogami, T; Ohe, Y; Ohtsu, A; Okuda, H; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Tamura, T; Tatewaki, N; Yamada, Y; Yamamoto, N; Yoshida, T | 1 |
| Belcastro, V; Bosotti, R; Brunetti-Pierri, N; di Bernardo, D; Ferriero, R; Iorio, F; Isacchi, A; Mithbaokar, P; Murino, L; Scacheri, E; Tagliaferri, R | 1 |
| Huang, Q; Li, J; Li, W; Peng, Y; Zhang, X; Zhu, Y | 1 |
| Adkins, DR; Arquette, MA; Cai, SR; Chen, RC; Creekmore, AN; Dancey, J; Ellis, MJ; Fleshman, JW; Fracasso, PM; Goodner, SA; Guo, Z; Lin, L; Ma, CX; McLeod, HL; Naughton, MJ; Picus, J; Piwnica-Worms, H; Pluard, TJ; Rader, JS; Rudek, MA; Ryan, CE; Soares, EM; Tan, BR; Tao, Y; Williams, KJ; Wright, LP | 1 |
| Armand, JP; Boven, E; Brega, NM; Countouriotis, AM; Hartog, V; Massard, C; Ruiz-Garcia, A; Soria, JC; Tillier, C | 1 |
| Eng, C | 1 |
| Lee, SY; McLeod, HL | 1 |
| Jaitner, S; Jung, A; Kirchner, T; Schäffauer, AJ | 1 |
| Benner, RJ; Benson, AB; Berlin, JD; Denis, LJ; Goff, LW; LoRusso, PM; Rothenberg, ML; Tan, AR; Yin, D | 1 |
| de Jong, FA; Mathijssen, RH; Sleijfer, S; Sparreboom, A; van Daele, PL; van de Geijn, FE; van der Bol, JM; van Fessem, MA; van Schaik, RH; Verweij, J | 1 |
| Doi, T; Eguchi-Nakajima, T; Fuse, N; Hamaguchi, T; Kato, K; Matsumoto, S; Matsumura, Y; Ohtsu, A; Shimada, Y; Takanashi, M; Yamada, Y | 1 |
| Cane, LM; Carvajal, RD; Dials, HJ; Dickson, MA; Gonen, M; Lefkowitz, RA; Rathkopf, D; Schwartz, GK; Shah, MA; Tse, A; Wu, N | 1 |
| Strassburg, CP | 1 |
| Dadashzadeh, S; Derakhshandeh, K; Saghiri, R; Soheili, M | 1 |
| Akiyama, Y; Ando, Y; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Saji, S; Sasaki, Y; Sugiyama, M; Sunakawa, Y; Yamamoto, W; Yamashita, K | 1 |
| Fan, M; Murdoch, WJ; Radosz, M; Shen, Y; Sui, M; Tang, J; Van Kirk, EA; Xu, P; Zhou, Z | 1 |
| Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW | 1 |
| Bandyopadhyay, K; Gjerset, RA | 1 |
| Chen, P; Huang, C; Li, K; Liu, M; Wang, L; Xue, J; Yan, Z; Zhu, Z | 1 |
| de Bruijn, P; de Jong, FA; Konings, IR; Lam, MH; Loos, WJ; Mathijssen, RH; van der Bol, JM; van Meerten, E; Verweij, J; Wiemer, EA | 1 |
| Bang, YJ; Belani, CP; Edwards, RP; Friedland, DM; Maruca, LJ; Ramalingam, S; Ramanathan, RK; Stoller, RG; Strychor, S; Wu, H; Zamboni, BA; Zamboni, WC | 2 |
| Gillespie, GY; Jope, RS; Song, L; Sun, M; Zhou, T | 1 |
| Chen, KC; Cheng, TL; Huang, PT; Leu, YL; Prijovich, ZM; Roffler, SR | 1 |
| Adams, DJ; Morgan, LR | 1 |
| Farndon, P; Li-Wan-Po, A | 1 |
| Eliasof, S; Hwang, J; Ryan, J; Svenson, S; Wolfgang, M | 1 |
| Bagley, RG; Bormann, C; Crawford, J; Dunham, S; Krumbholz, R; Kurtzberg, LS; Lavoie, EJ; Roth, S; Rouleau, C; Schmid, SM; Teicher, BA; Wang, F; Yao, M; Yu, XJ | 1 |
| Hou, W; Li, J; Liao, J; Liu, J; Liu, X; Stark, JM; Wang, J; Wang, P; Xie, Y; Xu, X; Yao, L; Zhong, J; Zhu, B | 1 |
| Crews, KR; Furman, WL; Houghton, PJ; McCarville, MB; McGregor, LM; Navid, F; Rodriguez-Galindo, C; Santana, VM; Stewart, CF; Tagen, M; Wozniak, A; Wu, J | 1 |
| Dzurenkova, A; Kadasi, L; Minarik, G; Mladosievicova, B; Soltysova, A; Sufliarska, S; Turna, J | 1 |
| Jee, HJ; Kim, AJ; Kim, HJ; Kim, M; Song, N; Yun, J | 1 |
| Gemma, A; Kakihata, K; Kon, A; Nagashima, M; Suzuki, T; Yoshii, N | 1 |
| Aiyama, R; Asakawa, N; Furuta, T; Hatano, H; Igarashi, Y; Kodaira, H; Matsuzaki, T; Nishiyama, Y; Sugimoto, Y; Takahashi, H; Yagi, N; Yamazaki, R | 1 |
| Anderson, K; Burris, HA; Jones, S; Marier, JF; Pheng, L; Porubek, D; Trinh, MM; Warner, S | 1 |
| Adjei, AA; Garmey, E; Schwartz, B | 1 |
| Dexheimer, TS; Pommier, Y; Sooryakumar, D; Teicher, BA | 1 |
| Boos, J; Lanvers-Kaminsky, C; Spaniol, K | 1 |
| Liu, L; Song, J; Wang, K; Wang, R; Zhang, B; Zhang, W | 1 |
| Cavenee, WK; Furnari, FB; Huang, JW; Li, M; Mitchell, PS; Taniguchi, T; Tewari, M; Wang, Y; Zhou, X | 1 |
| Manabe, S; Matsumura, Y; Tarin, D; Yasunaga, M | 1 |
| Cheng, P; Dong, G; Guo, W; Liu, W; Miao, Z; Sheng, C; Yao, J; Zhang, W; Zhang, Y; Zhu, L; Zhuang, C | 1 |
| Gan, L; Gan, Y; Gao, Y; Zhang, XX; Zhu, CL | 1 |
| Hashimoto, M; Hiraike, M; Honda, S; Misumi, N; Nabeshima, A; Nawata, F; Takase, I; Tanigawa, K | 1 |
| Ariyoshi, Y; Fukuoka, M; Kakihata, K; Masatani, S; Sakata, Y; Shimazaki, M; Shiozawa, T; Tadokoro, J; Yamaguchi, F | 1 |
| Cohen, EE; House, LK; Innocenti, F; Janisch, L; Karrison, T; Ramírez, J; Ratain, MJ; Wu, K | 1 |
| Beijnen, JH; Caron, WP; Clewell, H; Davis, WL; Dedrick, R; Ramanathan, RK; Schellens, JH; Tonda, M; Yu, N; Zamboni, WC | 1 |
| Chiang, CJ; Lin, CC; Lu, TL; Wang, HF | 1 |
| Cheng, P; Dong, G; Guo, W; Lei, N; Liu, W; Miao, Z; Sheng, C; Wang, S; Yao, J; Zhang, W; Zhang, Y; Zhu, L; Zhuang, C | 1 |
| Assenat, E; Bleuse, JP; Mazard, T; Pinguet, F; Portales, F; Poujol, S; Samalin, E; Thezenas, S; Thirion, A; Ychou, M | 1 |
| Chen, KJ; Cheng, J; Garcia, MA; Hou, S; Lin, WY; Lu, H; Shen, CK; Tang, L; Tseng, HR; Wang, H; Yin, Q | 1 |
| Anantha, M; Bally, MB; Sutherland, B; Verreault, M; Waterhouse, DN; Yapp, D | 1 |
| Akama, TO; Bobkov, AA; Fukuda, M; Fukuda, MN; Hatakeyama, S; Nakayama, J; Ohyama, C; Shibata, TK; Sugihara, K; Takano, Y; Tamura, N; Wong, SM | 1 |
| Chen, YQ; Feng, SY; Lin, KY; Ye, H; Zeng, CW; Zhang, H; Zhang, XJ | 1 |
| Cheng, J; Tang, L; Tong, R; Yin, Q | 1 |
| Li, X; Liu, C; Luo, X; Wang, H; Xie, C; Yan, S | 1 |
| Murayama, J; Okazaki, K; Saito, I; Watanabe, T | 1 |
| Ansari, KA; Nekkanti, V; Pillai, R; Venkateswarlu, V | 1 |
| Awada, A; Azim, HA | 1 |
| Cheng, T; Guan, XM; Lan, JF; Liu, XY; Shen, JM; Zhang, HX | 1 |
| Ai, R; Jin, H; Li, X; Lu, J; Sha, S; Yang, J | 1 |
| DeSimone, JM; Finniss, M; Gullapalli, A; Luft, JC; Napier, ME; Pandya, A; Parrott, MC | 1 |
| Cho, JK; Chun, C; Kuh, HJ; Song, SC | 1 |
| Botella, P; Corma, A; Fernández, E; Fimia, A; Madrigal, RF; Muniesa, C; Ortega, I; Quesada, M | 1 |
| Liang, WQ; Liu, DX; Ye, ZW; Zhao, YX | 1 |
| Redy, O; Shabat, D | 1 |
| Cao, Z; Dejesus, A; Giovanella, B; Kozielski, A; Liu, X; Mendoza, J; Vardeman, D; Wang, Y; Zhan, CG | 1 |
| Fujita, K; Ishida, H; Kato, Y; Miwa, K; Saji, S; Sasaki, T; Sasaki, Y; Sunakawa, Y; Yamashita, K | 1 |
| Bhuniya, S; Han, JH; Kang, C; Kim, JS; Kim, JY; Lee, MH; Sessler, JL | 1 |
| Buchbinder, A; Chaudhary, I; Fu, S; Ghalib, MH; Goel, S; Hong, D; Kurzrock, R; Lokiec, F; Mani, S; Morgan-Linnell, SK; Mulcahy, M; Rezai, K; Urien, S; Wheler, J | 1 |
| Dias, MM; McKinnon, RA; Sorich, MJ | 1 |
| Bach, PB; Conti, RM; Polite, BN; Rosenthal, MB; Shih, YC | 1 |
| Cendrós, JM; Cvitkovic, F; Delavault, P; Lesimple, T; Obach, R; Peraire, C; Perez-Mayoral, A; Principe, P; Pruñonosa, J; Soto, E; Trocóniz, IF | 1 |
| Chung, CH; Hong, SH; Jeon, YJ; Jo, MG; Jung, YK; Ka, SH; Oh, KH; Park, JM; Seol, JH; Yoo, HM | 1 |
| An, F; Diao, X; Hao, X; Li, W; Liu, Z; Wang, C; Yang, Y; Zhang, X | 1 |
| Li, P; Lin, Y; Ran, H; Ren, J; Tan, J; Wang, Z; Zhang, Q; Zheng, Y | 1 |
| Baracos, VE; Bibova, I; Dieleman, LA; Field, CJ; Gänzle, MG; Ketabi, A; Lin, XB; Sawyer, MB; Xue, H | 1 |
| Gilbert, KS; Secrist, JA; Waud, WR | 1 |
| Assadourian, S; Billemont, B; Cartot-Cotton, S; Khayat, D; Meric, JB; Rixe, O; Soussan-Lazard, K; Tejpar, S; Van Cutsem, E; Verslype, C | 1 |
| Bendell, JC; Burris, HA; Chan, E; Ikeda, S; Infante, JR; Jones, SF; Keedy, VL; Kodaira, H; Lee, W; Rothenberg, ML; Wu, H; Zamboni, WC | 1 |
| Larsen, AK; Petitprez, A | 1 |
| Bartek, J; Bartkova, J; Bouchal, J; Korinkova, G; Lau, A; Lenobel, R; Lukas, J; Mistrik, M; O'Connor, MJ; Oplustilova, L; Simkova, D; Wolanin, K | 1 |
| Kaina, B; Tomicic, MT | 1 |
| Covell, DG | 1 |
| Borrelli, S; Christodoulou, MS; Comi, D; Dalla Via, L; Evensen, L; Fontana, G; Gia, OM; Lorens, JB; Martinelli, M; Passarella, D; Pieraccini, S; Sironi, M; Zuco, V; Zunino, F | 1 |
| Aiba, K; Arakawa, Y | 1 |
| Bao, A; Brandl, M; Chang, TT; Flaten, GE; Goins, B; Phillips, WT | 1 |
| Cheng, S; Li, F; Yi, X; Yuan, Z; Zhang, J; Zhuo, R | 1 |
| Chang, G; Ci, T; Ding, J; Li, T; Yu, L | 1 |
| Al-Kasspooles, MF; Decedue, CJ; Henry, D; Howell, J; Niu, F; Roby, KF; Williamson, SK | 1 |
| Etoh, T; Hayashi, H; Inoue, K; Itoh, K; Kawamura, Y; Kikuyama, M; Kimura, M; Matsumura, T; Minami, S; Sonobe, M; Suzuki, T; Takagi, M; Tsuji, D; Utsuki, H; Yamazaki, T | 1 |
| Assadourian, S; Bloch, J; Cartot-Coton, S; Khayat, D; Soussan-Lazard, K; Spano, JP; Tejpar, S; Van Cutsem, E; Vandecaveye, V; Verslype, C | 1 |
| Arce Abaitua, B; Blumenfeld Olivares, JA; Cormenzana Carpio, M; Hernández-Marqués, C; Lassaletta-Atienza, A; Madero Lopez, L; Ruiz Hernández, A | 1 |
| Ahn, JS; Asami, Y; Erikson, RL; Jang, JH; Kim, BY; Kim, SO; Kim, YS; Kwon, YT; Lee, KS; N R, T; Sakchaisri, K; Soung, NK; Thimmegowda, NR | 1 |
| Al-Suwayeh, SA; Fang, JY; Hsu, SH; Huang, YJ; Wen, CJ | 1 |
| Chen, X; Chen, Y; Fei, J; Huang, A; Li, S; Niu, J; Ping, Q; Shi, Y; Su, Z; Sun, M; Tian, J; Xiao, Y; You, W; Zong, L | 1 |
| Bassett, D; Chao, J; Choi, CHJ; Chow, W; Chung, V; Davis, ME; Forman, SJ; Garmey, E; Hwang, J; Kalinoski, DL; Koczywas, M; Longmate, J; Melton, RJ; Morgan, R; Neidhart, JA; Neidhart, JD; Oliver, J; Peterkin, JJ; Ramanathan, RK; Ryan, JL; Schluep, T; Synold, TW; Twardowski, P; Weiss, GJ; Yen, Y | 1 |
| Cao, J; Cui, S; Gu, Y; Qian, Z; Zhu, H | 1 |
| Green, MR; Leong, SS; Perkel, JA; Putman, T; Rocha Lima, CM; Safa, AR; Sherman, CA | 1 |
| Karlsson, MO; Mathijssen, RH; Sparreboom, A; Verweij, J; Xie, R | 1 |
| Ma, MK; McLeod, HL; Xu, G; Zhang, W | 1 |
| Loos, WJ; Mathijssen, RH; Sparreboom, A; Verweij, J | 1 |
| Mansky, PJ; Straus, SE | 1 |
| Baidas, S; Marshall, JL; Rizvi, N | 1 |
| Kolesar, JM; Villalona-Calero, MA | 1 |
| Li, C | 1 |
| Hara, N; Harada, T; Inoue, K; Izumi, M; Kimotsuki, K; Minami, T; Nakanishi, Y; Osaki, S; Takano, K; Takayama, K; Wataya, H | 1 |
| Beijnen, JH; Breda, M; Fraier, D; Grazia Porro, M; Jansen, S; Lieverst, J; Pellizzoni, C; Rosing, H; Schellens, JH; Schoemaker, NE; Spinelli, R; Swart, M; ten Bokkel Huinink, WW; van Kesteren, C | 1 |
| Adams, AL; Brady, D; Engstrom, PF; Gallo, JM; Kilpatrick, D; Lewis, NL; Litwin, S; Meropol, NJ; Scher, R; Szarka, CE; Weiner, LM | 1 |
| Kim, DK; Lee, N | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Kaufmann, SH; Miller, LL; Pitot, HC; Rubin, J; Sloan, JA | 1 |
| Chiang, C; Hamilton, A; Hazarika, M; Hochster, H; Hornreich, G; Liebes, L; Muggia, FM; Newman, E; Potmesil, M; Sorich, J; Wadler, S | 1 |
| Arquette, MA; Denes, A; Fears, CL; Fracasso, PM; Goodner, SA; Govindan, R; Herzog, TJ; Mutch, DG; Picus, J; Rader, JS; Sun, SL; Tan, BR | 1 |
| Villalona-Calero, MA; Xu, Y | 1 |
| Siderov, J | 1 |
| Clark, JW; Fuchs, CS; Garcia-Carbonero, R; Michaelson, MD; Paul Eder, J; Ryan, DP; Supko, JG | 1 |
| Denis, L; Forouzesh, B; Goetz, A; Hammond, LA; Kwiatek, J; McGuire, J; Ochoa, L; Patnaik, A; Rizzo, J; Rowinsky, EK; Schwartz, G; Takimoto, CH; Tolcher, AW | 1 |
| Albanell, J; Baselga, J | 1 |
| Bernstein, ML; Blaney, SM; Dubowy, RL; Hershon, L; McLeod, WD; Souid, AK; Sullivan, J | 1 |
| Conroy, T; Gourgou, S; Hua, A; Kramar, A; Mery-Mignard, D; Seitz, JF; Ychou, M | 1 |
| McLeod, HL; Watters, JW | 1 |
| Desai, SD; Gounder, MK; Liu, LF; Rodriguez-Bauman, A; Rubin, EH; Wu, X; Yang, JM; Zhang, H | 1 |
| Chen, X; Wang, PG; Wu, B | 1 |
| Blackburn, A; Cunningham, C; Freeman, S; Gibson, B; Nemunaitis, J; Netto, G; Paulson, AS; Post, L; Randlev, B; Rich, D; Sands, B; Tong, A | 1 |
| Ando, M; Hanioka, N; Jinno, H; Kaniwa, N; Minami, H; Ohtsu, A; Ozawa, S; Saeki, M; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Tanaka-Kagawa, T; Yoshida, T | 1 |
| Aisner, J; Beers, S; Gounder, M; Licitra, EJ; Lin, Y; Musanti, R; Nelson, K; Poplin, E; Rajendra, R; Rubin, EH; Saleem, A; Schaaf, LJ; Smith, S; Thomas, C; Toppmeyer, D; Vyas, V | 1 |
| Boiocchi, M; Cecchin, E; Corona, G; Toffoli, G | 1 |
| Bates, NP; Boven, E; Braybrooke, JP; Cheverton, PD; Dobbs, N; Pinedo, HM; Ruijter, R; Talbot, DC | 1 |
| Abbruzzese, JL; Madden, TL; Newman, RA; Tran, HT; Xiong, HQ | 1 |
| Crane, CH; Liao, Z; Masferrer, J; Mason, KA; Milas, L | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Kuzur, ME; Miranda, FT; Raefsky, EA; White, MB; Willcutt, NT; Yardley, DA | 1 |
| Burris, HA; Gian, VG; Greco, FA; Hainsworth, JD; Jones, SF; Miranda, FT; Shipley, DL; Thompson, DS; Toomey, MA; Willcutt, NT | 1 |
| Hwang, JJ; Marshall, JL; Rizvi, N | 1 |
| Bailly, C; Lansiaux, A | 2 |
| Dahut, W; Grem, JL; Ismail, AS; Leguizamo, J; Liang, MD; Pang, J; Quinn, M; Takimoto, CH | 1 |
| Kobayashi, K | 1 |
| Coyle, J; De Jager, RL; Ducharme, M; Figueroa, JA; Garrison, MA; Geyer, CE; Hammond, LA; Rowinsky, EK; Schwartz, G; Smetzer, L; Takimoto, CH; Tolcher, AW | 1 |
| Gandara, DR; Houston, J; Lara, PN; Lau, DH; Lauder, J; Meyers, FJ; Tanaka, M; Wang, SE; Wild, CA | 1 |
| Maneely, D | 1 |
| Chen, X; Davis, AJ; Kochman, D; Kusenda, Z; Moore, MJ; Oza, AM; Siu, LL; Yi, QL | 1 |
| Adjei, AA; Ames, MM; Atherton, P; Erlichman, C; Galanis, E; Goetz, MP; Goldberg, RM; Pitot, H; Reid, JM; Rubin, J; Sloan, JA; Windebank, AJ | 1 |
| Katneni, K; Mamidi, RN; Srinivas, NR; Upreti, VV | 1 |
| de Jonge, MJ; Devlin, M; Gelderblom, H; Obach, R; Pentheroudakis, G; Principe, P; Pruñonosa, J; Salazar, R; Seguy, F; Twelves, C; van Hooije, C; Verweij, J | 1 |
| Desai, AA; Innocenti, F; Ratain, MJ | 1 |
| Doz, F; Frappaz, D; Germa, C; Imadalou, K; Mignard, D; O'Quigley, J; Pein, F; Risse, ML; Santos, A; Sicard, E; Vassal, G | 1 |
| Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL | 1 |
| Budman, D; Byrd, J; Enders Klein, C; Fleming, G; Hohl, R; Hollis, D; Kastrissios, H; Leichman, CG; Marshall, J; Ramirez, J; Ratain, MJ; Rosner, GL; Venook, AP; Villalona, M | 1 |
| Danks, MK; Potter, PM | 1 |
| Baas, F; Brendel, E; Buss, P; Mersmann, S; Mross, K; Reil, M; Schwartz, B; Steinbild, S; Voliotis, D | 1 |
| Chen, Q; Guan, ZZ; He, YJ; Hu, XH; Huang, HQ; Jiang, WQ; Li, YH; Lin, XB; Lin, Z; Liu, KF; Shen, WX | 1 |
| Viele, CS | 1 |
| Akaike, T; Fang, J; Greish, K; Maeda, H; Sawa, T | 1 |
| Davis, ID; Green, M; Jefford, M; McClure, B; Michael, M; Rosenthal, MA; Smith, J; Waite, B; Zalcberg, J | 1 |
| Alpaugh, RK; Cohen, SJ; Gallo, J; Gentner, L; Lewis, NL; Meropol, NJ; Palmer, PA; Rogatko, A; Schol, J; Verhaeghe, T; Weiner, LM; Yeslow, G; Zannikos, P | 1 |
| Crul, M | 1 |
| Albritton, K; Crews, KR; Fuller, CE; Goldsby, RE; Houghton, PJ; Iacono, LC; McCarville, MB; Santana, VM; Stewart, CF; Wagner, LM | 1 |
| Algazy, K; Giantonio, B; Hahn, S; Haller, DG; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W; Thorn, C; Vaughn, D; Veronese, ML; Whitehead, AS | 1 |
| Osheroff, N | 1 |
| Coy, DH; Fuselier, J; Jensen, RT; Mantey, SA; Martinez, A; Moody, TW; Nakagawa, T; Pradhan, TK; Schumann, M | 1 |
| Cozzi, P; Mongelli, N; Suarato, A | 1 |
| Eisenhauer, E; Fisher, B; Gelmon, K; Hirte, HW; MacKenzie, MJ; Ptaszynski, M; Siu, LL | 1 |
| Baker, SD; Brahmer, JR; Carducci, MA; Lee, CK; Sparreboom, A; Verweij, J; Wolff, AC; Zabelina, Y; Zhao, M | 1 |
| Liang, H; Sha, N | 1 |
| Cao, S; Durrani, FA; Rustum, YM | 1 |
| de Bruijn, P; de Heus, G; de Jonge, MJ; Eskens, FA; Kehrer, DF; Klaren, A; Mathijssen, RH; Palmer, PA; Planting, AS; Sparreboom, A; Verhaeghe, T; Verheij, C; Verweij, J; Xie, R; Zhang, S | 1 |
| Eisenhauer, E; Fisher, B; Gelmon, K; Hamilton, M; Hirte, H; Onetto, N; Ptaszynski, M; Walsh, W | 1 |
| de Vries, EG; Dumez, H; Gietema, JA; Groen, HJ; Maring, JG; Porro, M; van Oosterom, AT; Wachters, FM | 1 |
| Chen, AY; Chou, R; Gandara, D; Lau, D; Shih, SJ | 1 |
| Hasegawa, R; Jinno, H; Kamakura, S; Kamatani, N; Kaniwa, N; Katori, N; Kitakaze, M; Kitamura, Y; Komamura, K; Minami, H; Ohtsu, A; Ozawa, S; Saeki, M; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Ueno, K; Yoshida, T | 1 |
| Bissett, D; Cassidy, J; de Bono, JS; Fraier, D; Magnè, ML; Main, M; Muirhead, F; Pellizzoni, C; Porro, MG; Robson, L; Speed, W; Spinelli, R; Twelves, C | 1 |
| Kullmann, F; Schölmerich, J; Schultz, M | 1 |
| Chatterjee, A; Digumarti, R; Jiwatani, S; Katneni, K; Mamidi, RN; Srinivas, ML; Srinivas, NR; Subramaniam, S; Surath, A; Uppalapati, S; Upreti, VV | 1 |
| de Jong, FA; Mathijssen, RH; Sparreboom, A; Verweij, J; Xie, R | 1 |
| Behringer, D; Beinert, T; Brendel, E; Haase, CG; Korfee, S; Mross, K; Richly, H; Sauer, U; Scheulen, ME; Schleucher, N; Schweigert, M; Seeber, S; Strumberg, D; Tewes, M; Unger, C; Voliotis, D | 1 |
| Danesi, R; Figg, WD; Mathijssen, RH; Paoluzzi, L; Price, DK; Singh, AS; Sparreboom, A; Verweij, J | 1 |
| Kiribayashi, Y; Maeda, Y; Murakami, T; Nakamura, M; Ohune, T; Yamasaki, M | 1 |
| Agarwala, SS; Belani, CP; Egorin, MJ; Fakih, M; Friedland, DM; Jin, R; Jung, LL; Potter, DM; Ramanathan, RK; Strychor, S; Troetschel, M; Trump, DL; Vozniak, M; Wong, MM; Zamboni, WC | 1 |
| Belani, CP; Egorin, MJ; Fakih, M; Jin, R; Jung, LL; Potter, DM; Ramanathan, RK; Strychor, S; Trump, DL; Walko, C; Zamboni, WC | 1 |
| Iacono, LC; Stewart, CF; Turner, PK | 1 |
| de Jong, FA; King, C; Marsh, S; Mathijssen, RH; McLeod, HL; Sparreboom, A; Verweij, J | 1 |
| Jung, SH; Kirsh, KL; Loehrer, P; Nagy, C; Navari, RM; Passik, SD; Vinson, J | 1 |
| Innocenti, F; Mani, S; Prado, M; Ramírez, J; Ratain, MJ; Schilsky, RL; Undevia, SD; Vogelzang, NJ | 1 |
| Harrington, KJ; Marshall, CJ; Mavria, G; Porter, CD | 1 |
| Cunningham, D; Ng, M | 1 |
| Assadourian, S; Beijnen, JH; Huinink, WW; Kuppens, IE; Lefebvre, P; Sanderink, GJ; Schellens, JH; Schoemaker, NE | 1 |
| Paukstadt, W | 1 |
| Assadourian, S; deJonge, MJ; Dumez, H; Eskens, FA; Sanderink, GJ; Selleslach, J; Semiond, D; Soepenberg, O; Sparreboom, A; ter Steeg, J; van Oosterom, AT; Verweij, J | 1 |
| Cecchin, E; Toffoli, G | 1 |
| Dai, NT; Erlichman, C; Flatten, K; Karnitz, LM; Kaufmann, SH; Loegering, D; Vroman, BT | 1 |
| Cheverton, P; de Bruin, P; de Heus, G; de Jonge, MJ; Ducharme, MP; Eskens, FA; Soepenberg, O; Sparreboom, A; Verweij, J; Wanders, J | 1 |
| Adams, DJ | 1 |
| Hata, A; Kageyama, H; Koseki, H; Lin, L; Nakagawara, A; Nakamura, Y; Ozaki, T; Simonds, WF; Takada, Y; Zhang, JH | 1 |
| Assadourian, S; de Jong, FA; de Jonge, MJ; Dumez, H; Eskens, FA; Lefebvre, P; Sanderink, GJ; Selleslach, J; Soepenberg, O; Sparreboom, A; Ter Steeg, J; Thomas, J; van Oosterom, AT; van Schaik, RH; Verweij, J | 1 |
| Berg, S; Blaney, SM; Bomgaars, L; Kerr, J; Klenke, R; Kuttesch, J | 1 |
| Chatterjee, A; Digumarti, R; Jiwatani, S; Katneni, K; Mamidi, RN; Mullangi, R; Srinivas, ML; Srinivas, NR; Surath, A; Uppalapati, S; Upreti, VV | 1 |
| Blay, JY | 1 |
| Beringer, P; Garcia, AA; Iqbal, S; Jeffers, S; Lenz, HJ; Louie, S; Pujari, M | 1 |
| Alfonso, R; Carcas, A; Cortés-Funes, H; Díaz-Rubio, E; Frías, J; Grávalos, C; Guerra, P; Paz-Ares, L; Pronk, L; Sastre, J | 1 |
| Brenner, B; Cordon-Cardo, C; Drobnjak, M; Gonen, M; Kelsen, DP; Kortmansky, J; Lefkowitz, R; Motwani, M; O'Reilly, E; Saltz, L; Schwartz, GK; Shah, MA; Tong, W; Weyerbacher, A; Yi, S | 1 |
| Hoffman, RM | 1 |
| Champoux, JJ; Chen, HJ; Interthal, H; Kehl-Fie, TE; Leppard, JB; Zotzmann, J | 1 |
| Fioravanti, S; Grem, JL; Guo, X; Harold, N; Hopkins, JL; Leguizamo, JP; Leonard, GD; Lin, P; Monahan, BP; Morrison, G; Nguyen, D; Pang, J; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Wright, MA | 1 |
| Nitiss, JL; Nitiss, KC | 1 |
| Gao, M; Miller, KD; Sledge, GW; Zheng, QH | 1 |
| Adjei, AA; Croghan, GC; Dy, GK; Furth, A; Hanson, LJ; Mandrekar, S; Okuno, SH; Peethambaram, PP | 1 |
| Cain, A; Crews, KR; Daw, NC; Furman, W; Houghton, PH; Panetta, JC; Rodriguez-Galindo, C; Santana, VM; Stewart, CF; Tan, M | 1 |
| Büchler, MW; Cheverton, P; Friess, H; Kleeff, J; Langman, S; Wanders, J; Wente, MN | 1 |
| Cree, IA; Di Nicolantonio, F; Di Palma, S; Fernando, A; Gabriel, FG; Glaysher, S; Gulliford, T; Higgins, B; Hurren, J; Johnson, P; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Somers, SS; Toh, S; Whitehouse, PA; Yiangou, C | 1 |
| Beyer, U; Gnad-Vogt, SU; Hochhaus, A; Hofheinz, RD | 1 |
| Cao, S; Durrani, FA; Fakih, M; Rustum, YM | 1 |
| Bangash, N; Batist, G; Chen, EX; Lathia, C; Maclean, M; McIntosh, L; Miller, WH; Oza, AM; Petrenciuc, O; Seymour, L; Siu, LL | 1 |
| Goetz, MP; Grothey, A; Mandrekar, SJ; Sargent, DJ | 1 |
| Egorin, MJ; Goel, S; Iqbal, T; Mani, S; Parise, RA; Repinski, TV; Strychor, S; Zamboni, WC | 1 |
| Ayuso, MJ; Gálvez, M; Martín-Cordero, C | 1 |
| Cendrós, JM; Garrido, MJ; Obach, R; Peraire, C; Principe, P; Segura, C; Trocòniz, IF | 1 |
| Baker, SD; Gelderblom, H; Guchelaar, HJ; Nortier, JW; Rudek, MA; Sparreboom, A; van Erp, NP; Zhao, M | 1 |
| Carlisle, R; Goetz, A; Kwiatek, J; Posey, JA; Rizzo, J; Rowinsky, EK; Rudoltz, MS; Saif, MW; Simmons, P; Stevenson, S; Takimoto, CH; Tolcher, AW | 1 |
| Isomura, M; Miki, Y | 1 |
| Lokiec, F; Rezaí, K; Urien, S | 1 |
| Aida-Hyugaji, S; Ikegami, Y; Ishikawa, T; Nakagawa, H; Saito, H; Sawada, S | 1 |
| Adjei, AA; Alberts, SR; Atherton, PJ; Denis, L; Duncan, BA; Erlichman, C; McGovren, P; Miller, LL; Pitot, HC; Reid, JM; Rubin, J; Schaaf, LJ; Sharma, A; Sloan, JA; Yin, D | 1 |
| de Jong, FA; de Jonge, MJ; Mathijssen, RH; Verweij, J | 1 |
| Kandabashi, K; Sasaki, T | 1 |
| Billups, C; Crews, KR; Daw, NC; Dome, JS; Furman, WL; Gajjar, AJ; Houghton, PJ; Panetta, JC; Patrick, CC; Rodriguez-Galindo, C; Santana, VM; Stewart, CF; Wu, J | 1 |
| Ikegami, Y; Ishikawa, T; Nakagawa, H; Sano, K; Sawada, S | 1 |
| Azrak, RG; Badmaev, V; Creaven, PJ; Fakih, MG; Lawrence, D; Pendyala, L; Prey, JD; Reid, ME; Rustum, YM; Smith, PF | 1 |
| Innocenti, F | 1 |
| Davis, TA; Egorin, MJ; Jung, LL; King, CR; Mani, S; Marsh, S; Maruca, LJ; McLeod, HL; Parise, RA; Potter, DM; Ramanathan, RK; Strychor, S; Zamboni, WC | 1 |
| Duncan, J; McLeod, HL; Scheffer, GL; Scheper, RJ; Shannon, WD; Zhang, W | 1 |
| Hartmann, JT; Lipp, HP | 1 |
| Barrows, LR; Marshall, KM; Pond, CD | 1 |
| Ando, Y; Araki, K; Endo, H; Fujita, K; Kodama, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Yamamoto, W | 3 |
| Assadourian, S; Awada, A; de Boeck, G; de Bruijn, EA; Dumez, H; Guetens, G; Maes, RA; Piccart, M; Semiond, D; van Oosterom, A | 1 |
| Khoukaz, T | 1 |
| Innocenti, F; Ratain, MJ; Vokes, EE | 1 |
| Hanada, R; Kawa, K; Manabe, A; Matsunaga, T; Mimaya, J; Mugishima, H; Shimada, A; Shitara, T; Sugimoto, T; Tsuchida, Y; Tsurusawa, M | 1 |
| Duan, W; Kleiber, B; Kuhn, J; Otterson, G; Panico, K; Phillips, G; Schaaf, L; Shah, M; Villalona-Calero, M; Wu, WH; Young, D | 1 |
| O'Leary, J; Sewak, S; Sorich, J | 1 |
| McLeod, HL | 1 |
| Middleton, MR; Sabharwal, A | 1 |
| Assadourian, S; Beijnen, JH; Bonneterre, J; Bonneterre, ME; Boot, H; Dansin, E; Feger, C; Kuppens, IE; Schellens, JH | 1 |
| Cisar, LA; Compton, LD; Duncan, BA; Elfring, GL; Goel, R; Goldberg, RM; Gruia, G; Hammond, LA; Kuhn, JG; McGovren, JP; Miller, LL; Pirotta, N; Rothenberg, ML; Schaaf, LJ; Sharma, A; Tipping, SJ; Yin, D | 1 |
| Maitland, ML; Ratain, MJ; Vasisht, K | 1 |
| Ando, Y; Hasegawa, Y; Shimokata, K | 1 |
| Peddibhotla, S; Sharma, V; Tepe, JJ | 1 |
| Brunetto, AL; Castro, CG; Cruz, LB; Rech, A; Ribeiro, AS; Rosa, LG | 1 |
| Blanchard, RL; Nagar, S | 1 |
| Bally, MB; Harasym, NL; Harasym, TO; Janoff, AS; Johnstone, SA; Mayer, LD; Ramsay, EC; Shew, CR; Tardi, PG | 1 |
| Chowbay, B; Fan, L; Goh, BC; Jada, SR; Lee, SC; Li, HH; Lim, R; Tan, EH; Tham, LS; Wong, CI; Xiang, X; Zhou, QY | 1 |
| Sowin, TJ; Xiao, Z; Xue, J; Zhang, H | 1 |
| Antonia, S; Cantor, A; Fishman, M; Garrett, C; Gump, J; Lush, RM; Munster, PN; Rocha-Lima, C; Simon, GR; Sullivan, DM; Tetteh, L; Williams, C | 1 |
| Bui, MH; Chen, Z; Gu, WZ; Kovar, P; Li, G; Lin, NH; Rosenberg, SH; Sham, HL; Sowin, TJ; Tao, ZF; Tong, Y; Wang, G; Wang, JY; Xiao, Z; Xue, J; Zhang, H | 1 |
| Kitabayashi, I; Okamoto, K; Taya, Y | 1 |
| Appleman, LJ; Clark, J; Cusack, JC; Dees, EC; Eder, JP; Fidias, P; Kashala, O; O'Neil, BH; Orlowski, RZ; Rocha Lima, CM; Ryan, DP; Supko, JG | 1 |
| Baas, F; Brendel, E; Christensen, O; Gmehling, D; Mross, K; Radtke, M; Steinbild, S; Unger, C; Voliotis, D | 1 |
| Sekine, N; Terada, K | 1 |
| Baetz, T; Brail, LH; de Alwis, DP; Doppler, K; Eisenhauer, E; Fisher, B; Khan, AZ; MacLean, M; Moore, M; Siu, L; Walsh, W; Weitzman, A | 1 |
| Baselga, J; Capri, G; Carminati, P; Cerny, T; Cresta, S; D'Incalci, M; Gatti, B; Gianni, L; Hess, D; Malossi, A; Marsoni, S; Rota Caremoli, E; Sessa, C; Trigo, J; Zaniboni, A; Zanna, C; Zucchetti, M | 1 |
| Beretta, GL; Perego, P; Zunino, F | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Hashimoto, N; Imaizumi, K; Shimokata, K | 1 |
| Baker, S; Bulgaru, A; Camacho, F; Chaudhary, I; Desai, K; Einstein, M; Goel, S; Goldberg, G; Gollamudi, R; Karri, S; Kaubisch, A; Mani, S | 1 |
| Azrak, RG; Cao, S; Combs, GF; Durrani, FA; Fakih, M; Pendyala, L; Prey, J; Rustum, YM; Smith, PF | 1 |
| Beeram, M; Chu, Q; De Bono, J; Forouzesh, B; Hammond, LA; Hong, S; John, W; Latz, JE; Nguyen, B; Rowinsky, EK; Schwartz, G | 1 |
| de Jonge, MJ; McGovern, D; Obach, R; Principe, P; Scott, L; Soepenberg, O; Th Planting, AS; Twelves, C; Verweij, J | 1 |
| Antonia, S; Chiappori, A; de Lima Lopes, G; Haura, E; Langevin, M; Lush, R; Rocha-Lima, CM; Simon, G; Sullivan, D | 1 |
| Cusimano, L; Li, M; Saif, MW; Sellers, S; Wang, H; Wang, W; Zhang, R | 1 |
| Basse, B; Ubezio, P | 1 |
| Cowen, RL; Flint, PJ; Matzow, T; Saunders, MP; Southgate, TD; Telfer, BA; Williams, KJ | 1 |
| Guo, R; Jiang, X; Li, Y; Liu, B; Wang, Q; Yang, C; Yang, M; Zhang, L | 1 |
| de Bruijn, P; de Jong, FA; Engels, FK; Kitzen, JJ; Loos, WJ; Mathijssen, RH; Mathot, RA; Sparreboom, A; Verweij, J | 1 |
| Ando, Y; Araki, K; Eodo, H; Fujita, K; Kodama, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Yamamoto, W | 1 |
| Baker, SD; Carducci, MA; Dancey, J; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, DA; Messersmith, WA; Purcell, T; Rudek, MA | 1 |
| Kasuga, T; Midorikawa, Y; Nakachi, T | 1 |
| Innocenti, F; Kim, TW | 1 |
| Beretta, GL; Zunino, F | 1 |
| Hamaguchi, T; Kaniwa, N; Kubota, K; Minami, H; Ohmatsu, H; Ohtsu, A; Ozawa, S; Saeki, M; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Suzuki, K; Yamada, Y; Yamamoto, N; Yoshida, T | 1 |
| Liong, M; Lu, J; Tamanoi, F; Zink, JI | 1 |
| Billups, C; Fraga, CH; Furman, WL; Gajjar, A; Liu, T; McGregor, LM; O'Shaughnessy, MA; Owens, T; Panetta, JC; Rodriguez-Galindo, C; Stewart, CF; Throm, SL | 1 |
| Ando, Y; Fujita, K; Hasegawa, Y; Sasaki, Y | 1 |
| Akasawa, A; Jinno, H; Kamatani, N; Kaniwa, N; Kim, SR; Matsumoto, K; Minami, H; Ohtsu, A; Ozawa, S; Sai, K; Saijo, N; Saito, H; Saito, Y; Sawada, J; Shirao, K; Tanaka-Kagawa, T; Yamamoto, N; Yoshida, T | 1 |
| Efferth, T; Fu, YJ; Konkimalla, VS; Schwarz, G; Wink, M; Zu, YG | 1 |
| Chowbay, B; Goh, BC; Jada, SR; Lee, SC; Lim, R; Sandanaraj, E; Shu, X; Zhou, Q; Zhou, S | 1 |
| Janoff, AS; Mayer, LD | 1 |
| Bachelot, T; Biron, P; Blay, JY; Brantus, JF; Confavreux, C; Ghesquière, H; Guastalla, JP; Ray-Coquard, I; Rustam, F; Saba, C; Sebban, C | 1 |
| Flaherty, KT; Fleming, RA; Kerr, DJ; Koch, KM; Middleton, MR; Midgley, RS; O'Dwyer, PJ; Pratap, SE; Smith, DA; Stevenson, JP; Versola, M; Ward, C | 1 |
| Allievi, C; Angiuli, P; Burton, MK; Chiappori, AA; Daud, AI; De Conti, R; Eisenfeld, A; Garrett, CR; Homsi, J; Munster, PN; Simon, GR; Springett, G; Stromatt, S; Sullivan, DM | 1 |
| Harasym, NL; Harasym, TO; Harvie, P; Johnstone, SA; Mayer, LD; Tardi, PG | 1 |
| Adamson, PC; Bernstein, M; Blaney, SM; Bomgaars, LR; Chen, Z; Das, S; Kadota, R; Krailo, M | 1 |
| Haverstick, K; Page, RL; Saltzman, WM; Ying, V | 1 |
| Badmaev, V; Brady, W; Creaven, PJ; Fakih, MG; Pendyala, L; Prey, JD; Ross, ME; Rustum, YM; Smith, PF | 1 |
| Fukushima-Uesaka, H; Hamaguchi, T; Kamatani, N; Kaniwa, N; Kunitoh, H; Kurose, K; Minami, H; Ohe, Y; Ohtsu, A; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Tamura, T; Yamada, Y; Yamamoto, N; Yoshida, T | 1 |
| Cao, WJ; Li, Q; Wang, Y | 1 |
| Searle, B | 1 |
| Hashida, M; Kuga, H; Ochi, Y; Shiose, Y; Yamashita, F | 1 |
| Hirohashi, S; Kaniwa, N; Kurose, K; Ozawa, S; Saeki, M; Sai, K; Saijo, N; Saito, Y; Sakamoto, H; Sawada, J; Shirao, K; Yoshida, T | 1 |
| Li, X; Xu, W | 1 |
| Félix, GM; Luis, JV; Sergio, GC | 1 |
| Barrett, J; Bernstein, ML; Blaney, SM; Bomgaars, L; Gupta, M; Mondick, J; Rosner, GL; Thompson, PA; Yu, A | 1 |
| Eastman, A; Fanous, AA; Levesque, AA; Poh, A | 1 |
| Hazama, S; Oka, M | 1 |
| Boige, V; Cohen, M; Delbaldo, C; Faivre, S; Namouni, F; Pautier, P; Peck, R; Raymond, E; Soria, JC | 1 |
| Chen, CS; Chern, JW; Leu, YL; Wu, YJ | 1 |
| Bae, SM; Jeong, SY; Jo, HG; Kim, IS; Kim, K; Kim, YS; Kwon, IC; Lee, S; Min, KH; Park, K; Park, RW | 1 |
| Gabai, VL; Meng, L; O'Callaghan-Sunol, C; Sherman, MY; Yaglom, J | 1 |
| Greenberger, LM; Horak, ID; Kraft, P; Longley, C; Malaby, J; Mehlig, M; Sapra, P; Zhao, H | 1 |
| Li, YS; McHale, AP; Reid, CN | 1 |
| Ichas, F; Markovits, J; Montaudon, D; Moukarzel, J; Portail, JP; Pourquier, P; Robert, J; Tautu, MT; Verbiest, V | 1 |
| Hattori, Y; Kawano, K; Maitani, Y; Toma, K; Watanabe, M | 1 |
| Brell, JM; Cooney, MM; Dowlati, A; Egorin, MJ; Gibbons, J; Hoppel, CL; Ingalls, ST; Ivy, SP; Krishnamurthi, SS; Li, X; Overmoyer, BA; Remick, SC; Schluchter, MD; Weaver, KC; Zuhowski, EG | 1 |
| Innocenti, F; Panetta, JC; Ratain, MJ; Rosner, GL | 1 |
| Biason, P; Masier, S; Toffoli, G | 1 |
| Liew, ST; Yang, LX | 1 |
| Ehmer, U; Lankisch, TO; Manns, MP; Strassburg, CP | 1 |
| Jiang, TL; Liu, RM; Salmon, SE | 1 |
| Bonneterre, J | 1 |
| Donehower, RC; Grochow, LB; Kaufmann, SH; Rowinsky, EK; Slichenmyer, WJ | 1 |
| Fields, SZ; Hargis, JB; Lilenbaum, RC; Miller, AA; Rosner, GL; Schilsky, RL | 1 |
| Beidler, DR; Cheng, YC | 1 |
| Brewster, L; Green, MR; Hargis, JB; Hollis, DR; Lilenbaum, RC; Miller, AA; O'Brien, SM; Ratain, MJ; Rosner, GL; Schilsky, RL | 1 |
| Chabot, GG | 2 |
| Aonuma, M; Ejima, A; Hirota, Y; Kumazawa, E; Mitsui, I; Ohsuki, S; Sato, K; Sugimori, M; Terasawa, H; Uoto, K | 1 |
| Beijnen, JH; Davies, BE; Koier, I; Maes, RA; Rodenhuis, S; Rosing, H; ten Bokkel Huinink, WW; van Warmerdam, LJ | 1 |
| Arioka, H; Eguchi, K; Karato, A; Lieberman, R; Nakashima, H; Nomura, N; Ohmatsu, H; Shinkai, T; Shiraishi, J; Tamura, T | 1 |
| Arbuck, SG; Cheson, BD; Phillips, PH | 1 |
| Barbosa, K; Niedzwiecki, D; Saltz, L; Sirott, M; Tao, Y; Tong, W; Trochanowski, B; Tzy-Jyun, Y; Wright, P; Young, C | 1 |
| Arioka, H; Eguchi, K; Karato, A; Kunikane, H; Nishio, M; Ohe, Y; Oshita, F; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Sinha, BK | 1 |
| Chen, AY; Liu, LF | 1 |
| Eguchi, K; Hakusui, H; Miya, T; Mizuno, S; Morita, M; Ohe, Y; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Fujii, H; Hakusui, H; Igarashi, T; Itoh, K; Ohtsu, T; Sasaki, Y; Sudoh, K; Wakita, H; Yoshida, Y | 1 |
| Schellens, JH; Verweij, J | 1 |
| Catimel, G; Chabot, GG; Clavel, M; Cote, C; Dumortier, A; Engel, C; Gouyette, A; Guastalla, JP; Mahjoubi, M; Mathieu-Boué, A | 1 |
| Abigerges, D; Armand, JP; Bugat, R; Catimel, G; Chabot, GG; Culine, S; de Forni, M; Extra, JM; Hérait, P; Mahjoubi, M | 1 |
| Abigerges, D; Armand, JP; Chabot, GG; Gandia, D; Gouyette, A; Hérait, P | 1 |
| Beijnen, JH; Davies, BE; de Boer-Dennert, M; Maes, RA; Rosing, H; Schellens, JH; van Warmerdam, LJ; Verweij, J | 1 |
| Wall, ME; Wani, MC | 2 |
| Masuda, N | 1 |
| Saijo, N | 2 |
| Awada, A; Burris, HA; Cobb, PW; Eckardt, JR; Fields, S; Kuhn, JG; Rinaldi, DA; Smith, L; Von Hoff, DD | 1 |
| Bugat, R; Chabot, GG; Culine, S; de Forni, M; Extra, JM; Gouyette, A; Madelaine, I; Marty, ME; Mathieu-Boué, A | 1 |
| Cassidy, J | 1 |
| Eguchi, K; Kanzawa, F; Karato, A; Kubota, N; Nishio, K; Ohe, Y; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Burris, HA; Chen, SF; Eckardt, J; Fields, SM; Kuhn, JG; Rothenberg, M; Von Hoff, DD | 1 |
| Frucht, H; Goosenberg, E; Haas, NB; Halbherr, T; LaCreta, FP; O'Dwyer, PJ; Yao, KS | 1 |
| Baker, SD; Crom, WR; Heideman, RL; Jones, D; Pratt, CB; Stewart, CF | 1 |
| Brennan, JM; Haas, NB; Hudes, GR; LaCreta, FP; O'Dwyer, PJ; Ozols, RF; Walczak, J | 1 |
| Bowman, L; Furman, W; Heideman, R; Kuttesch, JF; Marina, N; Ochs, J; Pratt, CB; Sandlund, JT; Santana, VM; Stewart, C | 1 |
| Chachoua, A; Hochster, H; Liebes, L; Oratz, R; Raphael, B; Sorich, J; Speyer, J; Taubes, B; Vinci, RZ; Wernz, J | 1 |
| Abigerges, D; Armand, JP; Chabot, GG; Cote, C; Da Costa, L; Fadel, E; Gandia, D; Hérait, P | 1 |
| Potmesil, M | 1 |
| Cassidy, J; Graham, MA; Jodrell, D; Kaye, SB; Workman, P | 1 |
| Burris, HA; Eckardt, JR; Hilsenbeck, SG; Kuhn, JG; Nelson, J; Rodriguez, GI; Rothenberg, ML; Smith, LS; Tristan-Morales, M; Weiss, GR | 1 |
| Beijnen, J; de Boer-Dennert, M; Hansen, H; Koier, I; Lund, B; Planting, A; Rosing, H; Verweij, J | 1 |
| Chen, TL; Donehower, RC; Ettinger, DS; Grochow, LB; Lubejko, BG; Rock, MK; Rowinsky, EK; Sartorius, SE | 1 |
| Creemers, GJ; Lund, B; Verweij, J | 1 |
| Kohno, K; Kuwano, M; Matsuo, K; Sato, S; Tanimura, H; Uchiumi, T; Yamada, Y | 1 |
| Furue, H | 1 |
| Arbuck, SG; Cheson, BD | 1 |
| Ames, MM; Balis, FM; Blaney, SM; Cole, DE; Craig, C; Hammond, D; Krailo, M; Poplack, DG; Reaman, G; Reid, JM | 1 |
| Kojima, A; Saijo, N; Shinkai, T | 1 |
| Donehower, RC; Slichenmyer, WJ | 1 |
| Fukuoka, M | 1 |
| Creemers, GJ; de Boer-Dennert, M; Gerrits, CJ; Harteveld, M; Kunka, R; Marijnen, Y; Planting, AS; Schellens, JH; Selinger, K; Verweij, J; Wissel, P | 1 |
| Rothenberg, ML | 3 |
| Armand, JP | 1 |
| Bowling, MK; Donehower, RC; Grochow, LB; Kaufmann, SH; Peereboom, D; Rowinsky, EK; Sartorius, SE | 1 |
| Allegra, C; Arbuck, S; Chen, A; Corse, W; Dahut, W; Grem, J; Grollman, F; Hamilton, JM; Harold, N; Liang, M; Lieberman, R; Nakashima, H; Sorensen, M; Takimoto, C | 1 |
| Armand, JP; Couteau, C; Goncalves, E; Terret, C; Yakendji, K | 1 |
| Gupta, E; Mick, R; Ratain, MJ; Vokes, EE | 1 |
| Nakaya, K | 1 |
| Ogawa, M | 2 |
| Dancey, J; Eisenhauer, EA | 1 |
| Rivory, LP; Robert, J | 1 |
| Aureche, C; Depee, S; Selinger, K; Smith, G | 1 |
| Hanauske, AR | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N | 1 |
| O'Reilly, S; Rowinsky, EK | 1 |
| Crom, WR; Furman, WL; Gajjar, A; Heideman, RL; Houghton, PJ; Meyer, WH; Pratt, CB; Stewart, CF; Zamboni, WC | 1 |
| Bell, B; Dryer, ZA; Grier, H; Kurtzberg, J; Pratt, CB; Santana, VM; Stewart, CF; Tubergen, DG; Vietti, TJ; Winick, N; Zamboni, WC | 1 |
| Boothman, DA; Kinsella, TJ; Lamond, JP; Wang, M | 1 |
| Berkery, R; Dietz, A; Eng, M; Kanowitz, J; Kelsen, DP; Kemeny, NE; Locker, P; Saltz, LB; Schaaf, L; Spriggs, D; Staton, BA; Steger, C | 1 |
| Abigerges, D; Armand, JP; Catimel, G; Clavel, M; Extra, YM; Marty, M | 1 |
| Rowinsky, EK | 1 |
| Dieras, V; Pouillart, P | 1 |
| Chen, TL; Donehower, RC; Ettinger, DS; Forastiere, AA; Grochow, LB; O'Reilly, S; Rowinsky, EK; Sartorius, S; Slichenmyer, W | 1 |
| Baker, SD; Bowling, MK; Chen, TL; Donehower, RC; Ettinger, DS; Forastiere, AA; Grochow, LB; Kaufmann, SH; Peereboom, D; Rowinsky, EK; Sartorius, SE | 1 |
| Mani, S; Ratain, MJ | 1 |
| Bryant, M; Eder, JP; Grossbard, M; Huberman, M; Hurwitz, S; Kinchla, N; Kufe, DW; Lynch, T; Rodriguez, D; Rubin, E; Schnipper, L; Shapiro, C; Shulman, L; Stone, R; Supko, J; Toppmeyer, D; Vosburg, E; Xu, G | 1 |
| Armand, JP; Couteau, C; Rixe, O; Terret, C | 1 |
| Allegra, CJ; Arbuck, SG; Cantilena, LR; Chen, AP; Dahut, W; Grem, JL; Hamilton, JM; Harold, N; Liang, MD; Lieberman, R; Nakashima, H; Takimoto, CH | 1 |
| Anderson, S; Beidler, D; Belliveau, D; Burtness, BA; Cheng, YC; Fedele, J; Flynn, SD; Murren, JR; Pizzorno, G; Tocino, I; Zelterman, D | 1 |
| Burris, HA; Muggia, FM | 1 |
| Arioka, H; Nishio, K; Saijo, N | 1 |
| Abigerges, D; Armand, JP; Bugat, R; Catimel, G; Extra, JM; Hérait, P; Mahjoubi, M; Marty, M; Merrouche, Y; Suc, E | 1 |
| Broom, C; Burris, HA; Creemers, GJ; Eckardt, JR; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; Verweij, J; Von Hoff, DD | 1 |
| Heuser, A; Sauer, R | 1 |
| Furukawa, M; Harada, T; Kuwano, M; Tanaka, T | 1 |
| Berger, NA; Whitacre, CM | 1 |
| Allegra, CJ; Arbuck, SG; Band, RA; Cantilena, LR; Chen, AP; Dahut, W; Grem, JL; Hamilton, JM; Harold, N; Liang, MD; Lieberman, R; Marino, MT; Nakashima, H; Takimoto, CH | 1 |
| Gupta, E; Lestingi, TM; Mick, R; Ramirez, J; Ratain, MJ; Vokes, EE; Wang, X | 1 |
| Lee, KH; Morris-Natschke, SL; Wang, HK | 1 |
| Csóka, K; Dhar, S; Fridborg, H; Jonsson, E; Larsson, R; Nygren, P; Sundström, C | 1 |
| Loos, WJ; Nooter, K; Schellens, JH; Sparreboom, A; Stoter, G; Verweij, J | 1 |
| Andoh, T | 1 |
| Creemers, GJ; de Boer-Dennert, M; DePee, S; Gerrits, CJ; Harteveld, M; Planting, AS; Pritchard, JF; Schellens, JH; Verweij, J; Wissel, P | 1 |
| de Jonge, MJ; Gerrits, CJ; Schellens, JH; Stoter, G; Verweij, J | 1 |
| Kaye, SB; Vasey, PA | 1 |
| Ahmed, AE; Giovanella, BC; Jacob, S; Kozielski, AJ; Liehr, JG; Stehlin, JS | 1 |
| Edwards, CL; Ende, K; Freedman, RS; Giovanella, BC; Kavanagh, JJ; Kudelka, AP; Natelson, EA; Stehlin, JS; Verschraegen, CF | 1 |
| Eisenhauer, EA; Feld, R; Firby, PS; Goldberg, RA; Manzo, J; Michael, M; Moore, MJ; Oza, AM; Siu, LL; Thiessen, JJ; Wainman, N | 1 |
| Bryant, M; Eder, JP; Kufe, DW; Lynch, T; Shulman, LN; Supko, JG; Vosburgh, E; Xu, G | 1 |
| Baker, SD; Burke, TG; Burris, HA; DePee, S; Eckardt, JR; Eckhardt, SG; Fields, S; Kuhn, JG; Kunka, R; Littlefield, D; Rodriguez, G; Rothenberg, ML; Rowinsky, EK; Smith, L; Thurman, A; Von Hoff, DD; Warner, DL; White, L; Wissel, P | 1 |
| Crystal, RG; Hackett, NR; Kojima, A; Ohwada, A | 1 |
| Arbuck, SG; Kieffer, LV; Takimoto, CH | 1 |
| Boland, I; Cappelli, C; Gouyette, A; Imadalou, K; Lucchi, E; Morizet, J; Pein, F; Pondarré, C; Santos, A; Thomas, C; Vassal, G | 1 |
| Fleming, GF; Iyer, L; Janisch, L; Mani, S; Ratain, MJ; Schilsky, RL; Wang, X | 1 |
| Rowinsky, EK; Siu, LL | 1 |
| Bernstein, M; Blaney, S; Casto, DT; Dubowy, R; Grier, H; Kretschmar, C; Langevin, AM; Pratt, C; Thomas, PJ; Vietti, T; Weitman, SD | 1 |
| Jimbo, T; Kumazawa, E; Ochi, Y; Tohgo, A | 1 |
| de Jonge, MJ; Loos, WJ; Nooter, K; Porro, MG; Punt, CJ; Sparreboom, A; Verweij, J | 1 |
| Rosen, LS | 1 |
| Arbuck, SG; Takimoto, CH | 1 |
| Abang, AM | 1 |
| Armand, JP; Canal, P; Haaz, MC; Lokiec, F; Rivory, LP; Robert, J | 1 |
| Bartel, S; Bharti, A; Hurwitz, S; Levy, S; Lynch, C; Rosowsky, A; Rubin, E; Toppmeyer, D; Trites, D; Wood, V | 1 |
| Alden, M; Beranek, P; Cassidy, J; DeMaria, D; Depee, S; Kaye, S; Kunka, R; Littlefield, D; O'Dwyer, P; Paz-Ares, L; Reilly, D; Twelves, C; Wissel, P | 1 |
| Albanese, P; Elfring, GL; Eng, M; Hanover, CK; Ilson, D; Kanowitz, J; Kelsen, D; Kemeny, N; Miller, LL; Saltz, LB; Schaaf, LJ; Schwartz, GK; Semple, D; Spriggs, D; Steger, C | 1 |
| Muggia, FM; O'Leary, J | 1 |
| Pommier, Y; Pourquier, P | 1 |
| Canal, P; Chabot, GG; Lokiec, F; Robert, J | 1 |
| Cottu, PH; Espie, M; Extra, JM; Lerebours, F; Marty, M | 1 |
| Armand, JP; Boige, V; Raymond, E | 1 |
| Armand, JP; Couteau, C | 1 |
| Drengler, RL; Elfring, GL; Hammond, LA; Hodges, S; Kraynak, MA; Kuhn, JG; Locker, PK; Miller, LL; Rodriguez, GI; Rothenberg, ML; Schaaf, LJ; Staton, BA; Stephenson, JA; Villalona-Calero, MA; Von Hoff, DD | 1 |
| de Bruijn, P; de Jonge, MJ; Loos, WJ; Mathijssen, RH; Nooter, K; Sparreboom, A; Stoter, G; van Alphen, RJ; Vernillet, L; Verweij, J | 1 |
| Dallaire, BK; de Jonge, MJ; Loos, WJ; Sparreboom, A; Verweij, J | 1 |
| DeMaria, D; Grochow, LB; Kaye, SB; McDonald, A; O'Dwyer, PJ; Paz-Ares, L; Selinger, K; Sludden, J; Stevenson, JP; Twelves, C; Wissel, P | 1 |
| Candalh, E; Kramar, A; Lebecq, A | 1 |
| Gilbert, BE; Giovanella, BC; Knight, V; Koshkina, NV; Waldrep, JC | 1 |
| Chen, AY; Choy, H; Rothenberg, ML | 1 |
| Bowman, LC; Furman, WL; Hoffer, FA; Houghton, PJ; Ma, MK; Meyer, WH; Pappo, AS; Poquette, CA; Pratt, CB; Santana, VM; Stewart, CF; Walter, AW; Zamboni, WC | 1 |
| Beijnen, JH; Gruia, G; Herben, VM; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; Vernillet, L | 1 |
| Beijnen, JH; Herben, VM; Hillebrand, MJ; Lieverst, J; Porro, MG; Schellens, JH; Schoemaker, NE; Schot, M; ten Bokkel Huinink, WW; van Gijn, R | 1 |
| Dallaire, BK; de Jonge, MJ; Gelderblom, AH; Loos, WJ; Planting, AS; Punt, CJ; Sparreboom, A; van Beurden, V; van der Burg, ME; van Maanen, LW; Verweij, J; Wagener, DJ | 1 |
| Fukuda, M; Kawabata, S; Kinoshita, A; Kohno, S; Nakatomi, K; Noguchi, Y; Oka, M; Soda, H; Takatani, H; Terashi, K; Tsukamoto, K; Tsurutani, J | 1 |
| Allegra, CJ; Arbuck, SG; Band, RA; Berger, NA; Berger, SJ; Chen, AP; Cottrell, J; Flemming, D; Gosky, DM; Grem, JL; Guemei, A; Hamilton, JM; Harold, N; Hehman, H; Hirota, H; Ismail, AS; Llorens, V; Monahan, BP; Morrison, G; Quinn, M; Shapiro, JD; Takimoto, CH; Wright, J | 1 |
| Dupuy, JL; Gaulier, JM; Lacassie, E; Lachâtre, F; Lachâtre, G; Marquet, P; Ragot, S; Rousseau, A | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Hanson, LJ; Kastrissios, H; Klein, CE; Pitot, HC; Reid, JM; Rubin, J; Sloan, JA | 1 |
| Abad, T; Balcells, M; Dominguez, MS; Dorado, JF; García López, JL; Moyano, AJ; Nogué, M; Seguí, MA; Urruticoechea, L | 1 |
| Baker, DS; Bombardt, PA; Cathcart, KS; Compton, LD; Feenstra, KL; Johnson, MG; Lord, RS; Miller, LL; Pearson, LK; Pesheck, CV; Sams, JP; Schaaf, LJ; Slatter, JG; Verburg, MT | 1 |
| Furman, WL; Hanna, SK; Houghton, PJ; Ma, MK; Radomski, KM; Santana, VM; Smith, AK; Stewart, CF; Zamboni, WC | 1 |
| Boige, V; Cresteil, T; Deroussent, A; Gouyette, A; Pein, F; Raymond, E; Risse, ML; Santos, A; Vassal, G; Vernillet, L; Zanetta, S | 1 |
| Fukuoka, M; Nakagawa, K | 1 |
| Burtness, BA; Cheng, Y; DiStasio, SA; Leffert, JJ; Li, X; McKeon, A; Murren, JR; Peccerillo, K; Pizzorno, G | 1 |
| Ishikawa, N; Isobe, T; Oguri, T | 1 |
| Coyle, J; De Jager, RL; Drengler, R; Eckhardt, SG; Geyer, CE; Hammond, LA; Johnson, TR; Rizzo, J; Rowinsky, EK; Schwartz, G; Smetzer, L; Tolcher, A; Von Hoff, DD | 1 |
| Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH | 1 |
| Furman, W; Houghton, PJ; Radomski, K; Rodriguez-Galindo, C; Santana, VM; Stewart, CF | 1 |
| Dutcher, JP; Marcoullis, G; Novik, Y; O'Boyle, K; Secco, C; Wiernik, PH | 1 |
| Armand, JP; Bruno, R; Couteau, C; Ducreux, M; Lebecq, A; Lefresne-Soulas, F; Lokiec, F; Risse, ML; Riva, A; Rougier, P; Ruffié, P | 1 |
| Dhar, S; Graf, W; Jonsson, B; Jonsson, E; Larsson, R; Nygren, P | 1 |
| Haller, D; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W | 1 |
| Armand, JP; Boige, V; Ducreux, M; Faivre, S; Gatineau, M; Meely, K; Mekhaldi, S; Pautier, P; Raymond, E; Rixe, O | 1 |
| Hoff, PM; Pazdur, R; Royce, ME | 1 |
| Downey, A; Hamilton, A; Hochster, H; Hornreich, G; Liebes, L; Muggia, F; Potmesil, M; Sorich, J; Wasserstrom, H | 1 |
| Takimoto, CH; Thomas, R | 1 |
| Ahn, SK; Bang, YJ; Hong, CI; Kim, JK; Lee, JH; Lee, JM; Lim, KH | 1 |
| Abbruzzese, JL; Kavanagh, JJ; Kudelka, AP; Loyer, E; Rubin, E; Siegler, D; Verschraegen, CF; Vincent, M | 1 |
| Ajani, JA | 1 |
| Berg, SL; Bernstein, M; Blaney, S; Luchtman-Jones, L; Pratt, C; Sullivan, J; Weitman, S | 1 |
| Boushey, RP; Drucker, DJ; Yusta, B | 1 |
| Brescia, FJ; Green, MR; Rocha Lima, CM; Sherman, CA; Urbanic, JJ | 1 |
| Coyle, J; De Jager, R; Ducharme, MP; Dumas, P; Hoff, PM; Lassere, Y; Lee, JJ; Pazdur, R; Royce, ME | 1 |
| Takimoto, CH | 1 |
| Cheshire, PJ; Hanna, SK; Houghton, PJ; Kirstein, MN; Richmond, LB; Smith, AK; Stewart, CF | 1 |
| Kehrer, DF; Loos, WJ; Soepenberg, O; Sparreboom, A; Verweij, J | 1 |
| Abbott, EA; Bendele, RA; Brown, EN; Desjardins, JP; Dihel, L; Emerson, DL; Hamilton, M; Leray, JD; Ptaszynski, M; Richardson, FC; Tomkinson, BE | 1 |
| Fujii, H; Goya, T; Igarashi, T; Itoh, K; Minami, H; Miya, T; Ohtsu, T; Sasaki, Y | 1 |
| Agrawal, S; Alford, TL; Bailey, KS; Bono, CP; Chen, SF; Dexter, DL; Hill, B; Hollister, BA; Kandimalla, ER; Knoerzer, DL; Morton, PA; Yu, D | 1 |
| de Bruijn, P; de Jonge, MJ; Kehrer, DF; Nierop, CA; Ruijgrok, EJ; Sparreboom, A; van de Schraaf, J; Verweij, J | 1 |
| Prescott, LM | 1 |
| Aiba, K; Akaza, H; Hoctin-Boes, G; Isonishi, S; Kawai, K; Konishi, T; Mikami, O; Miki, T; Noguchi, S; Ohashi, Y; Saeki, T; Saijo, N; Smith, M; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Adjei, AA; Alberts, SR; Atherton, PJ; Burch, PA; Erlichman, C; Goldberg, RM; Kaufmann, SH; Okuno, SH; Pitot, HC; Rubin, J; Sloan, J | 1 |
| Lokich, J | 1 |
| Choy, H; MacRae, R | 1 |
| Allegra, CJ; Arbuck, SG; Band, RA; Chen, AP; Corse, W; Cottrell, J; Dahut, W; Grem, JL; Hamilton, JM; Harold, N; Liang, M; Llorens, V; Monahan, BP; Shapiro, JD; Smith, JA; Takimoto, CH; Thomas, RR; Wright, J | 1 |
| Atherton, P; Erlichman, C; Pitot, HC; Reid, J; Schaaf, L; Sloan, JA | 1 |
| Fujii, H; Igarashi, T; Itoh, K; Minami, H; Oguma, T; Sasaki, Y; Tamanoi, K | 1 |
| Algazy, K; Giantonio, B; Haller, DG; Hardy, C; Kluijtmans, LA; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W; Whitehead, AS | 1 |
| Kwaan, HC; Svoboda, K; Wang, J; Weiss, I | 1 |
| Boyer, J; Ferguson, PR; Harkin, DP; Johnston, PG; Latif, T; Longley, DB; Lynch, M; Maxwell, P | 1 |
| Berg, SL; Blaney, SM; Bomgaars, L | 1 |
| Coyle, J; De Jager, RL; Ducharme, MP; Hollywood, E; Ilson, D; Kelsen, D; Kemeny, N; Kleban, S; O'Reilly, E; Saltz, LB; Schwartz, GK; Sharma, S | 1 |
| Nishiyama, M; Okamoto, R; Okamura, T; Park, JS; Sekikawa, T; Sparreboom, A; Takano, H; Tanimoto, K; Verweij, J; Yamamoto, W | 1 |
| Eckhardt, SG; Elfring, GL; Hammond, LA; Hodges, S; Kuhn, JG; Locker, PK; Miller, LL; Petit, RG; Rinaldi, DA; Rodriguez, GI; Rothenberg, ML; Schaaf, LJ; Sharma, A; Villalona-Calero, MA; von Hoff, DD | 1 |
| Wilke, H | 1 |
| Baird, A; Burg, MA; Gonzalez, AM; Jensen-Pergakes, K; Larocca, D; Ravey, P | 1 |
| Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Freund, M; Köhne, CH; Schuff-Werner, P; Steiner, M | 1 |
| Garcia-Carbonero, R; Supko, JG | 1 |
| Calleja, E; Cosetti, M; Gerald, W; Gorlick, R; Healey, JH; Huvos, AG; LaQuaglia, M; Meyers, PA; Trippett, T; Wexler, LH | 1 |
| Calvert, H; Cortes-Funes, H; Dombernowsky, P; Gamucci, T; Gore, ME; Hanauske, AR; Heinrich, B; Kaye, SB; Lehnert, M; Loos, WJ; Paridaens, R; Pavlidis, N; Roelvink, M; Schellens, JH; Selinger, K; Sessa, C; van Oosterom, AT; Verweij, J; Wanders, J; Wissel, PS | 1 |
| Aikawa, M; Dupree, K; Escandón, E; Fox, JA; Lowe, J; Sinicropi, D; Totpal, K; Xiang, H | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Sekido, Y; Shimokata, K | 1 |
| Adamson, RH; Mead, JA; Sieber, SM | 1 |
| Carter, SK; Muggia, FM; Rozencweig, M; Slavik, M | 1 |
| Taylor, H; Wall, ME; Wani, MC | 1 |
| Burris, HA; Kuhn, JG; Rothenberg, ML; Von Hoff, DD | 1 |
| Kaye, SB; Schwartsmann, G; Workman, P | 1 |
| Diasio, RB; Stagg, MP | 1 |
| Giovanella, BC; Hinz, HR; Kozielski, AJ; Potmesil, M; Silber, R; Stehlin, JS | 1 |
| Furue, H; Hasegawa, K; Hattori, T; Niitani, H; Ohta, K; Taguchi, T; Wakui, A | 1 |
| Bergevin, PR; Blom, J; Tormey, DC | 1 |
| Brockman, RW | 1 |
| Delaunay, J; Schapira, G | 1 |
| Allen, LM; Creaven, PJ; Muggia, FM | 1 |
| Cohen, MH; Creaven, PJ; Hansen, HH; Muggia, FM; Selawry, OS | 1 |
177 review(s) available for camptothecin and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; DNA Topoisomerases, Type II; Drug Design; HSP90 Heat-Shock Proteins; Humans; Neoplasms; Topoisomerase II Inhibitors; Tubulin Modulators | 2020 |
Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.
Topics: Animals; Cardiovascular Diseases; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Molecular Targeted Therapy; Neoplasms; Nervous System Diseases | 2021 |
A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Neoplasms | 2021 |
Structural Modification Endows Small-Molecular SN38 Derivatives with Multifaceted Functions.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Neoplasms; Solubility | 2023 |
Camptothecin-based prodrug nanomedicines for cancer therapy.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Nanomedicine; Nanoparticles; Neoplasms; Prodrugs | 2023 |
Trastuzumab Deruxtecan: First Approval.
Topics: Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; Drug Approval; Humans; Immunoconjugates; Neoplasms; Topoisomerase I Inhibitors; Trastuzumab | 2020 |
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Camptothecin; Cell Adhesion Molecules; Clinical Trials as Topic; Humans; Immunoconjugates; Neoplasms; Treatment Outcome | 2020 |
Targeting HER2 expression in cancer: New drugs and new indications.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Carcinogenesis; Humans; Immunoconjugates; Mutation; Neoplasms; Receptor, ErbB-2; Trastuzumab | 2021 |
Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Topics: Animals; Antineoplastic Agents, Immunological; Camptothecin; Clinical Trials as Topic; Humans; Immunoconjugates; Neoplasms; Receptor, ErbB-2; Trastuzumab | 2021 |
Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise.
Topics: Antineoplastic Agents, Phytogenic; Camptotheca; Camptothecin; Cell Survival; Drug Carriers; Humans; Neoplasms; Structure-Activity Relationship; Topoisomerase I Inhibitors; World Health Organization | 2021 |
An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Dacarbazine; Humans; Irinotecan; Neoplasms; Temozolomide; Vincristine | 2021 |
Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy.
Topics: Animals; Antigens, CD; Antineoplastic Agents; B7 Antigens; B7-H1 Antigen; Camptothecin; CTLA-4 Antigen; Diterpenes; Epoxy Compounds; Flavonoids; Hepatitis A Virus Cellular Receptor 2; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Isothiocyanates; Lymphocyte Activation Gene 3 Protein; Mice; Neoplasms; Phenanthrenes; Phytochemicals; Plant Extracts; Programmed Cell Death 1 Receptor; Receptors, Immunologic; Saponins; Sulfoxides; Terpenes; Tumor Microenvironment | 2021 |
Sacituzumab govitecan: an antibody-drug conjugate.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Diarrhea; Female; Humans; Immunoconjugates; Irinotecan; Neoplasms; Neutropenia; Urologic Neoplasms | 2017 |
Silicon-containing analogs of camptothecin as anticancer agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Humans; Molecular Structure; Neoplasms; Silicon | 2018 |
A Review on Camptothecin Analogs with Promising Cytotoxic Profile.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptotheca; Camptothecin; Cell Proliferation; Humans; Molecular Structure; Neoplasms | 2018 |
The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Camptothecin; Cell Line, Tumor; Drug Development; Genes, erbB-2; Humans; Immunoconjugates; Molecular Targeted Therapy; Neoplasms; Topoisomerase I Inhibitors; Trastuzumab | 2019 |
Camptothecin resistance in cancer: insights into the molecular mechanisms of a DNA-damaging drug.
Topics: Animals; Antineoplastic Agents; Blood Proteins; Camptothecin; DNA; DNA Topoisomerases, Type I; Down-Regulation; Drug Resistance, Neoplasm; Humans; MicroRNAs; Neoplasms; Neoplastic Stem Cells | 2013 |
Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents.
Topics: Antineoplastic Agents; Area Under Curve; Camptothecin; Humans; Liposomes; Neoplasms | 2014 |
Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Delivery Systems; Humans; Irinotecan; Nanomedicine; Neoplasms; Prodrugs | 2013 |
Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
Topics: Age Factors; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Humans; Irinotecan; Neoplasms; Obesity; Oxonic Acid; Patient Selection; Polypharmacy; Renal Insufficiency; Tegafur | 2014 |
UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic | 2014 |
Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients.
Topics: Alleles; Amino Acid Sequence; Asian People; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Molecular Sequence Data; Neoplasms; Neutropenia; Polymorphism, Single Nucleotide; Topoisomerase I Inhibitors | 2014 |
The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Survival Analysis | 2014 |
Progress of drug-loaded polymeric micelles into clinical studies.
Topics: Antineoplastic Agents; Camptothecin; Delayed-Action Preparations; Drug Carriers; Epirubicin; Humans; Irinotecan; Micelles; Neoplasms; Paclitaxel; Platinum Compounds; Polymers | 2014 |
An overview on the development of new potentially active camptothecin analogs against cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Drug Discovery; Humans; Neoplasms; Topoisomerase I Inhibitors | 2014 |
Role of ABC transporters in fluoropyrimidine-based chemotherapy response.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport; Camptothecin; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Humans; Leucovorin; Neoplasms; Organoplatinum Compounds; Tegafur | 2015 |
Challenges in SN38 drug delivery: current success and future directions.
Topics: Animals; Camptothecin; Chemistry, Pharmaceutical; Drug Delivery Systems; Humans; Immunoconjugates; Irinotecan; Nanoparticles; Neoplasms; Prodrugs; Solubility | 2015 |
Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Camptothecin; Cisplatin; Doxorubicin; Humans; Irinotecan; Neoplasms; Paclitaxel; Polyethylene Glycols; Treatment Outcome | 2016 |
Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes.
Topics: Antineoplastic Agents; Camptothecin; Cell Survival; DNA Damage; DNA Topoisomerases, Type I; Drug Carriers; Humans; Nanostructures; Neoplasms; Organometallic Compounds | 2016 |
The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice.
Topics: Animals; Antineoplastic Agents; Camptothecin; Doxorubicin; Drug Interactions; Gene Expression; Hepatocytes; Humans; Inactivation, Metabolic; Irinotecan; Liver; Liver-Specific Organic Anion Transporter 1; Methotrexate; Mice; Mice, Transgenic; Neoplasms; Niacinamide; Organic Cation Transport Proteins; Phenylurea Compounds; Platinum Compounds; Sorafenib; Taxoids | 2016 |
Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.
Topics: Antineoplastic Agents; Asian People; ATP-Binding Cassette Transporters; Camptothecin; Docetaxel; Doxorubicin; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic; Solute Carrier Proteins; Taxoids; Treatment Outcome; White People | 2016 |
Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Camptothecin; Clinical Trials as Topic; Cyclophosphamide; Epithelial Cell Adhesion Molecule; Humans; Irinotecan; Neoplasms; Neoplastic Cells, Circulating; Reproducibility of Results; Software; Specimen Handling; Treatment Outcome | 2016 |
Pharmaceutical Investigation for Individualized and Optimal Cancer Pharmacotherapy.
Topics: Antineoplastic Agents; Camptothecin; Drug Monitoring; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Outpatients; Pharmacy Service, Hospital; Polymorphism, Genetic; Precision Medicine | 2016 |
The long story of camptothecin: From traditional medicine to drugs.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptotheca; Camptothecin; DNA Topoisomerases, Type I; Humans; Medicine, Traditional; Neoplasms; Structure-Activity Relationship | 2017 |
Clinical and pharmacogenetic factors associated with irinotecan toxicity.
Topics: Adult; Age Distribution; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacogenetics; Pharmacology, Clinical; Risk Assessment; Sex Distribution; Survival Analysis; Treatment Outcome | 2008 |
Diflomotecan, a promising homocamptothecin for cancer therapy.
Topics: Animals; Camptothecin; Clinical Trials as Topic; Humans; Neoplasms; Treatment Outcome | 2009 |
Novel camptothecin derivatives as topoisomerase I inhibitors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Drug Design; Enzyme Inhibitors; Humans; Neoplasms; Patents as Topic; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2009 |
DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.
Topics: Camptothecin; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Neoplasms; Topoisomerase I Inhibitors | 2009 |
Recent development in nano-sized dosage forms of plant alkaloid camptothecin-derived drugs.
Topics: Animals; Camptothecin; Clinical Trials as Topic; Drug Delivery Systems; Humans; Neoplasms; Patents as Topic | 2009 |
Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Cyclodextrins; Delayed-Action Preparations; Drug Design; Half-Life; Humans; Nanoparticles; Neoplasms; Neoplasms, Experimental | 2009 |
XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Delayed-Action Preparations; Humans; Irinotecan; Neoplasms; Polymers; Prodrugs; Topoisomerase I Inhibitors | 2009 |
Cancer therapies utilizing the camptothecins: a review of the in vivo literature.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Disease Models, Animal; Humans; Neoplasms | 2010 |
Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Diarrhea; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Polymorphism, Genetic | 2010 |
Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect.
Topics: Animals; Camptothecin; Capillary Permeability; Clinical Trials as Topic; Drug Evaluation, Preclinical; Extravasation of Diagnostic and Therapeutic Materials; Humans; Irinotecan; Micelles; Neoplasms | 2011 |
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP2D6; ErbB Receptors; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Pharmacogenetics; Tamoxifen | 2011 |
Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome).
Topics: Animals; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Crigler-Najjar Syndrome; Diagnosis, Differential; Genetic Predisposition to Disease; Genetic Variation; Gilbert Disease; Glucuronosyltransferase; Humans; Hyperbilirubinemia, Hereditary; Irinotecan; Jaundice, Chronic Idiopathic; Neoplasms | 2010 |
Clinical development of new formulations of cytotoxics in solid tumors.
Topics: Aminopterin; Anthracyclines; Antineoplastic Agents; Camptothecin; Chemistry, Pharmaceutical; Folic Acid Antagonists; Humans; Irinotecan; Neoplasms; Paclitaxel; Topoisomerase I Inhibitors | 2012 |
Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Biomarkers, Pharmacological; Camptothecin; Diarrhea; Genetic Association Studies; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Neoplasms; Neutropenia | 2012 |
Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Irinotecan; Molecular Targeted Therapy; Neoplasms; Signal Transduction; src-Family Kinases; Topoisomerase I Inhibitors; Up-Regulation | 2013 |
Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
Topics: Animals; Camptothecin; DNA Breaks, Double-Stranded; DNA Repair; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Humans; Inhibitor of Apoptosis Proteins; Neoplasms; Signal Transduction; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2013 |
[Predictive biomarkers for response to irinotecan, platinum drugs, and taxanes].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Humans; Irinotecan; Neoplasms; Platinum Compounds; Taxoids | 2012 |
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemical Phenomena; Chemistry, Physical; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2002 |
Poly(L-glutamic acid)--anticancer drug conjugates.
Topics: Anthracyclines; Antimetabolites; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; DNA; Drug Carriers; Drug Delivery Systems; Humans; Neoplasms; Paclitaxel; Polyglutamic Acid | 2002 |
Recent advances in topoisomerase I-targeting agents, camptothecin analogues.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Topics: Animals; Apoptosis; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; NF-kappa B; Risk Assessment; Sensitivity and Specificity; Topoisomerase I Inhibitors | 2002 |
Epithelial growth factor receptor interacting agents.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunization, Passive; Irinotecan; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Quinazolines; Recombinant Fusion Proteins; Xenograft Model Antitumor Assays | 2002 |
Cancer pharmacogenomics: current and future applications.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Dihydrouracil Dehydrogenase (NADP); Disease Models, Animal; DNA Adducts; DNA Repair; Fluorouracil; Glucuronosyltransferase; Glutathione Transferase; Humans; Irinotecan; Mercaptopurine; Methyltransferases; Neoplasms; Organoplatinum Compounds; Oxidoreductases; Pharmacogenetics; Polymorphism, Genetic; Thymidylate Synthase | 2003 |
Glucuronides in anti-cancer therapy.
Topics: Antineoplastic Agents; Camptothecin; Combined Modality Therapy; Drug Design; Glucuronidase; Glucuronides; Humans; Immunoconjugates; Immunotherapy; Neoplasms; Prodrugs | 2003 |
Pharmacogenetics of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Cytochrome P-450 Enzyme System; Glucuronosyltransferase; Humans; Inactivation, Metabolic; Irinotecan; Neoplasms; Polymorphism, Genetic; Topoisomerase I Inhibitors | 2003 |
Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Irinotecan; Isoenzymes; Membrane Proteins; Neoplasms; Prostaglandin-Endoperoxide Synthases; Radiotherapy | 2003 |
Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Evaluation; Drug Therapy, Combination; Enzyme Inhibitors; Epirubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase Inhibitors | 2003 |
Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic; Syndrome | 2003 |
[Chemotherapy-induced diarrhea].
Topics: Antidiarrheals; Antineoplastic Agents; Camptothecin; Diarrhea; Humans; Irinotecan; Neoplasms; Treatment Outcome | 2003 |
Overview of chemotherapy-induced diarrhea.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Fluorouracil; Humans; Irinotecan; Neoplasms; Nurse-Patient Relations; Nursing Assessment; Nursing Methodology Research; Octreotide; Oncology Nursing; Quality of Life | 2003 |
CKD-602. Chong Kun Dang.
Topics: Animals; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Drugs, Investigational; Humans; Neoplasms; Technology, Pharmaceutical; Topoisomerase I Inhibitors | 2003 |
Diflomotecan. Ipsen.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Drugs, Investigational; Enzyme Inhibitors; Humans; Neoplasms; Topoisomerase I Inhibitors | 2004 |
Recent anticancer cytotoxic agents.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; DNA, Neoplasm; Humans; Microtubules; Neoplasms; Prodrugs; Structure-Activity Relationship | 2004 |
Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Humans; Neoplasms; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors | 2004 |
Topoisomerase I interactive agents.
Topics: Adult; Antineoplastic Agents; Camptothecin; Child; DNA Topoisomerases, Type I; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Neoplasms | 2003 |
Cetuximab (Erbitux)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Combined Modality Therapy; ErbB Receptors; Humans; Irinotecan; Neoplasms; Treatment Outcome | 2004 |
Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Sensitivity and Specificity; Toxicogenetics | 2004 |
The impact of tumor physiology on camptothecin-based drug development.
Topics: Acidosis; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Hydrogen-Ion Concentration; Hypoxia; Male; Neoplasms | 2005 |
[Optimizing current drugs].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Camptothecin; History, 20th Century; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines | 2005 |
Gimatecan (sigma-tau industrie farmaceutiche riunite/novartis).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Chemistry, Pharmaceutical; Clinical Trials, Phase II as Topic; Humans; Molecular Structure; Neoplasms | 2005 |
Liposomal encapsulated anti-cancer drugs.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Camptothecin; Cardiomyopathies; Clinical Trials as Topic; Cytarabine; Humans; Liposomes; Neoplasms; Platinum Compounds; Vincristine | 2005 |
Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cysteine; Drug Synergism; Humans; Irinotecan; Mice; Neoplasms; Organoselenium Compounds; Rats; Selenocysteine; Selenomethionine | 2005 |
[SNPs associated with adverse effects].
Topics: Antineoplastic Agents; Camptothecin; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide | 2005 |
Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Drug Design; Drug Resistance, Neoplasm; Humans; Models, Molecular; Neoplasm Proteins; Neoplasms | 2006 |
Role of pharmacogenetics in irinotecan therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Camptothecin; Forecasting; Humans; Irinotecan; Multidrug Resistance-Associated Protein 2; Neoplasms; Pharmacogenetics; Polymorphism, Genetic | 2006 |
Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Cell Membrane; Drug Design; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Neoplasms; Topoisomerase I Inhibitors | 2006 |
Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Humans; Neoplasms; Podophyllotoxin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2006 |
Administration of anti-EGFR therapy: a practical review.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Clinical Protocols; Decision Trees; Drug Monitoring; ErbB Receptors; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Nursing Assessment; Oncology Nursing; Risk Assessment; Risk Factors | 2006 |
Individualizing cancer chemotherapy.
Topics: Camptothecin; Enzyme Inhibitors; Genetic Testing; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Neutropenia; Toxicogenetics | 2006 |
Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dacarbazine; DNA Adducts; DNA Methylation; DNA Topoisomerases, Type I; Drug Administration Schedule; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Guanine; Humans; Irinotecan; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Organoplatinum Compounds; Prognosis; Promoter Regions, Genetic; Temozolomide; Topoisomerase I Inhibitors | 2006 |
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
Topics: Camptothecin; Dihydrouracil Dehydrogenase (NADP); Genotype; Glucuronosyltransferase; Humans; Irinotecan; Mercaptopurine; Methyltransferases; Neoplasms; Pharmacogenetics; Treatment Outcome | 2006 |
Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Biological Assay; Camptothecin; Gene Frequency; Genotype; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Models, Genetic; Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Technology, Pharmaceutical | 2006 |
Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Models, Biological; Neoplasms; Pharmacogenetics; Polymorphism, Genetic | 2006 |
Topoisomerase I inhibitors: camptothecins and beyond.
Topics: Antineoplastic Agents; Camptothecin; DNA Damage; DNA Repair; DNA Replication; Enzyme Inhibitors; Humans; Neoplasms; Topoisomerase I Inhibitors | 2006 |
Mechanisms of cellular resistance to camptothecins.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Camptothecin; Drug Design; Drug Resistance, Neoplasm; Humans; Neoplasms | 2006 |
Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Neoplasms; Pharmacogenetics; Polymorphism, Genetic | 2006 |
Insights, challenges, and future directions in irinogenetics.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Asian People; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Liver; Neoplasms; Pharmacogenetics; Phenotype; Polymorphism, Genetic | 2007 |
Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blood Proteins; Camptothecin; DNA Topoisomerases, Type I; Humans; Neoplasms | 2007 |
UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic | 2007 |
Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Medicine, Chinese Traditional; Neoplasms; Pharmacogenetics; Pharmacognosy | 2007 |
Optimizing combination chemotherapy by controlling drug ratios.
Topics: Animals; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Synergism; Drug Therapy, Combination; Humans; Irinotecan; Liposomes; Neoplasms | 2007 |
[Are antiangiogenic antibodies universal for solid tumor?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fluorouracil; Humans; Hypertension; Kidney Neoplasms; Leucovorin; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2007 |
[Research advance of nanometric traditional Chinese herbal drugs for cancer treatment].
Topics: Arsenic Trioxide; Arsenicals; Camptothecin; Drug Carriers; Drugs, Chinese Herbal; Humans; Nanoparticles; Nanotechnology; Neoplasms; Oxides | 2007 |
Recent patents therapeutic agents for cancer.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Neoplasms; Organoplatinum Compounds; Patents as Topic; Podophyllotoxin; Taxoids | 2006 |
UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Gene Frequency; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Neoplasm Metastasis; Neoplasms; Neutropenia; Polymorphism, Genetic | 2008 |
Design, synthesis and development of novel camptothecin drugs.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Humans; Neoplasms | 2008 |
Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.
Topics: Antineoplastic Agents, Phytogenic; Atazanavir Sulfate; Bilirubin; Camptothecin; Genetic Variation; Gilbert Disease; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Irinotecan; Isoenzymes; Jaundice; Neoplasms; Oligopeptides; Pharmacogenetics; Pyridines; Risk Factors; Terminology as Topic | 2008 |
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Neutropenia; Topoisomerase I Inhibitors; Topotecan; Vomiting | 1995 |
Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Irinotecan; Neoplasms; Podophyllotoxin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1995 |
Mechanisms of resistance to topoisomerase inhibitors.
Topics: Animals; Antineoplastic Agents; Bacterial Proteins; Camptothecin; Drug Design; Drug Resistance; Escherichia coli; Fungal Proteins; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Saccharomyces cerevisiae; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1994 |
Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture.
Topics: Animals; Awards and Prizes; Camptothecin; Chemistry, Physical; Clinical Trials as Topic; Drug Screening Assays, Antitumor; History, 20th Century; Humans; Medical Oncology; Neoplasms; Neoplasms, Experimental; Paclitaxel; Societies, Medical; United States | 1995 |
[Phase III trial of new anticancer agents from a medical oncologists viewpoint].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Protocols; Clinical Trials, Phase III as Topic; Humans; Irinotecan; Neoplasms; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 1995 |
[Strategies for the overcoming of drug resistance].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance; Humans; Irinotecan; Neoplasms; Tumor Cells, Cultured | 1995 |
Chemotherapy administration: doses, infusions and choice of schedule.
Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Neoplasms | 1994 |
7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Survival; CHO Cells; Clinical Trials, Phase I as Topic; Cricetinae; DNA Topoisomerases, Type I; Drug Resistance; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Point Mutation; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1994 |
Camptothecins: from bench research to hospital wards.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neoplasms; Neoplasms, Experimental | 1994 |
Pharmacokinetics and early clinical studies of selected new drugs.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Aziridines; Camptothecin; Clinical Trials, Phase I as Topic; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Neoplasms; Suramin; Topotecan | 1993 |
Topoisomerase I inhibitors: topotecan and irenotecan.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Resistance; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1994 |
DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.
Topics: Antineoplastic Agents; Binding Sites; Camptothecin; Cell Differentiation; DNA Repair; Drug Design; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1993 |
[Topoisomerase inhibitors developing in Japan].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzopyrans; Camptothecin; Diketopiperazines; Glycosides; Humans; Irinotecan; Neoplasms; Phenazines; Piperazines; Razoxane; Topotecan | 1993 |
Recent clinical advances with camptothecin analogues.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Topotecan | 1995 |
[Current status and problems in clinical trial for new anticancer drug in Japan].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Informed Consent; Irinotecan; Japan; Neoplasms | 1996 |
CPT-11: an original spectrum of clinical activity.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Topoisomerase I Inhibitors | 1996 |
CPT-11: clinical experience in phase I studies.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors | 1996 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
[On the novel differentiation-apoptosis inducers in tumor cells].
Topics: Animals; Antineoplastic Agents; Apoptosis; Bufanolides; Camptothecin; Cell Differentiation; Etoposide; Humans; Neoplasms; Sodium-Potassium-Exchanging ATPase; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1996 |
[Chemotherapy of solid tumor].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Paclitaxel; Survival Rate | 1996 |
Current perspectives on camptothecins in cancer treatment.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1996 |
Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Humans; Neoplasms | 1995 |
The development of new chemotherapeutic agents.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Neoplasms; Pemetrexed; Quinazolines; Thiophenes; Trimetrexate | 1996 |
Irinotecan (CPT-11): pharmacology and clinical applications.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Neoplasms, Experimental | 1996 |
The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms | 1996 |
Topoisomerase I interactive drugs in children with cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Child; DNA Damage; DNA Topoisomerases, Type I; Humans; Mice; Neoplasms; Topotecan | 1996 |
The suitability of selected new anticancer agents for infusional therapy and the effects of others on infusional therapy practices.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dihydrouracil Dehydrogenase (NADP); Drug Delivery Systems; Enzyme Inhibitors; Fluorouracil; Humans; Infusions, Parenteral; Neoplasms; Oxidoreductases; Topoisomerase I Inhibitors; Uracil | 1995 |
Infusional chemotherapy with new drugs: taxanes, vinorelbine and topoisomerase I inhibitors.
Topics: Antineoplastic Agents; Camptothecin; Drug Delivery Systems; Enzyme Inhibitors; Humans; Infusions, Parenteral; Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Vinblastine; Vinorelbine | 1995 |
Promising new agents in oncologic treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Mice; Microtubules; Neoplasm Proteins; Neoplasms; Paclitaxel; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan | 1996 |
The current status of irinotecan (CPT-11) in the United States.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Approval; Female; Humans; Irinotecan; Neoplasms; United States; United States Food and Drug Administration | 1996 |
CPT-11. The European experience.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Europe; Humans; Irinotecan; Neoplasms | 1996 |
Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecin injection) in Japan.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Irinotecan; Japan; Neoplasms | 1996 |
Clinical development of topoisomerase-interactive drugs.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Neoplasms; Podophyllotoxin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1994 |
[Apoptosis and chemosensitivity].
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cisplatin; Drug Screening Assays, Antitumor; Genes, bcl-2; Humans; Irinotecan; Neoplasms; Tumor Cells, Cultured | 1997 |
[Topoisomerase I inhibitor with potential radiosensitizing effect].
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Child; Clinical Trials as Topic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topoisomerase I Inhibitors; Topotecan | 1997 |
[DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Mutation; Neoplasms; Teniposide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1997 |
Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents.
Topics: Animals; Antineoplastic Agents; Camptothecin; Chemistry, Pharmaceutical; Computer-Aided Design; Drug Design; Humans; Lethal Dose 50; Molecular Structure; Neoplasms; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1997 |
[Inhibitors of DNA topoisomerases].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Enzyme Inhibitors; Humans; Neoplasms; Nogalamycin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1997 |
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1997 |
Clinical pharmacokinetics of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors | 1997 |
DNA topoisomerase I inhibitors.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Camptothecin; DNA Damage; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1997 |
Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
Topics: Animals; Camptothecin; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1998 |
Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms | 1998 |
An overview of topoisomerase I-targeting agents.
Topics: Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1998 |
The clinical pharmacology of topoisomerase I inhibitors.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Neoplasms; Topoisomerase I Inhibitors | 1998 |
Camptothecins: a review of their development and schedules of administration.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Topotecan | 1998 |
[Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
Topics: Antineoplastic Agents; Benzimidazoles; Binding Sites; Camptothecin; DNA Replication; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Intercalating Agents; Macromolecular Substances; Neoplasm Proteins; Neoplasms; Topoisomerase I Inhibitors | 1998 |
[Irinotecan pharmacokinetics].
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Blood Proteins; Body Fluid Compartments; Camptothecin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Half-Life; Humans; Inactivation, Metabolic; Irinotecan; Liver; Mice; Models, Biological; Neoplasm Proteins; Neoplasms; Neoplasms, Experimental; Prodrugs; Rats; Tissue Distribution; Topoisomerase I Inhibitors | 1998 |
[Clinical activity spectrum of irinotecan].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bronchial Neoplasms; Camptothecin; Carcinoma, Small Cell; Child; Clinical Trials as Topic; Digestive System Neoplasms; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Hematologic Neoplasms; Humans; Irinotecan; Male; Neoplasm Proteins; Neoplasms; Remission Induction; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
[Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Hepatic Artery; Humans; Inactivation, Metabolic; Injections, Intra-Arterial; Injections, Intravenous; Irinotecan; Neoplasm Proteins; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Topoisomerase I Inhibitors | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
Novel anticancer drugs in Japan.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Fluorouracil; Humans; Irinotecan; Japan; Neoplasms | 1999 |
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Topotecan | 1999 |
[CPT-11 (irinotecan)--evidence from molecular and pharmacological studies and clinical applications].
Topics: Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Irinotecan; Male; Neoplasms | 2000 |
Clinical use of topoisomerase I inhibitors in anticancer treatment.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Mice; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2000 |
20th-century advances in drug therapy in oncology--Part. II.
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Camptothecin; Drug Therapy; Humans; Neoplasms; Podophyllotoxin; Taxoids; Topoisomerase I Inhibitors; Vinca Alkaloids | 2000 |
Novel oral chemotherapy agents.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasms; Tegafur; Temozolomide; Uracil | 2000 |
Intraperitoneal topoisomerase-I inhibitors. Preliminary findings with 9-aminocamptothecin.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Parenteral; Neoplasms; Ovarian Neoplasms; Topoisomerase I Inhibitors | 2000 |
The clinical development of 9-aminocamptothecin.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Humans; Neoplasms | 2000 |
The evolving role of irinotecan: a broad-spectrum chemotherapeutic agent. Introduction.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors | 2000 |
Docetaxel followed by gemcitabine and irinotecan in solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2001 |
Modulation of camptothecin analogs in the treatment of cancer: a review.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Delivery Systems; Drug Synergism; Enzyme Inhibitors; Humans; Neoplasms; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2001 |
[Platinum compounds in cancer therapy--past, present, and future].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Forecasting; Humans; Irinotecan; Medical Oncology; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Platinum | 2001 |
Irinotecan and radiation in combined-modality therapy for solid tumors.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Radiotherapy, Adjuvant; Topoisomerase I Inhibitors; Uterine Cervical Neoplasms | 2001 |
The development of camptothecin analogs in childhood cancers.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Infant; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2001 |
Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Neoplasms; Topoisomerase I Inhibitors | 2002 |
Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Bone Neoplasms; Camptothecin; Child; Child, Preschool; Diarrhea; Drug Evaluation; Enzyme Inhibitors; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neuroectodermal Tumors, Primitive; New York City; Osteosarcoma; Retrospective Studies; Rhabdomyosarcoma; Sarcoma, Ewing; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
Pharmacology of antitumor agents from higher plants.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aporphines; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Etoposide; Humans; Leukemia L1210; Leukemia, Experimental; Leukemia, Lymphoid; Maytansine; Melanoma; Naphthoquinones; Nasopharyngeal Neoplasms; Neoplasms; Neoplasms, Experimental; Phenanthrenes; Structure-Activity Relationship; Teniposide; Vinblastine; Vincristine | 1976 |
Clinical trials with the topoisomerase I inhibitors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Forecasting; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1992 |
Laboratory and phase I studies of new cancer drugs.
Topics: Antineoplastic Agents; Bryostatins; Camptothecin; Docetaxel; Humans; Lactones; Macrolides; Neoplasms; Paclitaxel; Taxoids | 1992 |
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Neoplasms; Organophosphonates; Paclitaxel; Pyrazoles; Quinazolines; Sulfonylurea Compounds; Terpenes; Trimetrexate | 1990 |
Guide to the use of cancer chemotherapeutic agents.
Topics: Alkylating Agents; Allopurinol; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Asparaginase; Azaserine; Azauridine; Bleomycin; Camptothecin; Carmustine; Cell Division; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Doxorubicin; Fluorouracil; Humans; Kinetics; Neoplasms; Nitrogen Mustard Compounds; Procarbazine; Triazines; Vincristine | 1972 |
Biochemical aspects of drug combinations.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Bleomycin; Camptothecin; Cell Division; Cytarabine; Deferoxamine; Diamines; DNA, Neoplasm; Doxorubicin; Drug Therapy, Combination; Leukemia L1210; Macromolecular Substances; Mice; Neoplasms; Neoplasms, Experimental; Nitrosourea Compounds; Purine Nucleotides; Ribonucleotide Reductases; Thioguanine; Triazoles | 1974 |
264 trial(s) available for camptothecin and Neoplasms
| Article | Year |
|---|---|
A validated HPLC-MS/MS method for determination of simmitecan and its metabolite chimmitecan in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor.
Topics: Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Humans; Limit of Detection; Linear Models; Neoplasms; Reproducibility of Results; Tandem Mass Spectrometry | 2021 |
Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes.
Topics: Animals; Antibodies, Monoclonal, Humanized; Camptothecin; Humans; Immunoconjugates; Indoles; Mutation; Neoplasms; Recombinational DNA Repair; Starfish | 2022 |
A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Dacarbazine; Humans; Irinotecan; Maximum Tolerated Dose; Metformin; Neoplasm Recurrence, Local; Neoplasms; Sarcoma, Ewing; Temozolomide; Vincristine | 2023 |
Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Cyclodextrins; Drug Liberation; Female; Half-Life; Humans; Male; Middle Aged; Models, Biological; Neoplasm Staging; Neoplasms; Nitriles; Phenylthiohydantoin; Phthalazines; Piperazines; Topoisomerase I Inhibitors | 2020 |
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Adhesion Molecules; Female; Glucuronosyltransferase; Half-Life; Humans; Immunoconjugates; Immunoglobulin G; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Response Evaluation Criteria in Solid Tumors; Time Factors | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Diphenylamine; Female; Humans; Irinotecan; Male; Morpholines; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; TOR Serine-Threonine Kinases; Triazines | 2017 |
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drugs, Chinese Herbal; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Polymorphism, Genetic; Treatment Outcome; Vomiting; Young Adult | 2017 |
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Polyethylene Glycols; Prodrugs; Treatment Outcome | 2013 |
A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Camptothecin; Carboplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Endometrial Neoplasms; Female; Granisetron; Humans; Irinotecan; Logistic Models; Middle Aged; Morpholines; Neoplasms; Ovarian Neoplasms; Temperance; Treatment Outcome; Vomiting | 2013 |
A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Child; Child, Preschool; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Recurrence; Temozolomide; Vincristine; Young Adult | 2013 |
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Infusions, Intravenous; Irinotecan; Liposomes; Male; Middle Aged; Models, Biological; Neoplasms; Polyethylene Glycols | 2013 |
Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Neoplasm; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Medulloblastoma; Neoplasm Recurrence, Local; Neoplasms; Rhabdomyosarcoma; Treatment Outcome; Young Adult | 2013 |
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2013 |
A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Indoles; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Pyrroles; Thrombocytopenia; Treatment Outcome | 2013 |
Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Neoplasms; Polyethylene Glycols; RNA, Messenger; Young Adult | 2014 |
Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Remission Induction; Sirolimus; Temozolomide; Young Adult | 2014 |
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia | 2014 |
Development and validation of a sensitive LC-MS/MS method for simultaneous quantification of sinotecan and its active metabolite in human blood.
Topics: Camptothecin; Chromatography, Liquid; Drug Stability; Female; Humans; Male; Neoplasms; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2014 |
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2014 |
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.
Topics: Adolescent; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasms; Polyethylene Glycols; Treatment Outcome; Young Adult | 2014 |
Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Interactions; Female; Gefitinib; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Quinazolines; Treatment Outcome; Young Adult | 2014 |
A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients.
Topics: Administration, Cutaneous; Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Granisetron; Humans; Leucovorin; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Prospective Studies; Remission Induction; Republic of Korea; Safety; Vomiting | 2015 |
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.
Topics: Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Genotype; Glucuronosyltransferase; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Nanoparticles; Neoplasms; Pharmacogenetics; Treatment Outcome | 2015 |
Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasms | 2015 |
Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dexamethasone; Female; Humans; Irinotecan; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palonosetron; Quality of Life; Quinuclidines; Serotonin Antagonists; Treatment Outcome | 2015 |
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Adhesion Molecules; Combined Modality Therapy; Drug Monitoring; Female; Humans; Immunoconjugates; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Increased Plasma Levels of Chemoresistance-Inducing Fatty Acid 16:4(n-3) After Consumption of Fish and Fish Oil.
Topics: Academic Medical Centers; Animals; Antineoplastic Agents; Biomarkers; Camptothecin; Cell Line, Tumor; Cisplatin; Dietary Supplements; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatty Acids; Fish Oils; Fishes; Food-Drug Interactions; Health Care Surveys; Humans; Irinotecan; Mice, Inbred BALB C; Neoplasms; Netherlands; Organoplatinum Compounds; Oxaliplatin; Seafood; Surveys and Questionnaires; Tumor Burden; Up-Regulation | 2015 |
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Topics: Adenocarcinoma; Adult; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Febrile Neutropenia; Female; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Salvage Therapy; Sulfonamides; Treatment Outcome | 2015 |
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cell Cycle Proteins; DNA Repair; Female; Histones; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Nuclear Proteins; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2016 |
A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Drug Carriers; Female; Glucuronosyltransferase; Homozygote; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Micelles; Middle Aged; Neoplasms; Polymers | 2016 |
Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Camptothecin; Cisplatin; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Remission Induction; Young Adult | 2008 |
Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; DNA Adducts; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2009 |
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasms; Pyrazoles; Sulfonamides; Treatment Outcome; Young Adult | 2009 |
A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Epirubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Camptothecin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HSP90 Heat-Shock Proteins; Humans; Irinotecan; Lactams, Macrocyclic; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2008 |
Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms | 2009 |
Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Camptothecin; Drug Administration Schedule; Female; Humans; In Vitro Techniques; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2009 |
Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Floxuridine; Humans; Irinotecan; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2009 |
Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2009 |
Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.
Topics: Adult; Aged; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Liposomes; Male; Middle Aged; Neoplasms; Polyethylene Glycols | 2009 |
A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Taxoids; Treatment Outcome | 2009 |
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Camptothecin; Drug Interactions; Female; Fluorouracil; Gastrointestinal Tract; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prodrugs | 2009 |
Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Phytogenic; Body Composition; Camptothecin; Female; Humans; Infusions, Intravenous; Liposomes; Male; Middle Aged; Neoplasms; Polyethylene Glycols | 2009 |
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Child; Child, Preschool; Drug Synergism; Female; Gefitinib; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Toxicity Tests; Young Adult | 2009 |
Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Child; Child, Preschool; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms | 2009 |
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Cisplatin; Genotype; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Multidrug Resistance-Associated Protein 2; Neoplasms; Neutropenia; Organic Anion Transporters; Polymorphism, Single Nucleotide | 2010 |
A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polyethylene Glycols; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Treatment Outcome; Young Adult | 2009 |
Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Prognosis; Survival Rate | 2009 |
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasms; Temozolomide; Vincristine; Young Adult | 2010 |
A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Organosilicon Compounds; Recurrence | 2010 |
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Synergism; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polymorphism, Genetic; Pyridines; Thiosemicarbazones; Treatment Outcome | 2010 |
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyridazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Young Adult | 2010 |
Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Temozolomide; Vincristine; Young Adult | 2010 |
Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Child; Child, Preschool; Female; Humans; Irinotecan; Leukocyte Count; Male; Models, Biological; Neoplasm Recurrence, Local; Neoplasms; Neutrophils; Nonlinear Dynamics; Regression Analysis | 2010 |
Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.
Topics: Adolescent; Adult; Age Factors; Aged; Camptothecin; Cell Count; Drug Resistance; Humans; Liposomes; Middle Aged; Monocytes; Mononuclear Phagocyte System; Neoplasms; Neutrophils; Polyethylene Glycols; Topoisomerase I Inhibitors | 2011 |
Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Treatment Outcome; Young Adult | 2010 |
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Staurosporine; Young Adult | 2011 |
A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2012 |
Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Middle Aged; Nanoparticles; Neoplasms | 2010 |
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Piperidines; Protein Kinase Inhibitors; Treatment Outcome | 2010 |
Delayed elimination of SN-38 in cancer patients with severe renal failure.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Prospective Studies; Renal Dialysis; Renal Insufficiency | 2011 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Endostatins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Recombinant Proteins; Survival Rate; Taxoids; Treatment Outcome | 2010 |
A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Time Factors | 2011 |
Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cross-Over Studies; Drug Interactions; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Tumor Cells, Cultured | 2011 |
Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
Topics: Adult; Aged; Camptothecin; Female; Humans; Liposomes; Male; Middle Aged; Models, Biological; Neoplasms; Polyethylene Glycols; Topoisomerase I Inhibitors | 2012 |
Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.
Topics: Adolescent; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cefpodoxime; Ceftizoxime; Child; Child, Preschool; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Topoisomerase I Inhibitors; Young Adult | 2012 |
Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Chemistry, Pharmaceutical; Emulsions; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Succinates; Technology, Pharmaceutical; Vitamin E | 2011 |
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cross-Over Studies; Drug Interactions; Humans; Irinotecan; Neoplasms; Thalidomide | 2011 |
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2012 |
Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.
Topics: Adult; Aged; Camptothecin; DNA, Neoplasm; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Safety; Tissue Distribution | 2012 |
Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Humans; Infusions, Intravenous; Leukocyte Count; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Neoplasms; Neutrophils; Tandem Mass Spectrometry; Treatment Outcome | 2012 |
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Young Adult | 2013 |
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Female; Glucuronosyltransferase; Humans; Irinotecan; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polyethylene Glycols; Treatment Outcome | 2012 |
Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients.
Topics: Antineoplastic Agents; Camptothecin; Computer Simulation; Humans; Injections, Intravenous; Liposomes; Metabolic Clearance Rate; Models, Biological; Monocytes; Neoplasms; Polyethylene Glycols; Tissue Distribution; Topoisomerase I Inhibitors | 2012 |
Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tissue Distribution | 2013 |
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies.
Topics: Adult; Aged; Area Under Curve; Biopsy; Camptothecin; Cellulose; Cyclodextrins; Demography; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Male; Maximum Tolerated Dose; Middle Aged; Nanoparticles; Neoplasm Staging; Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Irinotecan and gemcitabine in patients with solid tumors: phase I trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Vomiting | 2002 |
Phase I trial of irinotecan and epirubicin in advanced cancer. Preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasm Staging; Neoplasms; Patient Selection; Prognosis; Survival Rate; Treatment Outcome | 2002 |
Mitomycin as a modulator of irinotecan anticancer activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Mitomycin; Neoplasm Staging; Neoplasms; Patient Selection; Prognosis; Survival Analysis; Treatment Outcome | 2002 |
Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasms; Treatment Outcome | 2002 |
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin.
Topics: Acrylamides; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Urinary Bladder Diseases | 2002 |
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Quinazolines; Thiophenes | 2002 |
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Neutropenia | 2002 |
Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms | 2002 |
Phase I study of rubitecan and gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Risk Assessment; Survival Analysis; Treatment Outcome | 2002 |
A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms | 2003 |
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polyethylene Glycols | 2003 |
Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Cisplatin; Cohort Studies; DNA Adducts; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Metabolic Clearance Rate; Neoplasms; Safety | 2003 |
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2003 |
Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.
Topics: Adenoviridae; Adenovirus E1B Proteins; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Cytokines; Female; Fluorouracil; Genetic Therapy; Humans; Immunotherapy; Infusions, Intravenous; Interleukin-2; Irinotecan; Male; Middle Aged; Neoplasms; Pilot Projects; Tumor Suppressor Protein p53; Viral Vaccines; Virus Replication | 2003 |
Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cisplatin; Cohort Studies; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2003 |
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors | 2003 |
Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2003 |
Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Temozolomide; Treatment Outcome | 2003 |
Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Evaluation; Drug Therapy, Combination; Enzyme Inhibitors; Epirubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase Inhibitors | 2003 |
A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion.
Topics: Acetamides; Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Area Under Curve; Blood Cell Count; Camptothecin; Colloids; Drug Resistance, Neoplasm; Excipients; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms | 2003 |
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasms; Time Factors | 2003 |
Population-based maximum tolerated dose of irinotecan and carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2003 |
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Epirubicin; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2003 |
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases | 2003 |
Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms | 2003 |
A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Camptothecin; Child, Preschool; Drug Administration Schedule; Humans; Infant; Infusions, Intravenous; Irinotecan; Maximum Tolerated Dose; Neoplasms; Neutropenia | 2003 |
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Irinotecan; Kidney Diseases; Liver Diseases; Male; Middle Aged; Neoplasms; Pelvis; Radiotherapy | 2003 |
Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Benzenesulfonates; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Irinotecan; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2003 |
[Preliminary study of lyophilized 10-hydroxycamptothecin in advanced or recurrent malignancies].
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Male; Middle Aged; Neoplasms; Recurrence; Treatment Outcome | 2003 |
A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2004 |
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
Topics: Administration, Oral; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Quinolones | 2004 |
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Base Pair Mismatch; Camptothecin; Cell Line, Tumor; Child; Child, Preschool; Dacarbazine; DNA Repair; Female; Humans; Immunohistochemistry; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Temozolomide; Time Factors | 2004 |
Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Genotype; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Male; Methylenetetrahydrofolate Dehydrogenase (NADP); Middle Aged; Neoplasms; Polymorphism, Genetic; Tablets; Tegafur; Treatment Outcome; Uracil | 2004 |
A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Treatment Outcome | 2004 |
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Taxoids | 2004 |
Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones; Treatment Outcome | 2004 |
A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Time Factors | 2004 |
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Cystitis; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polyvinyls | 2004 |
Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT).
Topics: Acrylamides; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Sepsis; Thrombocytopenia | 2004 |
Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2004 |
A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors.
Topics: Camptothecin; Dipeptides; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2004 |
Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin) in cancer patients.
Topics: Adsorption; Adult; Aged; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Carbon; Defecation; Diarrhea; Female; Humans; Irinotecan; Male; Microspheres; Middle Aged; Neoplasms; Oxides; Time Factors; Treatment Outcome | 2004 |
Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Male; Middle Aged; Neoplasms; Time Factors; Treatment Outcome | 2004 |
Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.
Topics: Administration, Oral; Camptothecin; Drug Administration Schedule; Humans; Neoplasms | 2004 |
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.
Topics: Adult; Aged; Anorexia; Antiemetics; Antineoplastic Agents; Benzodiazepines; Camptothecin; Cohort Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mood Disorders; Nausea; Neoplasms; Olanzapine; Organoplatinum Compounds; Time Factors; Treatment Outcome; Vomiting | 2004 |
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endpoint Determination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Half-Life; Humans; Hypnotics and Sedatives; Immunosuppressive Agents; Irinotecan; Lymphoma; Male; Middle Aged; Neoplasms; Phenobarbital | 2004 |
Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Tract; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors | 2005 |
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2005 |
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Remission Induction; Salvage Therapy; Time Factors; Topoisomerase I Inhibitors | 2005 |
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Capsules; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diarrhea; Dietary Fats; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2005 |
A phase I study of irinotecan administered on a weekly schedule in pediatric patients.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms | 2006 |
Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study.
Topics: Adult; Aged; Camptothecin; Capsules; Chemistry, Pharmaceutical; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Thrombocytopenia | 2005 |
Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids | 2005 |
A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Female; Fluorouracil; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia | 2005 |
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p21; Drug Administration Schedule; Drug Interactions; Female; Flavonoids; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Piperidines; Treatment Outcome; Tumor Suppressor Protein p53 | 2005 |
A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Infusion Pumps; Irinotecan; Leucovorin; Male; Neoplasms; Neutropenia; Pharmacogenetics; Promoter Regions, Genetic; Thymidylate Synthase; Treatment Outcome | 2005 |
A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase Inhibitors; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Pyrazoles; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Topotecan; Treatment Outcome | 2006 |
DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors.
Topics: Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Delayed-Action Preparations; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Prodrugs; Tissue Distribution; Topoisomerase I Inhibitors | 2005 |
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Diarrhea; Dipeptides; Drug Administration Schedule; Female; Glycoconjugates; Half-Life; Humans; Male; Middle Aged; Neoplasms | 2005 |
Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Camptothecin; Cross-Over Studies; Fasting; Female; Food; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms | 2006 |
Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Female; France; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Multicenter Studies as Topic; Neoplasms; Neutropenia | 2006 |
Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polyethylene Glycols; Time Factors | 2005 |
Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Floxuridine; Fluorouracil; Humans; Irinotecan; Middle Aged; Models, Biological; Molecular Structure; Neoplasm Metastasis; Neoplasms; Prodrugs; Sesquiterpenes | 2005 |
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Powders; Sensitivity and Specificity | 2006 |
Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Cefixime; Child; Child, Preschool; Chromatography, High Pressure Liquid; Diarrhea; Feces; Female; Glucuronidase; Humans; Irinotecan; Lactones; Male; Neoplasms; Severity of Illness Index | 2006 |
A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Selenomethionine; Treatment Outcome | 2006 |
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP-Binding Cassette Transporters; Camptothecin; Female; Genotype; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasms; Polymorphism, Single Nucleotide | 2006 |
A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors | 2006 |
Irinotecan for children with relapsed solid tumors.
Topics: Camptothecin; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Male; Neoplasms; Neuroblastoma; Recurrence; Remission Induction; Rhabdomyosarcoma; Tumor Burden; Wilms Tumor | 2006 |
Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Time Factors | 2006 |
Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Gastrointestinal Tract; Half-Life; Humans; Irinotecan; Male; Neoplasm Metastasis; Neoplasms | 2006 |
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Liver Diseases; Liver Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Patient Selection | 2006 |
Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Cohort Studies; Etoposide; Female; Humans; Ifosfamide; Irinotecan; Low-Level Light Therapy; Male; Methotrexate; Mouth Mucosa; Neoplasms; Nutritional Status; Oral Hygiene; Severity of Illness Index; Stomatitis; Treatment Outcome | 2007 |
Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Asia; Camptothecin; Female; Genotype; Half-Life; Haplotypes; Humans; Inactivation, Metabolic; Irinotecan; Leukocyte Count; Liver-Specific Organic Anion Transporter 1; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Organic Anion Transporters | 2006 |
Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2006 |
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Proteasome Inhibitors; Pyrazines | 2006 |
Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Microsomes, Liver; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2007 |
A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Ontario; Time Factors; Treatment Outcome | 2007 |
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Female; Half-Life; Humans; Male; Middle Aged; Neoplasms; Treatment Outcome | 2007 |
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Carboxylesterase; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2007 |
A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Dietary Supplements; Drug Interactions; Female; Glutamates; Guanine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pemetrexed; Vitamins | 2007 |
A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Administration Schedule; Enzyme Inhibitors; Europe; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Treatment Outcome | 2007 |
Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms | 2007 |
A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Small Cell; Cholangiocarcinoma; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Female; Gastrointestinal Hemorrhage; Gemcitabine; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasms | 2007 |
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Staurosporine; Topoisomerase I Inhibitors | 2008 |
Haplotypes and a novel defective allele of CES2 found in a Japanese population.
Topics: Alleles; Animals; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Carboxylesterase; Chlorocebus aethiops; COS Cells; Haplotypes; Humans; Hypersensitivity; Irinotecan; Linkage Disequilibrium; Neoplasms; Polymorphism, Single Nucleotide; Prodrugs; RNA, Messenger; Sequence Analysis, DNA | 2007 |
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Lapatinib; Leucovorin; Male; Middle Aged; Neoplasms; Quinazolines; Tandem Mass Spectrometry | 2007 |
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Lactones; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polyglutamic Acid; Solubility; Time Factors | 2007 |
Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Female; Glucuronosyltransferase; Hepatoblastoma; Humans; Infant; Irinotecan; Male; Medulloblastoma; Neoplasms; Treatment Outcome | 2007 |
A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Selenomethionine; Treatment Outcome | 2008 |
Activated charcoal to prevent irinotecan-induced diarrhea in children.
Topics: Adolescent; Antineoplastic Agents; Camptothecin; Charcoal; Child; Child, Preschool; Diarrhea; Female; Humans; Infant; Irinotecan; Male; Neoplasms; Treatment Outcome | 2008 |
Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Epothilones; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Paresthesia; Vomiting | 2008 |
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2009 |
Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Kidney; Leukemia; Liver; Metabolic Clearance Rate; Neoplasms; Platelet Count; Topoisomerase I Inhibitors; Topotecan | 1994 |
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Neutropenia; Recombinant Proteins; Salivary Gland Neoplasms; Stomach Neoplasms; Topotecan | 1994 |
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Thrombocytopenia; Topotecan; United States | 1995 |
Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Linear Models; Male; Middle Aged; Models, Biological; Neoplasms; Sampling Studies | 1995 |
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan | 1995 |
Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor.
Topics: Adult; Aged; Camptothecin; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Recombinant Proteins; Structure-Activity Relationship; Topotecan | 1993 |
Phase I study of CPT-11 and etoposide in patients with refractory solid tumors.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Treatment Outcome | 1993 |
A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Humans; Irinotecan; Japan; Kinetics; Leukopenia; Male; Middle Aged; Neoplasms; Prospective Studies | 1995 |
Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Irinotecan; Kinetics; Lactones; Male; Middle Aged; Neoplasms; Prospective Studies | 1995 |
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Alopecia; Camptothecin; Chromatography, High Pressure Liquid; Diarrhea; Drug Administration Schedule; Female; Half-Life; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasms; Prodrugs; Salvage Therapy; Treatment Outcome | 1995 |
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
Topics: Adult; Aged; Bone Marrow Diseases; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Half-Life; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Prodrugs; Treatment Outcome | 1995 |
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Gastrointestinal Diseases; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Treatment Outcome; Vomiting | 1995 |
Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps; Infusions, Intravenous; Linear Models; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neoplasms; Remission Induction; Topotecan | 1995 |
Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan | 1994 |
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia | 1994 |
Preclinical and phase I trials of topoisomerase I inhibitors.
Topics: Antineoplastic Agents; Camptothecin; Cell Line; Female; Humans; Indoles; Irinotecan; Male; Neoplasms; Pyridines; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
Clinical, pharmacokinetic and biological studies of topotecan.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Leukocyte Count; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutrophils; Topotecan | 1994 |
Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity.
Topics: Adolescent; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Chromatography, High Pressure Liquid; Female; Humans; Infusions, Intravenous; Lactones; Leukocyte Count; Male; Neoplasms; Neutrophils; Platelet Count; Topotecan | 1994 |
Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cell Count; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan | 1994 |
Phase I study of topotecan for pediatric patients with malignant solid tumors.
Topics: Adolescent; Adult; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Female; Half-Life; Hematopoiesis; Humans; Infusions, Intravenous; Male; Neoplasms; Topotecan; Treatment Outcome | 1994 |
Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Diseases; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan; Treatment Outcome | 1994 |
Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Humans; Irinotecan; Loperamide; Male; Middle Aged; Neoplasms | 1994 |
Phase I and pharmacokinetic trial of weekly CPT-11.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Humans; Irinotecan; Least-Squares Analysis; Male; Middle Aged; Neoplasms | 1993 |
Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Camptothecin; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Pancreatic Neoplasms; Remission Induction; Topoisomerase I Inhibitors; Topotecan | 1993 |
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Feasibility Studies; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Muscle Cramp; Neoplasms; Neutropenia; Thrombocytopenia; Vomiting | 1994 |
Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
Topics: Adolescent; Adult; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Female; Humans; Infant; Infusions, Intravenous; Male; Neoplasms; Time Factors; Topotecan | 1993 |
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors | 1996 |
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1996 |
Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 1996 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
Topics: Antineoplastic Agents, Phytogenic; Biliary Tract; Camptothecin; Diarrhea; Female; Humans; Irinotecan; Male; Middle Aged; Models, Biological; Neoplasms | 1996 |
Determination of GI147211 in human blood by HPLC with fluorescence detection.
Topics: Antineoplastic Agents; Biotransformation; Calibration; Camptothecin; Chromatography, High Pressure Liquid; Drug Stability; Half-Life; Humans; Hydrolysis; Infusions, Intravenous; Neoplasms; Reference Standards; Spectrometry, Fluorescence | 1995 |
Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Female; Hematopoiesis; Humans; Male; Neoplasms; Topotecan | 1996 |
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms | 1996 |
Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Survival Rate; Treatment Outcome | 1996 |
Phase I and pharmacologic study of topotecan in patients with impaired renal function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Neoplasms; Reference Values; Topotecan | 1996 |
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Synergism; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Topotecan; Tumor Cells, Cultured | 1996 |
Trials of 9-amino-20(S)-camptothecin in Boston.
Topics: Adult; Antineoplastic Agents; Boston; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Female; Humans; Leukemia; Male; Middle Aged; Neoplasms | 1996 |
Clinical pharmacology of 9-aminocamptothecin.
Topics: Adult; Antineoplastic Agents; Camptothecin; Humans; Neoplasms; Topoisomerase I Inhibitors | 1996 |
High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Thrombocytopenia | 1997 |
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Half-Life; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan | 1997 |
Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Half-Life; Humans; Male; Middle Aged; Neoplasms | 1997 |
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Camptothecin; Fatigue; Female; Humans; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Stomatitis; Thrombocytopenia; Topoisomerase I Inhibitors; Treatment Outcome; Vomiting | 1997 |
A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Area Under Curve; Camptothecin; Enzyme Inhibitors; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topoisomerase I Inhibitors | 1998 |
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Colloids; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Regression Analysis; Salvage Therapy | 1998 |
Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chemistry, Pharmaceutical; Colloids; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms | 1998 |
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 1998 |
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Female; Humans; Male; Middle Aged; Neoplasms | 1998 |
Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Male; Maximum Allowable Concentration; Neoplasms; Treatment Outcome; United States | 1998 |
Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Biological Availability; Camptothecin; Capsules; Drug Administration Schedule; Humans; Injections, Intravenous; Intestinal Absorption; Middle Aged; Neoplasms | 1998 |
Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.
Topics: Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; France; Glucuronates; Humans; Irinotecan; Metabolic Clearance Rate; Models, Biological; Neoplasms | 1997 |
A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 1995 |
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Time Factors; Topoisomerase I Inhibitors | 1998 |
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Synergism; Female; Glucuronates; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Treatment Outcome | 1998 |
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 1999 |
Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Linear Models; Male; Middle Aged; Models, Biological; Neoplasms; Predictive Value of Tests; Reproducibility of Results | 1999 |
Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Saliva | 1999 |
Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Treatment Outcome | 1999 |
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Irinotecan; Male; Mice; Neoplasms; Neuroblastoma; Subrenal Capsule Assay; Treatment Outcome | 1999 |
Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Digestive System; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Glucuronates; Glucuronides; Hematopoiesis; Humans; Infusions, Intravenous; Irinotecan; Leukocyte Count; Male; Middle Aged; Neoplasms; Treatment Outcome | 1999 |
Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Colloids; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Carriers; Female; Hematopoiesis; Humans; Infusions, Intravenous; Lactones; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Thrombocytopenia | 1999 |
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Least-Squares Analysis; Likelihood Functions; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacokinetics; Thrombocytopenia | 1999 |
Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasms; Prospective Studies | 1999 |
Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Vomiting | 2000 |
Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Humans; Infusions, Intravenous; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Ifosfamide and irinotecan in solid tumors: a phase I dose-finding trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Ifosfamide; Irinotecan; Male; Middle Aged; Neoplasms; Salvage Therapy | 2000 |
Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bile; Biotransformation; Camptothecin; Chromatography, High Pressure Liquid; Feces; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Mass Spectrometry; Middle Aged; Neoplasms | 2000 |
Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasms; Neoplasms, Complex and Mixed; Neoplasms, Connective and Soft Tissue; Neoplasms, Glandular and Epithelial; Neutropenia; Time Factors | 2000 |
Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
Topics: Adolescent; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Child, Preschool; Chromatography, High Pressure Liquid; Chromatography, Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Humans; Irinotecan; Male; Mass Spectrometry; Microsomes, Liver; Mixed Function Oxygenases; Neoplasms; Topoisomerase I Inhibitors | 2000 |
Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Paclitaxel | 2000 |
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Thrombocytopenia; Vomiting | 2000 |
Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2000 |
Irinotecan and UFT/leucovorin in patients with advanced cancers.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Tegafur; Uracil | 2000 |
Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Topoisomerase I Inhibitors; Vomiting | 2000 |
Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative.
Topics: Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2000 |
Phase I study of 9-nitro-20(S)-camptothecin in combination with cisplatin for patients with advanced malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Neoplasms | 2000 |
A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Hematologic Tests; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Neoplasms; Topoisomerase I Inhibitors; Toxicity Tests; Treatment Outcome | 2001 |
Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Thrombocytopenia | 2001 |
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cross-Over Studies; Diarrhea; Humans; Irinotecan; Middle Aged; Neomycin; Neoplasms | 2001 |
Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 2001 |
Phase I clinical trial of weekly combined topotecan and irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2001 |
A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hematologic Tests; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Platelet Count | 2001 |
Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Camptothecin; Female; Glucuronates; Humans; Infusions, Intravenous; Irinotecan; Male; Models, Statistical; Neoplasms; Sampling Studies | 2001 |
Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2001 |
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Fatigue; Female; Genotype; Homocysteine; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasms; Neutropenia; Oxidoreductases Acting on CH-NH Group Donors; Quinazolines; Thiophenes | 2001 |
Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topoisomerase I Inhibitors | 2001 |
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2001 |
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Sampling Studies; Topoisomerase I Inhibitors | 2002 |
Laboratory and phase I studies of new cancer drugs.
Topics: Antineoplastic Agents; Bryostatins; Camptothecin; Docetaxel; Humans; Lactones; Macrolides; Neoplasms; Paclitaxel; Taxoids | 1992 |
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Neoplasms; Organophosphonates; Paclitaxel; Pyrazoles; Quinazolines; Sulfonylurea Compounds; Terpenes; Trimetrexate | 1990 |
[Phase I clinical study of CPT-11. Research group of CPT-11].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Drug Evaluation; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms | 1990 |
520 other study(ies) available for camptothecin and Neoplasms
| Article | Year |
|---|---|
Selective phenolic acylation of 10-hydroxycamptothecin using poly (ethylene glycol) carboxylic acid.
Topics: Acylation; Animals; Antineoplastic Agents; Camptothecin; Carboxylic Acids; Hydrogen Bonding; Hydroxyquinolines; Indicators and Reagents; Leukemia P388; Magnetic Resonance Spectroscopy; Neoplasms; Polyethylene Glycols; Rats; Tumor Cells, Cultured | 2003 |
CHMIS-C: a comprehensive herbal medicine information system for cancer.
Topics: Antineoplastic Agents, Phytogenic; Databases, Factual; Internet; National Institutes of Health (U.S.); Neoplasms; Phytotherapy; Plant Preparations; United States; United States Food and Drug Administration | 2005 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Synthesis of 2,6-diaryl-substituted pyridines and their antitumor activities.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Pyridines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2008 |
Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Nude; Neoplasms; Quinolones; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2008 |
On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents.
Topics: Acridines; Aminacrine; Antineoplastic Agents; Cell Line; Chemistry, Pharmaceutical; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Doxorubicin; Drug Design; Drug Screening Assays, Antitumor; Etoposide; Humans; Models, Chemical; Neoplasms; RNA, Small Interfering | 2009 |
Tessaric acid derivatives induce G2/M cell cycle arrest in human solid tumor cell lines.
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Drug Screening Assays, Antitumor; G2 Phase; Humans; Neoplasms; Quantitative Structure-Activity Relationship; Sesquiterpenes | 2009 |
Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; Drug Discovery; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Models, Molecular; Molecular Conformation; Naphthyridines; Neoplasms; Quinolones; Topoisomerase I Inhibitors; Transplantation, Heterologous | 2009 |
2-Thienyl-4-furyl-6-aryl pyridine derivatives: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Neoplasms; Pyrimidines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2010 |
New benzoxanthone derivatives as topoisomerase inhibitors and DNA cross-linkers.
Topics: Antineoplastic Agents; Benzene Derivatives; Cell Line, Tumor; Cell Proliferation; DNA; DNA Topoisomerases; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Xanthones | 2010 |
Synthesis and antiproliferative evaluation of certain iminonaphtho[2,3-b]furan derivatives.
Topics: Antineoplastic Agents; Benzofurans; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; DNA Fragmentation; Drug Screening Assays, Antitumor; Fibroblasts; Humans; Imines; Neoplasms | 2010 |
Improving anticancer activity and selectivity of camptothecin through conjugation with releasable substance P.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Drug Delivery Systems; Humans; Molecular Structure; Neoplasms; Neurotransmitter Agents; Substance P | 2011 |
Synthesis of 2,4-diaryl chromenopyridines and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzopyrans; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Female; Humans; Male; Neoplasms; Pyridines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2011 |
7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents.
Topics: Antineoplastic Agents; Aza Compounds; DNA Cleavage; DNA Topoisomerases, Type I; Humans; Models, Molecular; Molecular Structure; Neoplasms; Quinolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2011 |
Bakuchiol derivatives as novel and potent cytotoxic agents: a report.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; DNA Fragmentation; Humans; Neoplasms; Phenols; Psoralea | 2012 |
Dihydroxylated 2,4,6-triphenyl pyridines: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Neoplasms; Pyridines; Topoisomerase Inhibitors | 2012 |
Hybrids of privileged structures benzothiazoles and pyrrolo[2,1-c] [1,4]benzodiazepin-5-one, and diversity-oriented synthesis of benzothiazoles.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzodiazepines; Benzothiazoles; Etoposide; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2012 |
Synthesis and biological evaluation of 4β-sulphonamido and 4β-[(4'-sulphonamido)benzamide]podophyllotoxins as DNA topoisomerase-IIα and apoptosis inducing agents.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Comet Assay; DNA Breaks; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Etoposide; Humans; Neoplasms; Podophyllotoxin; Podophyllum | 2012 |
A novel thiazolidine compound induces caspase-9 dependent apoptosis in cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 9; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Neoplasms; Structure-Activity Relationship; Thiazolidines | 2012 |
Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.
Topics: Antineoplastic Agents; DNA Topoisomerases, Type II; Humans; Indoles; Models, Molecular; Neoplasms; Topoisomerase II Inhibitors | 2013 |
Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Blood-Brain Barrier; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Drug Design; Drug Resistance, Neoplasm; HCT116 Cells; Humans; K562 Cells; MCF-7 Cells; Mice; Mice, Nude; Microtubules; Neoplasms; Polymerization; Sulfonamides; Tubulin; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Synthesis and cytotoxic activity of nitric oxide-releasing isosteviol derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Diterpenes, Kaurane; Humans; Neoplasms; Nitric Oxide Donors | 2014 |
Synthesis, antitumor activity, and structure-activity relationship study of trihydroxylated 2,4,6-triphenyl pyridines as potent and selective topoisomerase II inhibitors.
Topics: Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; Molecular Docking Simulation; Molecular Structure; Neoplasms; Phenols; Pyridines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2014 |
Synthesis and preliminary mechanistic evaluation of 5-(p-tolyl)-1-(quinolin-2-yl)pyrazole-3-carboxylic acid amides with potent antiproliferative activity on human cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carboxylic Acids; Cell Cycle Checkpoints; Cell Proliferation; Drug Screening Assays, Antitumor; Flow Cytometry; G1 Phase; Humans; Molecular Structure; Neoplasms; Pyrazoles; Quinolones; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |
11H-Pyrido[3',2':4,5]pyrrolo[3,2-c]cinnoline and pyrido[3',2':4,5]pyrrolo[1,2-c][1,2,3]benzotriazine: two new ring systems with antitumor activity.
Topics: Antineoplastic Agents; Apoptosis; Caspase Inhibitors; Caspases; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Chemistry, Pharmaceutical; Enzyme Activation; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; Jurkat Cells; Lysosomes; Mitochondria; Neoplasms; Reactive Oxygen Species; Temperature; Triazines | 2014 |
Synthesis and bio-evaluation of novel quinolino-stilbene derivatives as potential anticancer agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Neoplasms; Quinolines; Stilbenes; Tubulin; Tubulin Modulators | 2015 |
Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties.
Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Furans; Humans; Leukemia; Mice; Neoplasms; Protein Kinase Inhibitors; Structure-Activity Relationship; Topoisomerase Inhibitors | 2016 |
Synthesis and anti-cancer activity evaluation of 5-(2-carboxyethenyl)-isatin derivatives.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Isatin; Jurkat Cells; Leukemia, T-Cell; Membrane Potential, Mitochondrial; Mitochondria; Neoplasms | 2016 |
Synthesis and in vitro growth inhibitory activity of novel silyl- and trityl-modified nucleosides.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Neoplasms; Nucleosides; Structure-Activity Relationship | 2016 |
Synthesis and antitumor activity of novel substituted uracil-1'(N)-acetic acid ester derivatives of 20(S)-camptothecins.
Topics: Acetates; Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; Humans; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Uracil | 2017 |
Design, synthesis and potent cytotoxic activity of novel 7-(N-[(substituted-sulfonyl)piperazinyl]-methyl)-camptothecin derivatives.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Design; Drug Screening Assays, Antitumor; Humans; Methylation; Neoplasms; Piperazine; Piperazines; Sulfones | 2017 |
6-OH-Phenanthroquinolizidine Alkaloid and Its Derivatives Exert Potent Anticancer Activity by Delaying S Phase Progression.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Neoplasms; Phenanthrolines; Quinolizines; S Phase | 2017 |
Design, synthesis and evaluation of 4-substituted anthra[2,1-c][1,2,5]thiadiazole-6,11-dione derivatives as novel non-camptothecin topoisomerase I inhibitors.
Topics: Anthraquinones; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Drug Design; Humans; Molecular Docking Simulation; Neoplasms; Thiadiazoles; Topoisomerase I Inhibitors | 2017 |
Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and IIα dual inhibitors with DNA non-intercalative catalytic activity.
Topics: Antineoplastic Agents; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Halogenation; Humans; Neoplasms; Pyridines; Topoisomerase II Inhibitors | 2017 |
Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-β-benzyl ester derivatives as potent topoisomerase IIα inhibitors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Aspartic Acid; Cell Line, Tumor; DNA Topoisomerases, Type II; DNA-Binding Proteins; HeLa Cells; Humans; Molecular Docking Simulation; Neoplasms; Phenylalanine; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2017 |
2-Chlorophenyl-substituted benzofuro[3,2-b]pyridines with enhanced topoisomerase inhibitory activity: The role of the chlorine substituent.
Topics: Antineoplastic Agents; Benzofurans; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Halogenation; Humans; Neoplasms; Pyridines; Topoisomerase Inhibitors | 2017 |
Structure-Based Drug Design and Identification of H
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Proliferation; Drug Design; Humans; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasms; Sepsis; Solubility; Structure-Activity Relationship; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Synthesis, modification, and cytotoxic evaluation of 2,3-secotriterpenic β-ketoesters.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Esterification; HCT116 Cells; Humans; Models, Molecular; Neoplasms; Triterpenes | 2018 |
Structural simplification of evodiamine: Discovery of novel tetrahydro-β-carboline derivatives as potent antitumor agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carbolines; Cell Proliferation; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; HCT116 Cells; Humans; Male; Mice, Nude; Molecular Structure; Neoplasms; Proof of Concept Study; Quinazolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays | 2021 |
Synthesis of Methoxy-, Methylenedioxy-, Hydroxy-, and Halo-Substituted Benzophenanthridinone Derivatives as DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Inhibitors and Their Biological Activity for Drug-Resistant Cancer.
Topics: Antineoplastic Agents; Apoptosis; Benzophenanthridines; Binding Sites; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Molecular Dynamics Simulation; Neoplasms; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2021 |
Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis.
Topics: Biomarkers; Cell Nucleolus; Cell Nucleus; Humans; Neoplasms; Pyrimidines; Pyrroles | 2022 |
Biomimetic synthesis of a novel O
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Biomimetics; Camptothecin; Cell Movement; Cell Proliferation; Drug Carriers; Glucose Oxidase; HeLa Cells; Humans; Indoles; Manganese Compounds; Metal Nanoparticles; Nanomedicine; Neoplasms; Oxides; Oxygen; Polymers; Surface Properties; Tumor Hypoxia | 2021 |
A camptothecin prodrug induces mitochondria-mediated apoptosis in cancer cells with cascade activations.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Benzofurans; Camptothecin; Cell Line, Tumor; Drug Therapy, Combination; Humans; Mitochondria; Neoplasms; Photochemotherapy; Photosensitizing Agents; Prodrugs; Reactive Oxygen Species | 2021 |
SN38-based albumin-binding prodrug for efficient targeted cancer chemotherapy.
Topics: Albumins; Animals; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Irinotecan; Mice; Neoplasms; Prodrugs | 2021 |
A modular ROS-responsive platform co-delivered by 10-hydroxycamptothecin and dexamethasone for cancer treatment.
Topics: Camptothecin; Cell Line, Tumor; Dexamethasone; Drug Delivery Systems; Drug Liberation; Micelles; Nanoparticles; Neoplasms; Reactive Oxygen Species | 2021 |
The importance of persistence in cancer drug development.
Topics: Antineoplastic Agents; Camptothecin; Drug Development; Humans; Immunoconjugates; Medical Oncology; Molecular Targeted Therapy; Neoplasms; Receptor, ErbB-2; Trastuzumab | 2021 |
Sequential Ultrasound-Triggered and Hypoxia-Sensitive Nanoprodrug for Cascade Amplification of Sonochemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Humans; Hypoxia; Nanoparticles; Neoplasms; Prodrugs; Reactive Oxygen Species; Tumor Microenvironment; Ultrasonic Therapy | 2022 |
Design, Synthesis, and Bioevaluation of Novel Enzyme-Triggerable Cell Penetrating Peptide-Based Dendrimers for Targeted Delivery of Camptothecin and Cancer Therapy.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell-Penetrating Peptides; Dendrimers; Drug Delivery Systems; Drug Design; Humans; Matrix Metalloproteinase 2; Neoplasms | 2022 |
A Hybrid Supramolecular Polymeric Nanomedicine for Cascade-Amplified Synergetic Cancer Therapy.
Topics: beta-Cyclodextrins; Camptothecin; Cell Line, Tumor; Humans; Iron; Nanomedicine; Nanoparticles; Neoplasms; Polymers | 2022 |
TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Camptothecin; DNA; DNA Topoisomerases, Type I; Humans; Mice; Neoplasms; Nuclear Proteins; Protein Kinase Inhibitors; Topoisomerase I Inhibitors | 2022 |
Isolation and Phytochemical Screening of Endophytic Fungi Isolated from Medicinal Plant Mappia foetida and Evaluation of Its In Vitro Cytotoxicity in Cancer.
Topics: Alternaria; Antineoplastic Agents; Camptothecin; Doxorubicin; Early Detection of Cancer; Endophytes; Ethanol; Fungi; Fusarium; Neoplasms; Pharmaceutical Preparations; Phytochemicals; Plant Extracts; Plants, Medicinal | 2022 |
Self-assembled Pt(II) metallacycles enable precise cancer combination chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Liberation; Drug Synergism; Folic Acid; Humans; Mice; Nanoparticles; Neoplasms; Platinum; Polymers; Stilbenes; Tumor Microenvironment | 2022 |
Redox-responsive carrier based on fluorinated gemini amphiphilic polymer for combinational cancer therapy.
Topics: Camptothecin; Drug Carriers; Drug Liberation; Fluorocarbon Polymers; HeLa Cells; Humans; Hydrogen Peroxide; Micelles; Neoplasms; Oxidation-Reduction; Polymers | 2022 |
Radiotherapy Reduces
Topics: Antineoplastic Agents; Camptothecin; Humans; Neoplasms; Oxides; Prodrugs | 2022 |
Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium.
Topics: Animals; Antibodies, Monoclonal, Humanized; Camptothecin; Humans; Immunoconjugates; Mice; Neoplasms; Receptor, ErbB-2; RNA, Messenger; Trastuzumab | 2022 |
Evaluation of UGT1A1 and CYP3A Genotyping and Single-Point Irinotecan and Metabolite Concentrations as Predictors of the Occurrence of Adverse Events in Cancer Treatment.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cytochrome P-450 CYP3A; Diarrhea; Genotype; Humans; Irinotecan; Neoplasms | 2023 |
[Research progress on camptothecin and its derivative nano-prodrugs based on tumor microenvironment response].
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Humans; Neoplasms; Prodrugs; Tumor Microenvironment | 2022 |
Single-Cell Chemical Proteomics (SCCP) Interrogates the Timing and Heterogeneity of Cancer Cell Commitment to Death.
Topics: A549 Cells; Antineoplastic Agents; Camptothecin; Humans; Neoplasms; Proteome; Proteomics | 2022 |
A Self-amplifying ROS-sensitive prodrug-based nanodecoy for circumventing immune resistance in chemotherapy-sensitized immunotherapy.
Topics: Camptothecin; Cell Line, Tumor; Humans; Immunotherapy; Macrophage Colony-Stimulating Factor; Nanoparticles; Neoplasms; Prodrugs; Reactive Oxygen Species | 2022 |
Iron(III) Coordinated Theranostic Polyprodrug with Sequential Receptor-Mitochondria Dual Targeting and T
Topics: Antineoplastic Agents; Camptothecin; Contrast Media; Humans; Iron; Magnetic Resonance Imaging; Mitochondria; Nanoparticles; Neoplasms; Precision Medicine; Theranostic Nanomedicine | 2022 |
Overexpression of satellite RNAs in heterochromatin induces chromosomal instability and reflects drug sensitivity in mouse cancer cells.
Topics: Animals; Camptothecin; Chromosomal Instability; DNA Damage; Heterochromatin; Mice; Neoplasms; RNA, Satellite | 2022 |
Reactive oxygen species activated by mitochondria-specific camptothecin prodrug for enhanced chemotherapy.
Topics: Antineoplastic Agents; Arginine; Camptothecin; Cell Line, Tumor; Humans; Lactones; Lysine; Mitochondria; Neoplasms; Prodrugs; Reactive Oxygen Species; Water | 2022 |
A novel carbon-nanodots-based theranostic nano-drug delivery system for mitochondria-targeted imaging and glutathione-activated delivering camptothecin.
Topics: Antineoplastic Agents; Camptothecin; Carbon; Cell Line, Tumor; Disulfides; Drug Delivery Systems; Glutathione; Humans; Ligands; Mitochondria; Nanoparticle Drug Delivery System; Nanoparticles; Neoplasms; Precision Medicine; Prodrugs; Water | 2022 |
Fabrication of a phototheranostic nanoplatform for single laser-triggered NIR-II fluorescence imaging-guided photothermal/chemo/antiangiogenic combination therapy.
Topics: Angiogenesis Inhibitors; Animals; Camptothecin; Cell Line, Tumor; Glutathione; Infrared Rays; Lasers; Mice; Nanoparticles; Neoplasms; Optical Imaging; Phototherapy; Photothermal Therapy; Polymers; Prodrugs; Stilbenes; Theranostic Nanomedicine | 2022 |
Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Humans; Immunoconjugates; Neoplasms; Receptor, ErbB-2; Trastuzumab | 2023 |
A Hypoxia-Activated Prodrug Conjugated with a BODIPY-Based Photothermal Agent for Imaging-Guided Chemo-Photothermal Combination Therapy.
Topics: Azo Compounds; Boron; Boron Compounds; Camptothecin; Cell Line, Tumor; Humans; Hyperthermia, Induced; Hypoxia; Nanoparticles; Neoplasms; Phototherapy; Photothermal Therapy; Porphobilinogen; Prodrugs | 2022 |
A promising strategy for synergistic cancer therapy by integrating a photosensitizer into a hypoxia-activated prodrug.
Topics: Camptothecin; Cell Line, Tumor; Humans; Hypoxia; Nanoparticles; Neoplasms; Photochemotherapy; Photosensitizing Agents; Prodrugs | 2022 |
ROS-cleavable diselenide nanomedicine for NIR-controlled drug release and on-demand synergistic chemo-photodynamic therapy.
Topics: Camptothecin; Cell Line, Tumor; Delayed-Action Preparations; Drug Liberation; Humans; Nanomedicine; Nanoparticles; Neoplasms; Photochemotherapy; Photosensitizing Agents; Reactive Oxygen Species | 2022 |
Activating cGAS-STING pathway with ROS-responsive nanoparticles delivering a hybrid prodrug for enhanced chemo-immunotherapy.
Topics: Animals; Camptothecin; CD8-Positive T-Lymphocytes; Cisplatin; Immunologic Factors; Immunotherapy; Mice; Nanoparticles; Neoplasms; Nucleotidyltransferases; Prodrugs; Reactive Oxygen Species | 2022 |
Glutathione-Responsive Nanoparticles of Camptothecin Prodrug for Cancer Therapy.
Topics: Camptothecin; CD8-Positive T-Lymphocytes; Glutathione; Humans; Nanoparticles; Neoplasms; Prodrugs | 2023 |
Opioid-induced microbial dysbiosis disrupts irinotecan (CPT-11) metabolism and increases gastrointestinal toxicity in a murine model.
Topics: Analgesics, Opioid; Animals; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Disease Models, Animal; Dysbiosis; Glucuronidase; Humans; Irinotecan; Male; Mice; Mice, Inbred C57BL; Morphine Derivatives; Neoplasms; RNA, Ribosomal, 16S | 2023 |
Zwitterionic rhodamine-CPT prodrug nanoparticles with GSH/H
Topics: Animals; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Hydrogen Peroxide; Mice; Molecular Docking Simulation; Nanoparticles; Neoplasms; Precision Medicine; Prodrugs; Rhodamines; Tissue Distribution | 2023 |
An MMP-2 sensitive and reduction-responsive prodrug amphiphile for actively targeted therapy of cancer by hierarchical cleavage.
Topics: Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Humans; Matrix Metalloproteinase 2; Micelles; Nanoparticles; Neoplasms; Prodrugs | 2023 |
Antigen-independent tumor targeting by CBX-12 (alphalex
Topics: Animals; Camptothecin; Cell Line, Tumor; Immunity; Immunotherapy; Neoplasms; Tumor Microenvironment | 2022 |
Enzyme and Reactive Oxygen Species-Responsive Dual-Drug Delivery Nanocomplex for Tumor Chemo-Photodynamic Therapy.
Topics: Animals; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Nanoparticles; Neoplasms; Photochemotherapy; Photosensitizing Agents; Porphyrins; Reactive Oxygen Species | 2023 |
Injectable hydrogel imbibed with camptothecin-loaded mesoporous silica nanoparticles as an implantable sustained delivery depot for cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Drug Carriers; Drug Delivery Systems; Hydrogels; Nanoparticles; Neoplasms; Porosity; Rats; Rats, Sprague-Dawley; Silicon Dioxide | 2023 |
A dandelion-like nanomedicine via hierarchical self-assembly for synergistic chemotherapy and photo-dynamic cancer therapy.
Topics: Camptothecin; Cell Line, Tumor; Glutathione; Humans; Nanomedicine; Nanoparticles; Neoplasms; Prodrugs | 2023 |
Artesunate ameliorates irinotecan-induced intestinal injury by suppressing cellular senescence and significantly enhances anti-tumor activity.
Topics: Animals; Artesunate; Camptothecin; Cellular Senescence; Humans; Intestinal Diseases; Irinotecan; Mice; Neoplasms; TOR Serine-Threonine Kinases | 2023 |
DNA preference of indenoisoquinolines: a computational approach.
Topics: Base Pairing; Camptothecin; DNA; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Neoplasms; Topoisomerase I Inhibitors | 2023 |
A ROS-response hyaluronic acid-coated/chitosan polymer prodrug for enhanced tumour targeting efficacy of SN38.
Topics: Animals; Camptothecin; Cell Line, Tumor; Chitosan; Hyaluronic Acid; Irinotecan; Mice; Neoplasms; Polymers; Prodrugs; Reactive Oxygen Species; Tumor Microenvironment | 2023 |
Evolution of Resistance to Irinotecan in Cancer Cells Involves Generation of Topoisomerase-Guided Mutations in Non-Coding Genome That Reduce the Chances of DNA Breaks.
Topics: Camptothecin; DNA; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type I; Irinotecan; Mutation; Neoplasms | 2023 |
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.
Topics: Animals; Camptothecin; Cyclin E; Humans; Immunoconjugates; In Situ Hybridization, Fluorescence; Mice; Neoplasms; Receptor, ErbB-2; Trastuzumab | 2023 |
HER2-Targeted Therapy Shows Promise across Tumor Types.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Neoplasms; Receptor, ErbB-2; Trastuzumab | 2023 |
Platelet-mimicking supramolecular nanomedicine with precisely integrated prodrugs for cascade amplification of synergistic chemotherapy.
Topics: Camptothecin; Cell Line, Tumor; Cisplatin; Humans; Nanomedicine; Neoplasms; Prodrugs | 2023 |
A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors.
Topics: Animals; Antineoplastic Agents; Camptothecin; DNA Damage; Humans; Mice; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols | 2023 |
Mutual ATRaction: Assessing Synergy of Berzosertib with Sacituzumab Govitecan.
Topics: Camptothecin; Humans; Immunoconjugates; Neoplasms | 2023 |
Topics: Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Patient Safety | 2023 |
Development of a novel sialic acid-conjugated camptothecin prodrug for enhanced cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Mice; N-Acetylneuraminic Acid; Nanoparticles; Neoplasms; Prodrugs | 2023 |
Manipulating Neovasculature-Targeting Capability of Biomimetic Nanodiscs for Synergistic Photoactivatable Tumor Infarction and Chemotherapy.
Topics: Biomimetics; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Endothelial Cells; Humans; Nanoparticles; Neoplasms | 2023 |
Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Neoplasms; Receptor, ErbB-2; Trastuzumab | 2023 |
[12]aneN
Topics: Camptothecin; HeLa Cells; Humans; Nanoparticles; Neoplasms; Nitroreductases; Nucleic Acids; Polyethylene Glycols; Prodrugs; Reactive Oxygen Species | 2023 |
Synthesis and biological activity assay of novel camptothecin-peptidic conjugates based on PEPT1.
Topics: Biological Transport; Camptothecin; Cell Line; Humans; Neoplasms; Peptide Transporter 1; Prodrugs | 2023 |
Acidity-responsive shell-sheddable camptothecin-based nanofibers for carrier-free cancer drug delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Delayed-Action Preparations; Humans; Hydrogen-Ion Concentration; Mice; Nanofibers; Neoplasms; Prodrugs; Tumor Microenvironment | 2019 |
A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Topics: Animals; Antibodies, Monoclonal, Humanized; Apoptosis; Camptothecin; Cell Proliferation; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Humans; Immunoconjugates; Macaca fascicularis; Male; Mice; Mice, Inbred NOD; Mice, Nude; Neoplasms; Rats; Receptor, ErbB-3; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Formulation of injectable glycyrrhizic acid-hydroxycamptothecin micelles as new generation of DNA topoisomerase I inhibitor for enhanced antitumor activity.
Topics: Administration, Intravenous; Animals; Camptothecin; Cell Proliferation; Drug Carriers; Drug Stability; Glycyrrhizic Acid; Hep G2 Cells; Humans; Male; Mice; Micelles; Neoplasms; Particle Size; Solubility; Topoisomerase I Inhibitors; Toxicity Tests; Xenograft Model Antitumor Assays | 2019 |
Tetrazine-Mediated Bioorthogonal System for Prodrug Activation, Photothermal Therapy, and Optoacoustic Imaging.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Gold; Heterocyclic Compounds, 1-Ring; Humans; Mice; Nanotubes; Neoplasms; Photochemotherapy; Prodrugs | 2019 |
Specific Modification with TPGS and Drug Loading of Cyclodextrin Polyrotaxanes and the Enhanced Antitumor Activity Study in Vitro and in Vivo.
Topics: Animals; Anticarcinogenic Agents; Camptothecin; Cell Line, Tumor; Cellulose; Cyclodextrins; Drug Delivery Systems; Humans; Mice; Nanoparticles; Neoplasms; Rotaxanes; Vitamin E; Xenograft Model Antitumor Assays | 2019 |
Structure-based design of charge-conversional drug self-delivery systems for better targeted cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Mice; Nanoparticles; Neoplasms; Pharmaceutical Preparations | 2020 |
Helix Self-Assembly Behavior of Amino Acid-Modified Camptothecin Prodrugs and Its Antitumor Effect.
Topics: Animals; Antineoplastic Agents; Arginine; Camptothecin; Carbon; Cell Line, Tumor; Cisplatin; Drug Delivery Systems; Female; Humans; Mice; Nanofibers; Neoplasms; Prodrugs; Solubility | 2020 |
Novel polymeric micelles as enzyme-sensitive nuclear-targeted dual-functional drug delivery vehicles for enhanced 9-nitro-20(S)-camptothecin delivery and antitumor efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Nucleus; Cell Survival; Drug Carriers; Humans; Mice; Mice, Nude; Micelles; Neoplasms; Particle Size; Peptides; Polymers; Transplantation, Heterologous | 2020 |
The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers.
Topics: Breast Neoplasms; Camptothecin; Cell Line, Tumor; Humans; Immunoconjugates; Neoplasms; Receptor, ErbB-2; Trastuzumab | 2020 |
Mesoporous NiS
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Survival; Combined Modality Therapy; Drug Delivery Systems; Drug Liberation; Drug Therapy; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Nanospheres; Neoplasms; Nickel; Phototherapy | 2019 |
Synergistic antitumor efficacy of hybrid micelles with mitochondrial targeting and stimuli-responsive drug release behavior.
Topics: alpha-Tocopherol; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Drug Synergism; Humans; Hyaluronic Acid; Mice; Micelles; Mitochondria; Neoplasms; Polyesters; Reactive Oxygen Species; Survival Rate | 2019 |
Hyaluronic Acid-Coated Camptothecin Nanocrystals for Targeted Drug Delivery to Enhance Anticancer Efficacy.
Topics: Antineoplastic Agents; Apoptosis; Camptotheca; Camptothecin; Cell Movement; Cell Survival; Drug Delivery Systems; Drug Liberation; Drug Stability; Hep G2 Cells; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hydrogen-Ion Concentration; MCF-7 Cells; Nanoparticles; Neoplasms; Particle Size; Phytotherapy; Plant Extracts; Protein Binding | 2020 |
Self-assembling nanoparticles of dually hydrophobic prodrugs constructed from camptothecin analogue for cancer therapy.
Topics: Animals; Benzodioxoles; Camptothecin; Chromones; Disulfides; Drug Stability; Humans; Hydrophobic and Hydrophilic Interactions; Indolizines; Lipids; Nanomedicine; Nanoparticles; Neoplasms; Prodrugs | 2020 |
Trastuzumab Deruxtecan DESTINY for Some Cancers.
Topics: Camptothecin; Congresses as Topic; Humans; Immunoconjugates; Neoplasms; Survival Analysis; Trastuzumab | 2020 |
2020 ASCO Annual Meeting.
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Cholangiocarcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Female; Humans; Immunoconjugates; Neoplasms; Ovarian Neoplasms; Protein Kinase Inhibitors; Societies, Medical; Trastuzumab; Urinary Bladder Neoplasms | 2020 |
Engineered liposomes bearing camptothecin analogue for tumour targeting:
Topics: Animals; Camptothecin; Liposomes; Mice; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2021 |
C1orf109L binding DHX9 promotes DNA damage depended on the R-loop accumulation and enhances camptothecin chemosensitivity.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle Checkpoints; DEAD-box RNA Helicases; DNA Damage; HEK293 Cells; HeLa Cells; Humans; Neoplasm Proteins; Neoplasms; Phosphoproteins; Protein Binding; R-Loop Structures | 2020 |
Drug-Bearing Peptide-Based Nanospheres for the Inhibition of Metastasis and Growth of Cancer.
Topics: A549 Cells; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; HeLa Cells; Hep G2 Cells; Humans; Melanoma, Experimental; Nanospheres; Nanostructures; Neoplasms; Peptides; Small Molecule Libraries | 2020 |
High-Efficiency Synergistic Effect of Supramolecular Nanoparticles Based on Cyclodextrin Prodrug on Cancer Therapy.
Topics: Camptothecin; Cyclodextrins; Nanoparticles; Neoplasms; Photochemotherapy; Prodrugs | 2020 |
Albumin-binding prodrugs via reversible iminoboronate forming nanoparticles for cancer drug delivery.
Topics: Albumins; Antineoplastic Agents; Camptothecin; Drug Delivery Systems; Humans; Nanoparticles; Neoplasms; Prodrugs | 2021 |
FEN1 inhibitor synergizes with low-dose camptothecin to induce increased cell killing via the mitochondria mediated apoptotic pathway.
Topics: Apoptosis; Camptothecin; DNA Damage; Flap Endonucleases; Humans; Mitochondria; Neoplasms | 2022 |
Kinetically-stable small-molecule prodrug nanoassemblies for cancer chemotherapy.
Topics: Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Humans; Neoplasms; Prodrugs | 2021 |
Chk1 inhibition induces a DNA damage bystander effect in cocultured tumour cells.
Topics: Ataxia Telangiectasia Mutated Proteins; Bystander Effect; Camptothecin; Cell Line, Tumor; Checkpoint Kinase 1; Coculture Techniques; Deoxycytidine; DNA; DNA Damage; DNA-Activated Protein Kinase; Gemcitabine; Histones; HT29 Cells; Humans; Jurkat Cells; Neoplasms; Protein Kinase Inhibitors; Signal Transduction | 2021 |
Apoptotic body-mediated intercellular delivery for enhanced drug penetration and whole tumor destruction.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Extracellular Vesicles; Humans; Nanoparticles; Neoplasms; Prodrugs | 2021 |
Reduction-responsive dehydroepiandrosterone prodrug nanoparticles loaded with camptothecin for cancer therapy by enhancing oxidation therapy and cell replication inhibition.
Topics: Camptothecin; Cell Line, Tumor; Dehydroepiandrosterone; DNA Replication; Drug Delivery Systems; Humans; Nanoparticles; Neoplasms; Oxidation-Reduction; Prodrugs | 2021 |
Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis.
Topics: Animals; Camptothecin; Disease Models, Animal; Fluorescent Dyes; Humans; Immunoconjugates; Mice; Nanoparticles; Neoplasms; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured | 2021 |
Interface-sensitized prodrug nanoaggregate as an effective in situ antitumor vaccine.
Topics: Camptothecin; Cell Line, Tumor; Drug Liberation; Humans; Neoplasms; Prodrugs; Vaccines | 2021 |
Shuttle-Shape Carrier-Free Platinum-Coordinated Nanoreactors with O
Topics: Animals; Antineoplastic Agents; Camptothecin; Catalysis; Cell Line, Tumor; Drug Carriers; Drug Liberation; Female; Humans; Hydrogen Peroxide; Light; Methylene Blue; Mice, Inbred BALB C; Nanostructures; Neoplasms; Oxygen; Photosensitizing Agents; Photothermal Therapy; Platinum; Polymers; Porosity; Singlet Oxygen; Theranostic Nanomedicine; Tumor Hypoxia | 2021 |
Engineering glutathione-responsive near-infrared polymeric prodrug system for fluorescence imaging in tumor therapy.
Topics: Animals; Camptothecin; Cell Line, Tumor; Female; Flow Cytometry; Glutathione; HeLa Cells; Humans; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Optical Imaging; Prodrugs; Tissue Distribution | 2021 |
Orthogonal Design of a Water-Soluble
Topics: Animals; Benzylidene Compounds; Calixarenes; Camptothecin; Cell Line, Tumor; Drug Carriers; Drug Design; Drug Liberation; Female; Fluorescent Dyes; Fluorometry; Humans; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Prodrugs; Quaternary Ammonium Compounds; Solubility; Water | 2021 |
Integrated pan-cancer of AURKA expression and drug sensitivity analysis reveals increased expression of AURKA is responsible for drug resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Benzodioxoles; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Chromones; Dactinomycin; Datasets as Topic; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Neoplasms; Prognosis; Pyridines; Triazoles | 2021 |
A pH-responsive prodrug delivery system of 10-HCPT for controlled release and tumor targeting.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carbon-13 Magnetic Resonance Spectroscopy; Cell Line, Tumor; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endocytosis; Humans; Hydrogen-Ion Concentration; Mice, Inbred BALB C; Micelles; Neoplasms; Prodrugs; Proton Magnetic Resonance Spectroscopy; Rats; Solubility; Spectrometry, Fluorescence; Tissue Distribution | 2017 |
Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Humans; Liposomes; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Phospholipids; Prodrugs; Solubility; Succinic Acid | 2017 |
Quercetin exerts synergetic anti-cancer activity with 10-hydroxy camptothecin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; DNA Topoisomerases, Type I; Drug Synergism; Female; Humans; Membrane Potential, Mitochondrial; Mice, Nude; Neoplasms; Quercetin; Topoisomerase I Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Orthotopic patient-derived xenografts of paediatric solid tumours.
Topics: Animals; Bortezomib; Camptothecin; Cell Cycle Proteins; Child; Clone Cells; Drug Therapy, Combination; Epigenesis, Genetic; Female; Heterografts; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Indoles; Irinotecan; Mice; Neoplasms; Nuclear Proteins; Panobinostat; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Rhabdomyosarcoma; Vincristine; Xenograft Model Antitumor Assays | 2017 |
Transformative Nanomedicine of an Amphiphilic Camptothecin Prodrug for Long Circulation and High Tumor Uptake in Cancer Therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Delivery Systems; Female; HCT116 Cells; Humans; Mice; Mice, Nude; Nanoconjugates; Nanoparticles; Neoplasms; Oxidation-Reduction; Prodrugs; Solubility; Surface-Active Agents | 2017 |
Tumor pH-Responsive Release of Drug-Conjugated Micelles from Fiber Fragments for Intratumoral Chemotherapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Doxorubicin; Hydrogen-Ion Concentration; Micelles; Neoplasms; Polyethylene Glycols | 2017 |
UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Neutropenia; Polymorphism, Genetic | 2017 |
Polymer Prodrug-Based Nanoreactors Activated by Tumor Acidity for Orchestrated Oxidation/Chemotherapy.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Carriers; Glucose Oxidase; Humans; Hydrogen Peroxide; Hydrogen-Ion Concentration; Methacrylates; Nanostructures; Neoplasms; Oxidation-Reduction; Oxidative Stress; Polyethylene Glycols; Prodrugs | 2017 |
Executioner caspases and CAD are essential for mutagenesis induced by TRAIL or vincristine.
Topics: Apoptosis; Aspartate Carbamoyltransferase; Camptothecin; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Dacarbazine; Dihydroorotase; DNA Damage; Doxorubicin; Enzyme Activation; Humans; Irinotecan; Mutagenesis; Mutation; Neoplasms; Signal Transduction; Temozolomide; TNF-Related Apoptosis-Inducing Ligand; Vincristine | 2017 |
LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation.
Topics: Animals; Camptothecin; Carcinogenesis; Cell Line, Tumor; Cellular Senescence; Chromatin; Demethylation; E2F1 Transcription Factor; G1 Phase Cell Cycle Checkpoints; Gene Knockdown Techniques; Histone Demethylases; Histones; Humans; Mice; Neoplasms; Pargyline; Promoter Regions, Genetic; S Phase; Transcription Factors; Xenograft Model Antitumor Assays | 2018 |
Theranostic Hyaluronic Acid-Iron Micellar Nanoparticles for Magnetic-Field-Enhanced in vivo Cancer Chemotherapy.
Topics: Administration, Intravenous; Animals; Apoptosis; Camptothecin; Cell Line, Tumor; Drug Carriers; Female; Ferric Compounds; Humans; Hyaluronan Receptors; Hyaluronic Acid; Magnetic Fields; Magnetic Resonance Imaging; Mice; Mice, Nude; Micelles; Nanoparticles; Neoplasms; Positron-Emission Tomography; Theranostic Nanomedicine | 2018 |
Dimeric camptothecin-loaded RGD-modified targeted cationic polypeptide-based micelles with high drug loading capacity and redox-responsive drug release capability.
Topics: Camptothecin; Cations; Drug Carriers; Drug Liberation; Humans; MCF-7 Cells; Micelles; Neoplasms; Oligopeptides; Oxidation-Reduction; Peptides; Polyethylene Glycols | 2017 |
Acid-activatable oxidative stress-inducing polysaccharide nanoparticles for anticancer therapy.
Topics: Acrolein; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Drug Carriers; Humans; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Oxidative Stress; Polysaccharides; Prodrugs; Reactive Oxygen Species | 2018 |
Antitumor potential of a novel camptothecin derivative, ZBH-ZM-06.
Topics: Acetylcholinesterase; Antineoplastic Agents; Camptothecin; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Irinotecan; Neoplasms; Poly(ADP-ribose) Polymerases; Prodrugs | 2018 |
Dual-drug loaded nanoneedles with targeting property for efficient cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Survival; Drug Carriers; Drug Liberation; Drug Synergism; HeLa Cells; Humans; Methotrexate; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Microscopy, Electron, Scanning; Nanoparticles; Neoplasms; Polyethylene Glycols; Polyglactin 910; Tissue Distribution; Transplantation, Heterologous | 2017 |
MOF Suppresses Replication Stress and Contributes to Resolution of Stalled Replication Forks.
Topics: Antineoplastic Agents; Camptothecin; Cell Death; Cisplatin; DNA Damage; DNA Repair; DNA Replication; HeLa Cells; Histone Acetyltransferases; Homologous Recombination; Humans; Hydroxyurea; Neoplasms; S Phase | 2018 |
Near-Infrared Cyanine-Loaded Liposome-like Nanocapsules of Camptothecin-Floxuridine Conjugate for Enhanced Chemophotothermal Combination Cancer Therapy.
Topics: Camptothecin; Floxuridine; Humans; Liposomes; Nanocapsules; Neoplasms | 2018 |
A novel self-assembled nanoparticle platform based on pectin-eight-arm polyethylene glycol-drug conjugates for co-delivery of anticancer drugs.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Female; Half-Life; Hemolysis; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Particle Size; Pectins; Polyethylene Glycols; Transplantation, Heterologous; Triterpenes; Ursolic Acid | 2018 |
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Female; Glucuronosyltransferase; Heterocyclic Compounds, 4 or More Rings; Humans; Irinotecan; Male; Middle Aged; Models, Biological; Neoplasms; Polyethylene Glycols | 2018 |
Developing a Phosphospecific IHC Assay as a Predictive Biomarker for Topoisomerase I Inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antibody Formation; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Humans; Immunohistochemistry; Mice, Inbred BALB C; Neoplasms; Phosphorylation; Topoisomerase I Inhibitors | 2018 |
Reduction-responsive amphiphilic polymeric prodrugs of camptothecin-polyphosphoester for cancer chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Delayed-Action Preparations; Drug Liberation; HT29 Cells; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Micelles; Neoplasms; Oxidation-Reduction; Polymers; Prodrugs; Rats, Sprague-Dawley; Surface-Active Agents | 2018 |
Polymeric Nanoparticles with a Glutathione-Sensitive Heterodimeric Multifunctional Prodrug for In Vivo Drug Monitoring and Synergistic Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Delayed-Action Preparations; Drug Monitoring; Drug Synergism; Glutathione; HCT116 Cells; Humans; Mice; Neoplasms; Photosensitizing Agents; Polymers; Prodrugs | 2018 |
Concurrent Drug Unplugging and Permeabilization of Polyprodrug-Gated Crosslinked Vesicles for Cancer Combination Chemotherapy.
Topics: Camptothecin; Doxorubicin; Drug Therapy, Combination; Humans; Neoplasms; Polymers | 2018 |
Multistimuli-Responsive Amphiphilic Poly(ester-urethane) Nanoassemblies Based on l-Tyrosine for Intracellular Drug Delivery to Cancer Cells.
Topics: Animals; Camptothecin; Doxorubicin; Drug Delivery Systems; Endocytosis; HeLa Cells; Humans; Lysosomes; MCF-7 Cells; Mice; Nanoparticles; Neoplasms; Polyesters; Polyurethanes; Tyrosine | 2018 |
Reality of the emetogenic level of irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Emetics; Female; Humans; Induction Chemotherapy; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Outpatients; Quality of Life; Retrospective Studies; Severity of Illness Index; Vomiting | 2018 |
A theranostic nanocomposite system based on iron oxide-drug nanocages for targeted magnetic field responsive chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Drug Delivery Systems; Ferric Compounds; HeLa Cells; Humans; Magnetic Fields; MCF-7 Cells; Nanocomposites; Neoplasms; Pyrroles; Quinones; Theranostic Nanomedicine | 2018 |
Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Camptothecin; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasms; Predictive Value of Tests; Quality of Life; Retrospective Studies; Salivation; Syndrome; Young Adult | 2018 |
O-GlcNAc elevation through activation of the hexosamine biosynthetic pathway enhances cancer cell chemoresistance.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Doxorubicin; Drug Resistance, Neoplasm; Energy Metabolism; Glycosylation; HeLa Cells; Hexosamines; HL-60 Cells; Humans; MCF-7 Cells; Neoplasms; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Cells, Cultured; X-Box Binding Protein 1 | 2018 |
pH-sensitive prodrug conjugated polydopamine for NIR-triggered synergistic chemo-photothermal therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Nucleus; Cell Survival; Drug Carriers; Drug Liberation; Female; HeLa Cells; Humans; Hydrogen-Ion Concentration; Hyperthermia, Induced; Indoles; Infrared Rays; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Photochemotherapy; Polymers; Prodrugs; Xenograft Model Antitumor Assays | 2018 |
Amphiphilic Hybrid Dendritic-Linear Molecules as Nanocarriers for Shape-Dependent Antitumor Drug Delivery.
Topics: Amines; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; Drug Liberation; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred BALB C; Nanospheres; Nanotubes; Neoplasms; Particle Size; Polyethylene Glycols; Rats; Surface-Active Agents; Treatment Outcome | 2018 |
NIR-controlled morphology transformation and pulsatile drug delivery based on multifunctional phototheranostic nanoparticles for photoacoustic imaging-guided photothermal-chemotherapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Combined Modality Therapy; Doxorubicin; Drug Liberation; Fluorescent Dyes; Heterografts; Humans; Hypothermia, Induced; Infrared Rays; Lasers; Mice; Nanocapsules; Neoplasms; Photoacoustic Techniques; Photochemotherapy; Polyhydroxyethyl Methacrylate; Polymers; Prodrugs; Pyrroles; Theranostic Nanomedicine | 2018 |
Nrp-1 receptor targeting peptide-functionalized TPGS micellar nanosystems to deliver 10-hydroxycampothecin for enhanced cancer chemotherapy.
Topics: A549 Cells; Apoptosis; Camptothecin; Cell Nucleus; DNA Topoisomerases, Type I; Drug Carriers; Drug Synergism; Hep G2 Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Micelles; Mitochondria; Nanoparticles; Neoplasms; Neuropilin-1; Peptides; Polymers; Reactive Oxygen Species; Topoisomerase I Inhibitors; Vitamin E | 2018 |
Cancer-targeted design of bioresponsive prodrug with enhanced cellular uptake to achieve precise cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Transport; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Glutathione; Hep G2 Cells; Humans; MCF-7 Cells; Mice; Mice, Nude; Neoplasms; Prodrugs | 2018 |
Improvement of oral efficacy of Irinotecan through biodegradable polymeric nanoparticles through in vitro and in vivo investigations.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Brain; Caco-2 Cells; Camptothecin; Chitosan; Drug Carriers; Humans; Intestinal Absorption; Irinotecan; Lactic Acid; Male; MCF-7 Cells; Nanoparticles; Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar | 2018 |
Supramolecular Polymer-Based Nanomedicine: High Therapeutic Performance and Negligible Long-Term Immunotoxicity.
Topics: Antineoplastic Agents, Phytogenic; beta-Cyclodextrins; Breast Neoplasms; Camptothecin; Female; Glutathione; HeLa Cells; Humans; Nanomedicine; Neoplasms; Positron-Emission Tomography; Solubility | 2018 |
Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Biological Availability; Camptothecin; Disulfides; Doxorubicin; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Liberation; Drug Synergism; Female; Folic Acid; Folic Acid Transporters; HeLa Cells; Humans; Hydrazones; Lysosomes; MCF-7 Cells; Methotrexate; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Nanostructures; Neoplasm Transplantation; Neoplasms; Prodrugs | 2018 |
Near Infrared Light Triggered Cucurbit[7]uril-Stabilized Gold Nanostars as a Supramolecular Nanoplatform for Combination Treatment of Cancer.
Topics: Animals; Antineoplastic Agents; Bridged-Ring Compounds; Camptothecin; Combined Modality Therapy; Gold; Humans; Hyperthermia, Induced; Imidazoles; Infrared Rays; MCF-7 Cells; Mice; Microscopy, Confocal; Microscopy, Electron, Transmission; Nanostructures; Neoplasms; Photochemotherapy; Spectrometry, Fluorescence; Tissue Distribution; Xenograft Model Antitumor Assays | 2018 |
[Factors Affecting Development of Cholinergic Symptoms after Irinotecan Administration].
Topics: Abdominal Pain; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cholinergic Agents; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Retrospective Studies; Sweat | 2018 |
Redox sensitive lipid-camptothecin conjugate encapsulated solid lipid nanoparticles for oral delivery.
Topics: Administration, Oral; Animals; Biological Availability; Caco-2 Cells; Camptothecin; Drug Carriers; Drug Compounding; Drug Stability; Female; Hep G2 Cells; HT29 Cells; Humans; Intestinal Absorption; Lipids; MCF-7 Cells; Mice, Inbred BALB C; Nanoparticles; Nanotechnology; Neoplasms; Oxidation-Reduction; Palmitic Acids; Prodrugs; Technology, Pharmaceutical; Topoisomerase I Inhibitors | 2018 |
Carrier-free Janus nano-prodrug based on camptothecin and gemcitabine: Reduction-triggered drug release and synergistic in vitro antiproliferative effect in multiple cancer cells.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Janus Kinases; Nanoparticles; Neoplasms; Oxidation-Reduction; Prodrugs | 2018 |
Design, synthesis and pharmacological evaluation of a novel PEG-cRGD-conjugated irinotecan derivative as potential antitumor agent.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chickens; Female; Humans; Integrin alphaVbeta3; Irinotecan; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Peptides, Cyclic; Polyethylene Glycols; Rats, Sprague-Dawley | 2018 |
Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cholinergic Agents; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Male; Middle Aged; Neoplasms; Prognosis; Quality of Life; Retrospective Studies; Risk Factors; Syndrome | 2019 |
Preexisting Interstitial Lung Disease and Lung Injury Associated with Irinotecan in Patients with Neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Follow-Up Studies; Humans; Irinotecan; Lung Diseases, Interstitial; Lung Injury; Male; Middle Aged; Neoplasms; Prognosis; Retrospective Studies; Risk Factors | 2018 |
Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents.
Topics: Animals; Antineoplastic Agents; Binding Sites; Camptothecin; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Female; Histone Deacetylase Inhibitors; Humans; Mice; Mice, Nude; Molecular Dynamics Simulation; Neoplasms; Topoisomerase I Inhibitors; Transplantation, Heterologous | 2018 |
Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy.
Topics: Animals; Apoptosis; Biological Transport; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Endocytosis; Female; Gene Silencing; Gene Transfer Techniques; HeLa Cells; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Liposomes; Mice, Nude; Neoplasms; Particle Size; Prodrugs; RNA, Small Interfering; Survivin; Tissue Distribution; Transferrin | 2018 |
Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Dimerization; Dithiothreitol; Drug Carriers; Endocytosis; Female; Fluorescence Resonance Energy Transfer; HEK293 Cells; Humans; Ligands; Mice; Micelles; Nanoparticles; Neoplasms; Neurotensin; Oxidation-Reduction; Polymers; Prodrugs; Temperature; Triple Negative Breast Neoplasms | 2018 |
High Drug Loading, Reversible Disulfide Core-Cross-Linked Multifunctional Micelles for Triggered Release of Camptothecin.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cross-Linking Reagents; Drug Carriers; Drug Compounding; Drug Liberation; Drug Screening Assays, Antitumor; Drug Stability; Glutathione; Hep G2 Cells; Humans; MCF-7 Cells; Micelles; Nanoparticles; Neoplasms; Particle Size; Polyethylene Glycols; Thioctic Acid | 2018 |
Hydroxycamptothecin nanoparticles based on poly/oligo (ethylene glycol): Architecture effects of nanocarriers on antitumor efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; Drug Compounding; Drug Stability; Drug Storage; Ethylene Glycol; Humans; Injections, Intravenous; Mice; Mice, Inbred BALB C; Molecular Conformation; Nanoparticles; Neoplasms; Particle Size; Rats; Tissue Distribution | 2019 |
Treating Tumors at Low Drug Doses Using an Aptamer-Peptide Synergistic Drug Conjugate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aptamers, Nucleotide; Camptothecin; Cell Line; Cell Proliferation; Doxorubicin; Drug Screening Assays, Antitumor; Humans; Maximum Tolerated Dose; Molecular Structure; Neoplasms; Peptides | 2019 |
Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Camptothecin; Cell Line, Tumor; Energy Metabolism; Fluorouracil; Glucose; Leucovorin; Liver; Male; Metabolomics; Mice; Muscle Strength; Muscle, Skeletal; Neoplasms; Reactive Oxygen Species; Receptors, LDL | 2019 |
Probing a dipeptide-based supramolecular assembly as an efficient camptothecin delivering carrier for cancer therapy: computational simulations and experimental validations.
Topics: Animals; Antineoplastic Agents, Phytogenic; Binding Sites; Camptothecin; Cell Line, Tumor; Cell Survival; Dipeptides; Drug Carriers; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Molecular Docking Simulation; Nanoparticles; Neoplasms; Optical Imaging; Transplantation, Heterologous | 2019 |
Integrin-independent support of cancer drug resistance by tetraspanin CD151.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Integrins; Laminin; Neoplasms; RNA, Messenger; Tetraspanin 24 | 2019 |
Hexahistidine-metal assemblies: A promising drug delivery system.
Topics: Antineoplastic Agents; Camptothecin; Coordination Complexes; Delayed-Action Preparations; HeLa Cells; Histidine; Humans; Lysosomes; Neoplasms | 2019 |
Light/pH-Triggered Biomimetic Red Blood Cell Membranes Camouflaged Small Molecular Drug Assemblies for Imaging-Guided Combinational Chemo-Photothermal Therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biomimetics; Camptothecin; Cell Membrane; Erythrocytes; HeLa Cells; Humans; Hydrogen-Ion Concentration; Indocyanine Green; Infrared Rays; Male; Mice; Mice, Nude; Nanoparticles; Neoplasms; Phototherapy; Rats; Rats, Sprague-Dawley | 2019 |
Mitochondria-specific drug release and reactive oxygen species burst induced by polyprodrug nanoreactors can enhance chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Drug Liberation; Female; Flow Cytometry; Humans; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Mitochondria; Nanomedicine; Nanotechnology; Neoplasms; Oxidative Stress; Photochemotherapy; Prodrugs; Reactive Oxygen Species | 2019 |
Polymersome nanoreactors with tumor pH-triggered selective membrane permeability for prodrug delivery, activation, and combined oxidation-chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Membrane Permeability; Drug Carriers; Female; Glucose Oxidase; Humans; Hydrogen Peroxide; Hydrogen-Ion Concentration; Mice, Inbred ICR; Neoplasms; Oxidation-Reduction; Paclitaxel; Polymers; Prodrugs | 2019 |
In vitro evaluation of FL118 and 9-Q20 cytotoxicity and cellular uptake in 2D and 3D different cell models.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Benzodioxoles; Biological Transport; Camptothecin; Cell Proliferation; HCT116 Cells; Hep G2 Cells; Humans; In Vitro Techniques; Indolizines; Neoplasms | 2019 |
Hypoxia inducible factor 1 inhibitors for cancer therapy.
Topics: Antineoplastic Agents; Camptothecin; Digoxin; Flavonoids; Humans; Hypoxia-Inducible Factor 1; Mustard Compounds; Neoplasms; Oligonucleotides; Phenylpropionates; Polyethylene Glycols; Topotecan | 2019 |
Enzyme-activatable polymer-drug conjugate augments tumour penetration and treatment efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; gamma-Glutamyltransferase; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Neoplasms; Polymers; Transcytosis | 2019 |
Redox/NIR dual-responsive MoS
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Disulfides; Drug Carriers; Drug Liberation; Female; Fluorescent Dyes; Humans; Hyaluronic Acid; Hyperthermia, Induced; Infrared Rays; Mice, Nude; Molybdenum; Nanoparticles; Neoplasm Transplantation; Neoplasms; Oxidation-Reduction; Photochemotherapy | 2019 |
A Camptothecin-Grafted DNA Tetrahedron as a Precise Nanomedicine to Inhibit Tumor Growth.
Topics: Camptothecin; DNA; Humans; Nanomedicine; Neoplasms | 2019 |
Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Differentiation, B-Lymphocyte; Antigens, Neoplasm; Camptothecin; Cell Adhesion Molecules; Doxorubicin; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histocompatibility Antigens Class II; Humans; Irinotecan; Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Clinical Trials as Topic; DNA-Binding Proteins; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; HCT116 Cells; Heterocyclic Compounds, 3-Ring; Humans; Mice; Neoplasms; Pyrones; Radiation-Sensitizing Agents; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Death; Diarrhea; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Leukopenia; Logistic Models; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Sex Factors; Skin Neoplasms; Stomach Neoplasms; Thrombocytopenia | 2013 |
ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.
Topics: Acrylonitrile; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplasms; Neoplastic Stem Cells; Side-Population Cells; Tumor Cells, Cultured; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2013 |
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Female; Fluorouracil; Germany; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Practice Guidelines as Topic; Prospective Studies; Vomiting; Young Adult | 2013 |
Linear-dendritic drug conjugates forming long-circulating nanorods for cancer-drug delivery.
Topics: Animals; Camptothecin; Cell Death; Chromatography, High Pressure Liquid; Diagnostic Imaging; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Stability; Endocytosis; Humans; Magnetic Resonance Spectroscopy; MCF-7 Cells; Mice; Mice, Inbred BALB C; Micelles; Nanotubes; Neoplasms; Polyethylene Glycols; Polylysine; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Time Factors; Tissue Distribution | 2013 |
A theoretical study on mechanism of the anticancer drug camptothecin's E-ring-opening.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Hydrogen Bonding; Models, Chemical; Molecular Conformation; Neoplasms; Water | 2013 |
Tumor redox heterogeneity-responsive prodrug nanocapsules for cancer chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Molecular Structure; Nanocapsules; Neoplasms; Oxidation-Reduction; Prodrugs; Structure-Activity Relationship | 2013 |
A high-throughput yeast assay identifies synergistic drug combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Humans; Irinotecan; Mitomycin; Neoplasms; Two-Hybrid System Techniques | 2013 |
Anticancer drugs deliver themselves to cancer cells.
Topics: Antineoplastic Agents; Camptothecin; Drug Carriers; Humans; Nanostructures; Neoplasms; Peptides; Protein Structure, Secondary | 2013 |
The pH-controlled nanoparticles size of polydopamine for anti-cancer drug delivery.
Topics: Antineoplastic Agents; Biocompatible Materials; Camptothecin; Cell Line, Tumor; Drug Carriers; HeLa Cells; Humans; Hydrogen-Ion Concentration; Indoles; Kinetics; Microscopy, Electron, Transmission; Nanoparticles; Neoplasms; Particle Size; Polymers; Spectroscopy, Fourier Transform Infrared; Time Factors | 2013 |
Hydrophobic anticancer drug delivery by a 980 nm laser-driven photothermal vehicle for efficient synergistic therapy of cancer cells in vivo.
Topics: Animals; Antineoplastic Agents; Camptothecin; Copper; Drug Carriers; Hep G2 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Male; Mice; Nanoparticles; Neoplasms; Sulfides | 2013 |
Continuously manufactured magnetic polymersomes--a versatile tool (not only) for targeted cancer therapy.
Topics: Antineoplastic Agents; Bombesin; Camptothecin; Carbocyanines; Cell Line, Tumor; Cell Survival; Drug Carriers; Humans; Magnetite Nanoparticles; Neoplasms; Poloxamer; Polyethylene Glycols; Precision Medicine; Propylene Glycols | 2013 |
Preparation, characterization, biodistribution and antitumor efficacy of hydroxycamptothecin nanosuspensions.
Topics: Animals; Antineoplastic Agents, Phytogenic; Calorimetry, Differential Scanning; Camptothecin; Cell Line, Tumor; Chemical Precipitation; Drug Compounding; Female; Mice; Mice, Inbred ICR; Nanoparticles; Neoplasms; Particle Size; Powder Diffraction; Sonication; Suspensions; Tissue Distribution; X-Ray Diffraction | 2013 |
Carrier-free functionalized multidrug nanorods for synergistic cancer therapy.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Carriers; Drug Synergism; Drug Therapy, Combination; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; KB Cells; MCF-7 Cells; Methotrexate; Mice; Mice, Inbred BALB C; Nanoparticles; Nanotubes; Neoplasms; Paclitaxel | 2013 |
Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India.
Topics: Camptothecin; Cost Savings; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drugs, Generic; Gemcitabine; Humans; India; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Poverty; Taxoids | 2013 |
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbolines; Cell Cycle Checkpoints; Checkpoint Kinase 1; Dacarbazine; Deoxycytidine; DNA Damage; Gemcitabine; HCT116 Cells; High-Throughput Nucleotide Sequencing; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Synthesis and activity of a folate targeted monodisperse PEG camptothecin conjugate.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Delivery Systems; Folate Receptors, GPI-Anchored; Folic Acid; Humans; KB Cells; Neoplasms; Polyethylene Glycols; Prodrugs | 2013 |
Shape design of high drug payload nanoparticles for more effective cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Carriers; Half-Life; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Nanotubes; Neoplasms; Particle Size; Polyethylene Glycols; Transplantation, Heterologous | 2013 |
Multiple shoot cultures of Ophiorrhiza rugosa var. decumbens Deb and Mondal--a viable renewable source for the continuous production of bioactive Camptotheca alkaloids apart from stems of the parent plant of Nothapodytes foetida (Wight) Sleumer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptotheca; Camptothecin; Humans; Jurkat Cells; Magnoliopsida; MCF-7 Cells; Neoplasms; Phytotherapy; Plant Extracts; Plant Shoots; Plant Somatic Embryogenesis Techniques; Plant Stems; Rubiaceae; U937 Cells | 2014 |
The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1α activity by changing miR expression patterns in human cancer cells.
Topics: Camptothecin; Cell Hypoxia; DNA Topoisomerases, Type I; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; MicroRNAs; Neoplasms; RNA, Messenger; Topoisomerase I Inhibitors | 2014 |
Acidity-promoted cellular uptake and drug release mediated by amine-functionalized block polycarbonates prepared via one-shot ring-opening copolymerization.
Topics: Amines; Camptothecin; Dihydropyridines; Doxorubicin; Drug Liberation; HeLa Cells; Humans; Hydrogen-Ion Concentration; Neoplasms; Polymers | 2014 |
DNA-based nanosensors for next-generation clinical diagnostics via detection of enzyme activity.
Topics: Antineoplastic Agents, Phytogenic; Biosensing Techniques; Camptothecin; DNA Probes; DNA Topoisomerases; Enzyme Assays; Humans; Nanotechnology; Neoplasms; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Topoisomerase Inhibitors | 2014 |
Nanopharmaceutical may offer benefits in combinations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Cyclodextrins; Humans; Nanoparticles; Neoplasms | 2013 |
CARS based label-free assay for assessment of drugs by monitoring lipid droplets in tumour cells.
Topics: Algorithms; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Drug Screening Assays, Antitumor; Etoposide; Fluorescent Dyes; HCT116 Cells; Humans; Lipid Droplets; Lipids; Microscopy, Fluorescence; Neoplasms; Spectrum Analysis, Raman; Staurosporine | 2014 |
Smart nanorods for highly effective cancer theranostic applications.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bridged Bicyclo Compounds, Heterocyclic; Camptothecin; Cell Line, Tumor; Disulfides; Drug Carriers; Half-Life; HeLa Cells; Humans; Magnetic Resonance Imaging; Mice, Inbred BALB C; Nanotubes; Neoplasms; Phototherapy; Polyethylene Glycols; Polymers; Radiography; Tissue Distribution | 2014 |
Synthesis and optimization of a bifunctional hyaluronan-based camptothecin prodrug.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Drug Stability; Hep G2 Cells; Humans; Hyaluronic Acid; Molecular Weight; Neoplasms; Prodrugs; Solubility | 2014 |
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Folic Acid; HeLa Cells; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids; Topotecan; Treatment Outcome; Vinca Alkaloids; Xenograft Model Antitumor Assays | 2014 |
Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Hydrogen-Ion Concentration; Intracellular Space; Irinotecan; Lipids; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Proteins; Neoplasms; Particle Size; Polymers; Porosity; Silicon Dioxide; Static Electricity; Time Factors; X-Ray Diffraction; Xenograft Model Antitumor Assays | 2014 |
The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circadian Rhythm; Fatigue; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Monitoring, Physiologic; Motor Activity; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Rest; Weight Loss | 2014 |
Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Cytoprotection; Female; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Rats; Rats, Inbred F344; Selenocysteine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Self-assembling peptide of D-amino acids boosts selectivity and antitumor efficacy of 10-hydroxycamptothecin.
Topics: Amino Acids; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Humans; Mice; Mice, Inbred BALB C; Neoplasms; Peptides | 2014 |
Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer.
Topics: Antineoplastic Agents; Base Sequence; Camptothecin; Cell Proliferation; Cyclodextrins; Cytokines; DNA Primers; Humans; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Pharmacogenetics; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
Old drug new use--amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity.
Topics: Amoxapine; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Activation; Female; Glycoproteins; Irinotecan; Mice; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Neoplasms; Protective Agents; Protein Binding; Xenograft Model Antitumor Assays | 2014 |
Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans.
Topics: Adult; Animals; Biopsy, Large-Core Needle; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lung; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasms; Organosilicon Compounds; Pilot Projects; Random Allocation; Survival Analysis; Tissue Distribution; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2014 |
Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Young Adult | 2014 |
Human serum albumin conjugates of 7-ethyl-10-hydroxycamptothecin (SN38) for cancer treatment.
Topics: Animals; Blood Cell Count; Camptothecin; Cell Death; Cell Survival; Drug Stability; Electrophoresis, Polyacrylamide Gel; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Neoplasms; Particle Size; Serum Albumin; Static Electricity; Tissue Distribution | 2014 |
Determination of irinotecan and its metabolite SN-38 in rabbit plasma and tumors using a validated method of tandem mass spectrometry coupled with liquid chromatography.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptotheca; Camptothecin; Chromatography, High Pressure Liquid; Irinotecan; Limit of Detection; Neoplasms; Rabbits; Reproducibility of Results; Tandem Mass Spectrometry | 2014 |
Irinotecan pharmacogenetics: a finished puzzle?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Male; Neoplasms | 2014 |
Allelic expression of phase II metabolizing enzymes and relationship to irinotecan toxicity.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Oncology Nursing; Polymorphism, Single Nucleotide | 2014 |
Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Female; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Rats; Selenium | 2014 |
Multi-layered nanoparticles for combination gene and drug delivery to tumors.
Topics: Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Gene Transfer Techniques; HCT116 Cells; HEK293 Cells; Humans; Lactic Acid; Nanoparticles; Neoplasms; Plasmids; Polyethyleneimine; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; TNF-Related Apoptosis-Inducing Ligand; Transfection | 2014 |
Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.
Topics: Adult; Algorithms; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Genome-Wide Association Study; Genome, Human; Genomics; Humans; Irinotecan; KCNQ Potassium Channels; Knowledge Bases; Male; Neoplasms; Polymorphism, Single Nucleotide; ROC Curve | 2014 |
Responsive delivery of drug cocktail via mesoporous silica nanolamps.
Topics: Antineoplastic Agents; Cadmium Compounds; Camptothecin; Cell Line, Tumor; Delayed-Action Preparations; Doxorubicin; Fluorescence; Humans; Hydrogen-Ion Concentration; Nanocomposites; Neoplasms; Porosity; Quantum Dots; Silicon Dioxide; Sulfides | 2014 |
Molecularly precise dendrimer-drug conjugates with tunable drug release for cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carbocyanines; Cell Line, Tumor; Cell Survival; Dendrimers; Drug Carriers; Flow Cytometry; Humans; Hydrogen-Ion Concentration; Mice; Mice, Nude; Neoplasms; Polylysine; Transplantation, Heterologous | 2014 |
Polysaccharide nano-vesicular multidrug carriers for synergistic killing of cancer cells.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Carriers; Endocytosis; Esterases; Humans; Mice; Microscopy, Atomic Force; Microscopy, Confocal; Nanoparticles; Nanotechnology; Neoplasms; Polymers; Polysaccharides | 2014 |
Dual sensitive and temporally controlled camptothecin prodrug liposomes codelivery of siRNA for high efficiency tumor therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Genetic Therapy; Humans; Liposomes; Mice; Neoplasms; Polo-Like Kinase 1; Prodrugs; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA Interference; RNA, Small Interfering | 2014 |
Pre-treatment serum total bilirubin level as an indicator of optimal CPT-11 dosage.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Biomarkers; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; Predictive Value of Tests; Retrospective Studies | 2015 |
Hypersensitivity reactions to racemic calcium folinate (leucovorin) during FOLFOX and FOLFIRI chemotherapy administrations.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Hypersensitivity; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasms; Organoplatinum Compounds | 2015 |
Polypeptide-based Micelles for Delivery of Irinotecan: Physicochemical and In vivo Characterization.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Carriers; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanoparticles; Neoplasms; Polyethylene Glycols; Solubility; Technology, Pharmaceutical; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Rationally Engineering Phototherapy Modules of Eosin-Conjugated Responsive Polymeric Nanocarriers via Intracellular Endocytic pH Gradients.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Endocytosis; Eosine Yellowish-(YS); Fluorescent Dyes; Humans; Hydrogen-Ion Concentration; Micelles; Nanostructures; Neoplasms; Photochemotherapy; Polymers | 2015 |
Synergism through combination of chemotherapy and oxidative stress-induced autophagy in A549 lung cancer cells using redox-responsive nanohybrids: a new strategy for cancer therapy.
Topics: 3T3-L1 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Camptothecin; Cell Line, Tumor; Energy Metabolism; Glutathione; Humans; Intracellular Space; Lipid Peroxidation; Malondialdehyde; Mice; Mice, Nude; Mitochondria; Models, Biological; Nanoparticles; Neoplasms; Oxidation-Reduction; Oxidative Stress; Porosity; Silicon Dioxide; Xenograft Model Antitumor Assays | 2015 |
The aspect ratio effect of drug nanocrystals on cellular internalization efficiency, uptake mechanisms, and in vitro and in vivo anticancer efficiencies.
Topics: Animals; Antineoplastic Agents; Camptothecin; Drug Carriers; Drug Screening Assays, Antitumor; Female; Humans; Liver; Mice; Mice, Inbred BALB C; Microscopy, Confocal; Nanomedicine; Nanoparticles; Neoplasm Transplantation; Neoplasms; Polyethylene Glycols | 2015 |
Preparation and identification of multifunctional mesoporous silica nanoparticles for in vitro and in vivo dual-mode imaging, theranostics, and targeted tracking.
Topics: Animals; Body Weight; Camptothecin; Cell Death; Europium; Gadolinium; HeLa Cells; Humans; Magnetic Resonance Imaging; Mice; Multimodal Imaging; Nanoparticles; Neoplasms; Porosity; Silicon Dioxide; X-Ray Diffraction | 2015 |
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Irinotecan; Liposomes; Male; Middle Aged; Neoplasms; Polyethylene Glycols | 2015 |
[DNA topoisomerase I--targeting drugs].
Topics: Camptothecin; Humans; Irinotecan; Molecular Targeted Therapy; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2015 |
Irinotecan induces cell cycle arrest, but not apoptosis or necrosis, in Caco-2 and CW2 colorectal cancer cell lines.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Caco-2 Cells; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Humans; Irinotecan; Male; Mice, Nude; Necrosis; Neoplasms; Tumor Burden | 2015 |
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Cohort Studies; Female; Genetic Markers; Genotype; Humans; Irinotecan; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasms; Neutropenia | 2016 |
Targeted tumor theranostics using folate-conjugated and camptothecin-loaded acoustic nanodroplets in a mouse xenograft model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Folic Acid; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Nanostructures; Neoplasms; Theranostic Nanomedicine; Xenograft Model Antitumor Assays | 2015 |
Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Doxorubicin; Drug Synergism; Female; Humans; Hyaluronic Acid; Mice, Inbred BALB C; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Burden | 2015 |
A clickable and photocleavable lipid analogue for cell membrane delivery and release.
Topics: Antineoplastic Agents, Phytogenic; Azides; Camptothecin; Cell Membrane; Cell Proliferation; Delayed-Action Preparations; Drug Delivery Systems; HeLa Cells; Humans; Light; Lipids; Liposomes; Neoplasms; Optical Imaging; Photochemical Processes; Saccharomyces cerevisiae | 2015 |
Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules.
Topics: Antineoplastic Agents; Bone Marrow Cells; Camptothecin; Cell Cycle; Cell Proliferation; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Humans; Models, Biological; Neoplasms; Neutropenia; Neutrophils; Stem Cells | 2015 |
Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Neoplasms; Remission Induction; Topoisomerase I Inhibitors | 2015 |
Characterization of 9-nitrocamptothecin-in-cyclodextrin-in-liposomes modified with transferrin for the treating of tumor.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cyclodextrins; Drug Carriers; Drug Delivery Systems; Drug Stability; Lactones; Liposomes; Mice; Mice, Inbred ICR; Neoplasms; Rats; Rats, Sprague-Dawley; Transferrin | 2015 |
Synthesis and Biological Evaluation of Novel Water-Soluble Poly-(ethylene glycol)-10-hydroxycamptothecin Conjugates.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Hep G2 Cells; HT29 Cells; Humans; Neoplasms; Polyethylene Glycols; Solubility | 2015 |
hMSH5 Facilitates the Repair of Camptothecin-induced Double-strand Breaks through an Interaction with FANCJ.
Topics: Basic-Leucine Zipper Transcription Factors; Camptothecin; Cell Cycle Proteins; Cell Survival; Checkpoint Kinase 1; Checkpoint Kinase 2; DNA Breaks, Double-Stranded; DNA Damage; DNA Repair; DNA Replication; Fanconi Anemia Complementation Group Proteins; Homologous Recombination; Humans; Neoplasms; Protein Kinases; Rad51 Recombinase | 2015 |
Silica Nanopills for Targeted Anticancer Drug Delivery.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Electrochemistry; Humans; Microscopy, Confocal; Microscopy, Electron, Scanning; Microtubules; Nanomedicine; Nanoparticles; Neoplasms; Nerve Tissue Proteins; Neuroblastoma; Receptors, Nerve Growth Factor; Silicon Dioxide; Surface Properties | 2015 |
Identification of Circadian Determinants of Cancer Chronotherapy through In Vitro Chronopharmacology and Mathematical Modeling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Circadian Clocks; DNA Topoisomerases, Type I; Drug Chronotherapy; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Irinotecan; Mice; Models, Theoretical; Neoplasms | 2015 |
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Gene Expression; Humans; Irinotecan; Lung; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Phosphorylation; Serine; Topotecan | 2015 |
HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Female; HSP90 Heat-Shock Proteins; Humans; Irinotecan; Mice, Inbred ICR; Mice, SCID; Microscopy, Fluorescence; Molecular Targeted Therapy; Neoplasms; Resorcinols; Topoisomerase I Inhibitors; Treatment Outcome; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure.
Topics: Acute Kidney Injury; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Kidney; Models, Biological; Neoplasms; Protein Binding | 2016 |
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Child; Drug Screening Assays, Antitumor; Female; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Male; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines | 2015 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway | 2015 |
Hyaluronic Acid Modified Hollow Prussian Blue Nanoparticles Loading 10-hydroxycamptothecin for Targeting Thermochemotherapy of Cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Carriers; Drug Therapy; Ferrocyanides; HeLa Cells; Humans; Hyperthermia, Induced; Nanoparticles; Neoplasms | 2016 |
Multi-responsive photothermal-chemotherapy with drug-loaded melanin-like nanoparticles for synergetic tumor ablation.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Death; Doxorubicin; Drug Liberation; Drug Stability; Endocytosis; HeLa Cells; Humans; Hyperthermia, Induced; Indoles; Inhibitory Concentration 50; Irinotecan; Male; MCF-7 Cells; Melanins; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; NIH 3T3 Cells; Phototherapy; Polyethylene Glycols; Polymers | 2016 |
In vitro and in vivo anti-tumor efficacy of 10-hydroxycamptothecin polymorphic nanoparticle dispersions: shape- and polymorph-dependent cytotoxicity and delivery of 10-hydroxycamptothecin to cancer cells.
Topics: Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Humans; Nanoparticles; Neoplasms; Particle Size; Solubility; Tissue Distribution | 2016 |
Self-sufficing H2O2-responsive nanocarriers through tumor-specific H2O2 production for synergistic oxidation-chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Damage; Drug Carriers; Drug Liberation; Female; Hydrogen Peroxide; Mice, Inbred BALB C; Micelles; Nanostructures; Neoplasms; Oxidation-Reduction; Polymers | 2016 |
Novel 20(S)-sulfonylamidine derivatives of camptothecin and the use thereof as a potent antitumor agent: a patent evaluation of WO2015048365 (A1).
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; DNA Damage; Drug Design; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Mice; Neoplasms; Patents as Topic | 2016 |
Molecular Genetics External Quality Assessment Pilot Scheme for Irinotecan-Related UGT1A1 Genotyping in China.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; China; Genotype; Genotyping Techniques; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Topoisomerase I Inhibitors | 2016 |
Well-defined hydroxyethyl starch-10-hydroxy camptothecin super macromolecule conjugate: cytotoxicity, pharmacodynamics research, tissue distribution test and intravenous injection safety assessment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Guinea Pigs; Half-Life; Hemolysis; Hydroxyethyl Starch Derivatives; Injections, Intravenous; Lactones; Male; Mice; Neoplasms; Prodrugs; Rabbits; Rats; Solubility; Tissue Distribution | 2016 |
Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Camptothecin; Diarrhea; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Genetic | 2016 |
Rad18 is required for functional interactions between FANCD2, BRCA2, and Rad51 to repair DNA topoisomerase 1-poisons induced lesions and promote fork recovery.
Topics: Camptothecin; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Repair; DNA Topoisomerases, Type I; DNA-Binding Proteins; Fanconi Anemia Complementation Group D2 Protein; HCT116 Cells; Humans; Neoplasms; Rad51 Recombinase; RNA, Small Interfering; Transfection; Ubiquitin-Protein Ligases | 2016 |
Transcriptome analysis of stem wood of Nothapodytes nimmoniana (Graham) Mabb. identifies genes associated with biosynthesis of camptothecin, an anti-carcinogenic molecule.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Neoplasms; Plant Leaves; Plant Stems; Plants; Topoisomerase I Inhibitors; Transcriptome | 2016 |
Low-molecular-weight polymer-drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Delivery Systems; Drug Synergism; Humans; Hyaluronic Acid; Molecular Weight; Neoplasms; Polymers; Polyvinyl Alcohol | 2016 |
Tunable release of chemotherapeutic and vascular disrupting agents from injectable fiber fragments potentiates combination chemotherapy.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; beta-Cyclodextrins; Bibenzyls; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Liberation; Drug Therapy, Combination; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Inbred BALB C; Neoplasms; Tumor Microenvironment | 2016 |
Improved tumor targeting and antitumor activity of camptothecin loaded solid lipid nanoparticles by preinjection of blank solid lipid nanoparticles.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Camptothecin; Cell Death; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Humans; Injections; Lactones; Lipids; Male; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Particle Size; Rats, Sprague-Dawley; Time Factors; Tissue Distribution; Xenograft Model Antitumor Assays | 2016 |
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Bystander Effect; Camptothecin; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Female; Humans; Immunoconjugates; Maytansine; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Receptor, ErbB-2; Stomach Neoplasms; Topoisomerase I Inhibitors; Trastuzumab | 2016 |
A Selective Small Molecule DNA2 Inhibitor for Sensitization of Human Cancer Cells to Chemotherapy.
Topics: A549 Cells; Binding Sites; Camptothecin; Carboxylic Acids; Cell Line, Tumor; Computer Simulation; DNA Helicases; DNA Replication; Drug Screening Assays, Antitumor; Drug Therapy; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; MCF-7 Cells; Neoplasms; Nitroquinolines; Small Molecule Libraries | 2016 |
Synthesis, characterization, and evaluation of mPEG-SN38 and mPEG-PLA-SN38 micelles for cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Drug Liberation; Endocytosis; Fluorescein-5-isothiocyanate; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Nude; Micelles; Neoplasms; Polyesters; Polyethylene Glycols; Tissue Distribution; Treatment Outcome | 2016 |
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; Camptothecin; Carbolines; Cell Line; Dogs; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Proteins; Neoplasms | 2016 |
Tunable conjugation densities of camptothecin on hyaluronic acid for tumor targeting and reduction-triggered release.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Proliferation; Drug Liberation; Dynamic Light Scattering; Endocytosis; Humans; Hyaluronic Acid; MCF-7 Cells; Mice; Micelles; Neoplasm Metastasis; Neoplasms; Particle Size; Survival Analysis; Tissue Distribution | 2016 |
Vitamin D Enhances the Efficacy of Irinotecan through miR-627-Mediated Inhibition of Intratumoral Drug Metabolism.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cytochrome P-450 CYP3A; Disease Models, Animal; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Mice; MicroRNAs; Neoplasms; Pharmacogenetics; RNA Interference; Vitamin D; Xenograft Model Antitumor Assays | 2016 |
Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Asian People; Camptothecin; Drug Interactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Ramucirumab | 2016 |
Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling.
Topics: Biomarkers, Tumor; Camptothecin; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Neoplasm Proteins; Neoplasms; Pathology, Molecular | 2016 |
Sequential designs for individualized dosing in phase I cancer clinical trials.
Topics: Algorithms; Antineoplastic Agents; Area Under Curve; Camptothecin; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Humans; Irinotecan; Neoplasms; Phenotype | 2017 |
Achieving High Drug Loading and Sustained Release of Hydrophobic Drugs in Hydrogels through In Situ Crystallization.
Topics: Camptothecin; Crystallization; Delayed-Action Preparations; Drug Delivery Systems; Humans; Hydrogels; Hydrophobic and Hydrophilic Interactions; Lactic Acid; Neoplasms; Polyethylene Glycols | 2017 |
Combination of baicalein and 10-hydroxy camptothecin exerts remarkable synergetic anti-cancer effects.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Combinations; Drug Synergism; Flavanones; G2 Phase; Humans; Mice; Mice, Nude; Neoplasms; Phytotherapy; Plant Extracts; Scutellaria baicalensis; Xenograft Model Antitumor Assays | 2016 |
Multifunctional Metal-Organic Framework Nanoprobe for Cathepsin B-Activated Cancer Cell Imaging and Chemo-Photodynamic Therapy.
Topics: Camptothecin; Cathepsin B; Humans; Metal-Organic Frameworks; Neoplasms; Photochemotherapy; Photosensitizing Agents | 2017 |
Rapidly cell-penetrating and reductive milieu-responsive nanoaggregates assembled from an amphiphilic folate-camptothecin prodrug for enhanced drug delivery and controlled release.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Folic Acid; Glutathione; Humans; Neoplasms; Prodrugs | 2017 |
Subcellular co-delivery of two different site-oriented payloads for tumor therapy.
Topics: Acrylamides; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; DNA Damage; Docetaxel; Drug Delivery Systems; Humans; Male; Mice; Mice, Inbred BALB C; Micelles; Neoplasms; NIH 3T3 Cells; Organosilicon Compounds; Polymers; Taxoids; Tretinoin; Xenograft Model Antitumor Assays | 2017 |
Supramolecular "Trojan Horse" for Nuclear Delivery of Dual Anticancer Drugs.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Humans; Macromolecular Substances; Mice; Molecular Structure; Nanomedicine; Neoplasms | 2017 |
Acoustically active perfluorocarbon nanoemulsions as drug delivery carriers for camptothecin: drug release and cytotoxicity against cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Drug Carriers; Emulsions; Fluorocarbons; Humans; Neoplasms; Sonication; Tumor Cells, Cultured | 2009 |
Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Carriers; fas Receptor; Humans; Immunoconjugates; Intracellular Space; Lactic Acid; Microscopy, Fluorescence; Nanoparticles; Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2008 |
[Role of UGT1A1*28 and UGT1A1*6 for irinotecan-induced adverse drug reaction].
Topics: Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Multigene Family; Neoplasms; Polymorphism, Genetic | 2008 |
A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Breath Tests; Camptothecin; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Erythromycin; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Neoplasms; Prognosis; Survival Rate; Tissue Distribution; Treatment Outcome; Young Adult | 2009 |
FLEX data, KRAS and ERCC1 testing in oncology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; DNA-Binding Proteins; Drug Delivery Systems; Drug Resistance, Neoplasm; Endonucleases; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2008 |
Inhibition of cell growth and invasion by epidermal growth factor-targeted phagemid particles carrying siRNA against focal adhesion kinase in the presence of hydroxycamptothecin.
Topics: Antineoplastic Agents, Phytogenic; Bacteriophages; Base Sequence; Camptothecin; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Combined Modality Therapy; Epidermal Growth Factor; Focal Adhesion Protein-Tyrosine Kinases; Genetic Vectors; Humans; Molecular Sequence Data; Neoplasm Invasiveness; Neoplasms; RNA Interference; RNA, Small Interfering | 2008 |
Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin.
Topics: Animals; Antineoplastic Agents; Biological Availability; Camptothecin; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cyanoacrylates; Cytoplasm; Drug Delivery Systems; Endocytosis; Humans; K562 Cells; Liposomes; Male; Mice; Mice, Inbred Strains; Neoplasms; Particle Size; Polyethylene Glycols; Rats; Rats, Wistar; Sarcoma 180; Tissue Distribution; Transferrin | 2009 |
Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Male; Neoplasms; Polymorphism, Genetic | 2008 |
[Feasibility of peripheral vein during FOLFOX/FOLFIRI chemotherapy through peripheral venous system].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Feasibility Studies; Female; Fluorouracil; Humans; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Phlebitis; Time Factors; Venules | 2008 |
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Oxonic Acid; Paclitaxel; Quality of Life; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
A novel camptothecin derivative incorporated in nano-carrier induced distinguished improvement in solubility, stability and anti-tumor activity both in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Stability; Emulsifying Agents; Emulsions; Fluorescent Dyes; Glycerol; Hemolysis; Humans; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Male; Mice; Microscopy, Fluorescence; Nanostructures; Neoplasms; Oxazines; Particle Size; Rabbits; Solubility; Xenograft Model Antitumor Assays | 2009 |
[Report from the 44th Congress of the American Society of Clinical Oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Mass Screening; Medical Oncology; Neoplasms; Organoplatinum Compounds; Societies, Medical | 2008 |
9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Drug Evaluation, Preclinical; Folic Acid; HeLa Cells; Humans; Micelles; Neoplasms; Polymers | 2009 |
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Camptothecin; DNA Topoisomerases, Type I; Histones; HT29 Cells; Humans; Isoquinolines; Models, Molecular; Neoplasms; Protein Structure, Tertiary; Topoisomerase I Inhibitors | 2009 |
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasms; Neutropenia; Organic Anion Transporters; Polymorphism, Genetic | 2009 |
Crystalline camptothecin-20(S)-O-propionate hydrate: a novel anticancer agent with strong activity against 19 human tumor xenografts.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Crystallization; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Compounding; Humans; Mice; Models, Biological; Models, Molecular; Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Pro-apoptotic activities of novel synthetic quinones in human cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cell Survival; DNA Fragmentation; Dose-Response Relationship, Drug; HeLa Cells; Humans; Neoplasms; Quinones; Time Factors | 2009 |
Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements.
Topics: Animals; Camptothecin; Cell Line, Tumor; Copper; Cyclodextrins; Fluorescent Antibody Technique; Kidney; Mice; Mice, SCID; Models, Biological; Nanoparticles; Neoplasms; Polymers; Positron-Emission Tomography; Tissue Distribution; Whole Body Imaging | 2009 |
Antiangiogenesis targeting tumor microenvironment synergizes glucuronide prodrug antitumor activity.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Glucuronides; Humans; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Neutrophils; Prodrugs; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2009 |
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Haplotypes; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Genetic; Risk Factors | 2009 |
TREX1 acts in degrading damaged DNA from drug-treated tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; DNA; DNA Damage; DNA Repair; Exodeoxyribonucleases; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Phosphoproteins; Protein Transport; RNA, Messenger | 2009 |
Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Drug Stability; Enzyme Inhibitors; Female; Half-Life; Humans; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microsomes, Liver; Neoplasms; Organosilicon Compounds; Time Factors; Topoisomerase I Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Calcium-Binding Proteins; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chaperonin 60; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Irinotecan; Membrane Proteins; Mice; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Receptors, Notch; Secondary Prevention; Xenograft Model Antitumor Assays | 2009 |
Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bone Marrow Cells; Camptothecin; Case-Control Studies; Female; Humans; Immune Tolerance; Irinotecan; Male; Middle Aged; Models, Biological; Neoplasm Proteins; Neoplasms; Polymorphism, Single Nucleotide; Retrospective Studies | 2009 |
In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Female; Fluorouracil; Interleukins; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Organoplatinum Compounds; Oxaliplatin; T-Lymphocytes | 2009 |
The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress.
Topics: Antineoplastic Agents, Phytogenic; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Cycle; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; DNA Replication; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Lysine; Neoplasms; Phosphorylation; Protein Kinases; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; RNA Interference; SKP Cullin F-Box Protein Ligases; Stress, Physiological; Time Factors; Ubiquitination | 2009 |
Mismatch repair system decreases cell survival by stabilizing the tetraploid G1 arrest in response to SN-38.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Cell Survival; Checkpoint Kinase 1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; DNA Damage; DNA Mismatch Repair; G1 Phase; Humans; Irinotecan; MutL Protein Homolog 1; Neoplasms; Nuclear Proteins; Phosphorylation; Ploidies; Protein Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2010 |
Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Benzamides; Camptothecin; Cell Line, Tumor; Cyclohexanones; Drug Resistance, Neoplasm; Humans; Neoplasms; NF-kappa B; Oncogenes | 2009 |
Downregulation of ANP32B, a novel substrate of caspase-3, enhances caspase-3 activation and apoptosis induction in myeloid leukemic cells.
Topics: Acetophenones; Antineoplastic Agents; Apoptosis; Benzopyrans; Camptothecin; Carcinoma; Caspase 3; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Down-Regulation; Enzyme Activation; Female; Humans; Leukemia, Myeloid; Male; Neoplasm Proteins; Neoplasms; Nuclear Proteins; Recombinant Fusion Proteins; RNA Interference; RNA, Small Interfering; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Substrate Specificity | 2010 |
Individualizing dosing of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Dosage Calculations; Humans; Irinotecan; Metabolic Clearance Rate; Models, Biological; Neoplasms; Precision Medicine; Randomized Controlled Trials as Topic | 2010 |
Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Japan; Neoplasms; Neutropenia; Phenotype; Polymorphism, Genetic; Risk Assessment; Risk Factors; Severity of Illness Index | 2010 |
Tumoral acidic pH-responsive MPEG-poly(beta-amino ester) polymeric micelles for cancer targeting therapy.
Topics: Acids; Animals; Camptothecin; Esters; Humans; Lactates; Lactic Acid; Mice; Mice, Nude; Micelles; Neoplasms; Polyethylene Glycols; Polymers | 2010 |
Inhibition of epidermal growth factor receptor-overexpressing cancer cells by camptothecin, 20-(N,N-diethyl) glycinate.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Evaluation, Preclinical; ErbB Receptors; Glycine; Humans; Neoplasms | 2010 |
Targeted cancer therapy with novel high drug-loading nanocrystals.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carrier Proteins; Chemistry, Pharmaceutical; Drug Delivery Systems; Excipients; Female; Folate Receptors, GPI-Anchored; Glycerol; Hemolysis; Humans; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Nanoparticles; Neoplasm Transplantation; Neoplasms; Paclitaxel; Poloxamer; Receptors, Cell Surface; Surface-Active Agents | 2010 |
BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Hypoxia; Cell Proliferation; Dipeptides; Drug Administration Schedule; Drug Synergism; Female; Humans; Hydrogen-Ion Concentration; Mice; Mice, Nude; Neoplasms; Prodrugs; Xenograft Model Antitumor Assays | 2011 |
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Lung Neoplasms; Mice; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Asian People; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Enzyme Inhibitors; Gene Frequency; Genotype; Humans; Irinotecan; Japan; Multivariate Analysis; Neoplasms; Polymorphism, Single Nucleotide | 2010 |
Discovery of drug mode of action and drug repositioning from transcriptional responses.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Algorithms; Antineoplastic Agents; Autophagy; Blotting, Western; Camptothecin; Cell Line, Tumor; Doxorubicin; Drug Discovery; Drug Screening Assays, Antitumor; Flavonoids; Fuzzy Logic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Irinotecan; Neoplasms; Oligonucleotide Array Sequence Analysis; Phosphorylation; Piperidines; Pyrazoles; Pyrroles; RNA Polymerase II | 2010 |
Nanodiamonds as intracellular transporters of chemotherapeutic drug.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Carriers; Humans; Nanodiamonds; Neoplasms; Particle Size; Serum | 2010 |
Are herbal medicines ripe for the cancer clinic?
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Complementary Therapies; Gastrointestinal Tract; Herbal Medicine; Humans; Irinotecan; Mice; Neoplasms | 2010 |
[mRNA quantification. The next challenge in routine diagnostics].
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Molecular Diagnostic Techniques; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; RNA, Messenger; Survival Rate; Thymidylate Synthase | 2010 |
Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Fever; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Irinotecan; Male; Mannose-Binding Lectin; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic | 2010 |
Preparation and in vitro characterization of 9-nitrocamptothecin-loaded long circulating nanoparticles for delivery in cancer patients.
Topics: Antineoplastic Agents; Calorimetry, Differential Scanning; Camptothecin; Chromatography, High Pressure Liquid; Drug Carriers; Drug Delivery Systems; Drug Stability; Humans; In Vitro Techniques; Lactic Acid; Microscopy, Electron, Scanning; Nanomedicine; Nanoparticles; Neoplasms; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; X-Ray Diffraction | 2010 |
Charge-reversal polyamidoamine dendrimer for cascade nuclear drug delivery.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Nucleus; Dendrimers; Drug Carriers; Female; Fluorescein-5-isothiocyanate; Humans; Hydrogen-Ion Concentration; Kinetics; Magnetic Resonance Spectroscopy; Neoplasms; Ovarian Neoplasms; Polyamines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines.
Topics: Antineoplastic Agents; Camptothecin; Casein Kinase II; Cell Line, Tumor; DNA Topoisomerases, Type I; Humans; Neoplasms; Phosphorylation; Protein Structure, Tertiary | 2011 |
The role of DDX3 in regulating Snail.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Proliferation; DEAD-box RNA Helicases; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Male; Neoplasm Invasiveness; Neoplasms; Snail Family Transcription Factors; Topoisomerase Inhibitors; Transcription Factors | 2011 |
Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of β-glucuronidase in tumors.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Bystander Effect; Camptothecin; Combined Modality Therapy; Genetic Therapy; Genetic Vectors; Glucuronates; Glucuronidase; Humans; Irinotecan; Neoplasms; Prodrugs; Tumor Cells, Cultured | 2011 |
Tumor physiology and charge dynamics of anticancer drugs: implications for camptothecin-based drug development.
Topics: Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; Humans; Kinetics; Neoplasms; Topoisomerase I Inhibitors | 2011 |
Barking up the wrong genome--we are not alone.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Diarrhea; Enzyme Inhibitors; Glucuronidase; Glucuronosyltransferase; Humans; Irinotecan; Mice; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prodrugs; Topoisomerase I Inhibitors | 2011 |
Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptotheca; Camptothecin; Cell Line, Tumor; Clinical Trials as Topic; Cyclodextrins; Drug Evaluation, Preclinical; Humans; Mice; Nanoparticles; Neoplasms; Polyethylene Glycols; Solubility | 2011 |
Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Cells, Cultured; HCT116 Cells; HeLa Cells; HT29 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Models, Biological; Naphthyridines; Neoplasms; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2011 |
Protein phosphatase PP6 is required for homology-directed repair of DNA double-strand breaks.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; DNA Breaks, Double-Stranded; DNA Repair; Enzyme Activation; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HeLa Cells; Histones; Humans; Neoplasms; Osteosarcoma; Phosphoprotein Phosphatases; Phosphorylation; RNA, Small Interfering; Substrate Specificity | 2011 |
APEX microarray panel for genotyping polymorphisms in cancer chemotherapy and estimation frequencies in a Slovak population.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Camptothecin; Drug Resistance, Neoplasm; Fluorouracil; Gene Frequency; Genetic Association Studies; Humans; Irinotecan; Linkage Disequilibrium; Methotrexate; Neoplasms; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Slovakia | 2011 |
Nek6 suppresses the premature senescence of human cancer cells induced by camptothecin and doxorubicin treatment.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cellular Senescence; Doxorubicin; Humans; Neoplasms; NIMA-Related Kinases; Protein Serine-Threonine Kinases | 2011 |
Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Hypersensitivity; Female; Humans; Irinotecan; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasms; Pneumonia; Product Surveillance, Postmarketing; Pulmonary Alveoli; Steroids; Tomography, X-Ray Computed | 2011 |
Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
Topics: Acrylonitrile; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; HCT116 Cells; Humans; Irinotecan; K562 Cells; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Neoplasm Proteins; Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Irinotecan; Mice; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Receptors, Growth Factor | 2011 |
Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.
Topics: Antineoplastic Agents; Base Sequence; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; HCT116 Cells; Histones; Humans; Naphthyridines; Neoplasms; Topoisomerase I Inhibitors | 2011 |
An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Benzimidazoles; Blotting, Western; Camptothecin; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Child; Coloring Agents; Enzyme Activation; Enzyme Inhibitors; Humans; Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA, Messenger; Tetrazolium Salts; Thiazoles; Thiophenes; Topoisomerase I Inhibitors | 2011 |
Design of acid-activated cell penetrating peptide for delivery of active molecules into cancer cells.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell-Penetrating Peptides; Drug Delivery Systems; HeLa Cells; Histidine; Humans; Hydrogen-Ion Concentration; Molecular Sequence Data; Neoplasms | 2011 |
MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression.
Topics: Camptothecin; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Survival; Cisplatin; DNA Damage; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Genomic Instability; HeLa Cells; Humans; MicroRNAs; Neoplasms; Nuclear Proteins; Radiation, Ionizing; RNA-Binding Proteins; Stress, Physiological | 2011 |
Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Collagen; Endothelium, Vascular; Female; Immunoconjugates; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasms; Polyethylene Glycols; Stromal Cells; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2011 |
Synthesis of 9-(heteroarylmethylidene)amino derivatives of homocamptothecin with biological activities.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Humans; Neoplasms; Topoisomerase I Inhibitors | 2011 |
Lipid-polymer composite microspheres for colon-specific drug delivery prepared using an ultrasonic spray freeze-drying technique.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Drug Delivery Systems; Excipients; Fatty Acids; Freeze Drying; Humans; Microspheres; Neoplasms; Particle Size; Polymethacrylic Acids; Solubility; Ultrasonics | 2011 |
[Protective effects of d-chlorpheniramine maleate pre-treatment against acute side effects of Irinotecan(CPT- 11)].
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Camptothecin; Chlorpheniramine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2011 |
Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Genital Neoplasms, Female; Glucuronosyltransferase; Humans; Incidence; Infusions, Intravenous; Irinotecan; Japan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Patient Selection; Polymorphism, Genetic; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Surveys and Questionnaires; Thrombocytopenia | 2011 |
Allometric scaling of pegylated liposomal anticancer drugs.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Body Weight; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Dogs; Doxorubicin; Female; Humans; Liposomes; Male; Mice; Models, Theoretical; Neoplasms; Polyethylene Glycols; Rats; Software; Species Specificity; Time Factors | 2011 |
Functionalized nanoscale oil bodies for targeted delivery of a hydrophobic drug.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Carriers; Escherichia coli; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Phospholipids; Plant Oils; Plant Proteins; Plants; Recombinant Fusion Proteins | 2011 |
Synthesis and biological evaluation of novel homocamptothecins conjugating with dihydropyrimidine derivatives as potent topoisomerase I inhibitors.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; HCT116 Cells; Humans; Neoplasms; Pyrimidines; Topoisomerase I Inhibitors | 2011 |
The therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Carriers; Female; Humans; Mice; Mice, Inbred C57BL; Nanoparticles; Neoplasms; Positron-Emission Tomography; Tissue Distribution | 2012 |
Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Chemistry, Pharmaceutical; Humans; Irinotecan; Lipids; Liposomes; Models, Biological; Models, Chemical; Neoplasms | 2011 |
Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide.
Topics: Amino Acid Sequence; Animals; Annexin A1; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbohydrates; Cell Line, Tumor; Drug Delivery Systems; HCT116 Cells; Humans; Hydrazines; Injections, Intravenous; Irinotecan; Luminescent Measurements; Mice; Mice, Inbred C57BL; Mice, Nude; Molecular Mimicry; Molecular Sequence Data; Neoplasms; Neovascularization, Pathologic; Peptides; Protein Binding; Xenograft Model Antitumor Assays | 2011 |
Camptothecin induces apoptosis in cancer cells via microRNA-125b-mediated mitochondrial pathways.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Camptothecin; HeLa Cells; Humans; MicroRNAs; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Up-Regulation | 2012 |
Drug-polyester conjugated nanoparticles for cancer drug delivery.
Topics: Antineoplastic Agents; Camptothecin; Catalysis; Chromatography, High Pressure Liquid; Drug Delivery Systems; Nanoparticles; Neoplasms; Pharmaceutical Preparations; Polyesters; Succinic Anhydrides | 2011 |
Antitumor activities of emulsion electrospun fibers with core loading of hydroxycamptothecin via intratumoral implantation.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antineoplastic Agents, Phytogenic; beta-Cyclodextrins; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Carriers; Emulsions; Humans; Lactates; Mice; Neoplasm Transplantation; Neoplasms; Polyethylene Glycols; Tumor Burden | 2012 |
[Examination of factors affecting adverse reactions and dosage reduction in UGT1A1 genotyped patients: a retrospective survey of irinotecan].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Genetic; Retrospective Studies | 2012 |
Development and pharmacological evaluation of a PEG based nanoparticulate camptothecin analog for oral administration.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Carriers; Drug Stability; Female; Humans; Lecithins; Male; Mice; Mice, Nude; Nanoparticles; Neoplasms; Particle Size; Polyethylene Glycols; Rats; Rats, Wistar; Solubility; Topoisomerase I Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Luminescent/magnetic hybrid nanoparticles with folate-conjugated peptide composites for tumor-targeted drug delivery.
Topics: Antineoplastic Agents, Phytogenic; Cadmium Compounds; Camptothecin; Cell Line, Tumor; Chitosan; Drug Delivery Systems; Folic Acid; Humans; Luminescence; Luminescent Agents; Magnetite Nanoparticles; Micelles; Neoplasms; Oligopeptides; Quantum Dots; Tellurium | 2012 |
Comparison of caspase-3 activation in tumor cells upon treatment of chemotherapeutic drugs using capillary electrophoresis.
Topics: Antineoplastic Agents; Camptothecin; Caspase 3; Cisplatin; Drug Screening Assays, Antitumor; Electrophoresis, Capillary; Enzyme Activation; Etoposide; HeLa Cells; Hep G2 Cells; Humans; Neoplasms; Time Factors; Tumor Necrosis Factor-alpha | 2012 |
Incorporation and controlled release of silyl ether prodrugs from PRINT nanoparticles.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Dasatinib; Delayed-Action Preparations; Deoxycytidine; Ethers; Gemcitabine; Humans; Nanoparticles; Neoplasms; Prodrugs; Pyrimidines; Silanes; Thiazoles | 2012 |
Injectable poly(organophosphazene)-camptothecin conjugate hydrogels: synthesis, characterization, and antitumor activities.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Stability; Drug Storage; Female; Glycine; Humans; Hydrogels; Injections; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Organophosphorus Compounds; Phase Transition; Polymers; Temperature; Xenograft Model Antitumor Assays | 2012 |
Multifunctional hybrid materials for combined photo and chemotherapy of cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Gold; Hot Temperature; Humans; Laser Therapy; Metal Nanoparticles; Microscopy, Electron, Transmission; Neoplasms; Silicon Dioxide | 2012 |
In-vivo pharmacokinetics, tissue distribution and anti-tumour effect of hydroxycamptothecin delivered in oil-in-water submicron emulsions.
Topics: Animals; Anions; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptotheca; Camptothecin; Cations; Drug Carriers; Emulsions; Injections, Intravenous; Male; Mice; Mice, Inbred Strains; Neoplasms; Oils; Phytotherapy; Plant Extracts; Rats; Rats, Sprague-Dawley; Tissue Distribution; Water | 2012 |
Modular theranostic prodrug based on a FRET-activated self-immolative linker.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Delivery Systems; Drug Design; Drug Monitoring; Fluorescence Resonance Energy Transfer; Fluorescent Dyes; Humans; Models, Biological; Molecular Structure; Neoplasms; Penicillin Amidase; Prodrugs | 2012 |
Anticancer activity of new haloalkyl camptothecin esters against human cancer cell lines and human tumor xenografts grown in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Esters; Humans; Mice; Mice, Nude; Models, Molecular; Neoplasms; Prodrugs; Transplantation, Heterologous | 2012 |
Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasms; Neutropenia; Polypharmacy; Retrospective Studies | 2013 |
Direct fluorescence monitoring of the delivery and cellular uptake of a cancer-targeted RGD peptide-appended naphthalimide theragnostic prodrug.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Humans; Microscopy, Confocal; Naphthalimides; Neoplasms; Oligopeptides; Prodrugs | 2012 |
Infused chemotherapy use in the elderly after patent expiration.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Cost Savings; Cross-Sectional Studies; Female; Health Services for the Aged; Humans; Irinotecan; Male; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Patents as Topic; Practice Patterns, Physicians'; Time Factors; United States | 2012 |
Chemosensitivity is controlled by p63 modification with ubiquitin-like protein ISG15.
Topics: Amino Acid Motifs; Animals; Antibiotics, Antineoplastic; Camptothecin; Caspase 2; Cell Line, Tumor; Cellular Senescence; Cisplatin; Cysteine Endopeptidases; Cytokines; Doxorubicin; Enzyme Activation; Humans; Inhibitor of Apoptosis Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Protein Isoforms; Protein Processing, Post-Translational; Protein Structure, Tertiary; Proteolysis; Transcription Factors; Transcriptional Activation; Tumor Suppressor Proteins; Ubiquitins; Xenograft Model Antitumor Assays | 2012 |
Carrier-free, functionalized drug nanoparticles for targeted drug delivery.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Maleic Anhydrides; Nanoparticles; Neoplasms; Polyethylene Glycols | 2012 |
Ultrasound triggered drug release from 10-hydroxycamptothecin-loaded phospholipid microbubbles for targeted tumor therapy in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Male; Mice; Microbubbles; Neoplasms; Phosphatidylcholines; Phosphatidylethanolamines; Polyethylene Glycols; Sonication; Tumor Burden | 2012 |
Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cecum; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Feces; Female; Intestines; Irinotecan; Metagenome; Neoplasms; Rats | 2012 |
Preclinical combination therapy of thiarabine plus various clinical anticancer agents.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Camptothecin; Cell Line, Tumor; Cisplatin; Cyclophosphamide; Female; HT29 Cells; Humans; Irinotecan; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms; Paclitaxel; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Topics: Acid Anhydride Hydrolases; Antineoplastic Agents; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Camptothecin; Carcinoma; Cell Cycle Proteins; Cell Line, Tumor; DNA Damage; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gamma Rays; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Intracellular Signaling Peptides and Proteins; Male; MRE11 Homologue Protein; Neoplasms; Nuclear Proteins; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Recombinational DNA Repair; Tumor Suppressor p53-Binding Protein 1 | 2012 |
Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.
Topics: Algorithms; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cluster Analysis; Colchicine; Computational Biology; Cyclin-Dependent Kinases; Dasatinib; Databases, Genetic; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Pimozide; Purines; Pyrimidines; Terfenadine; Thiazoles; Tubulin Modulators; Verapamil | 2012 |
Camptothecin-7-yl-methanthiole: semisynthesis and biological evaluation.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases; Glutathione; Humans; Models, Molecular; Neoplasms; Prodrugs; Topoisomerase I Inhibitors | 2012 |
Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Delivery Systems; Humans; Lipids; Liposomes; Mice; Neoplasms; Solubility; Tissue Distribution | 2013 |
A prodrug nanoassembly entrapping drugs as a tumor-targeted delivery system.
Topics: Animals; Antineoplastic Agents; Biotinylation; Camptothecin; Cell Line, Tumor; Cell Survival; Chlorocebus aethiops; COS Cells; Doxorubicin; Drug Delivery Systems; Humans; Neoplasms; Polyethylene Glycols; Prodrugs | 2013 |
Simply mixing with poly(ethylene glycol) enhances the fraction of the active chemical form of antitumor drugs of camptothecin family.
Topics: Animals; Antineoplastic Agents; Camptothecin; Mice; Mice, Nude; Neoplasms; Polyethylene Glycols | 2013 |
Preclinical antitumor activity of a nanoparticulate SN38.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Female; HCT116 Cells; Humans; Irinotecan; Mice; Mitomycin; Nanoparticles; Neoplasms; Survival Analysis; Xenograft Model Antitumor Assays | 2013 |
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacogenetics; Polymorphism, Genetic; Stomach Neoplasms | 2013 |
[Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors].
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasms; Retrospective Studies; Temozolomide | 2013 |
STK295900, a dual inhibitor of topoisomerase 1 and 2, induces G(2) arrest in the absence of DNA damage.
Topics: Aniline Compounds; Antineoplastic Agents, Phytogenic; Benzimidazoles; Camptothecin; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Dose-Response Relationship, Drug; Etoposide; G2 Phase Cell Cycle Checkpoints; HCT116 Cells; HeLa Cells; Hep G2 Cells; HT29 Cells; Humans; Immunoblotting; MCF-7 Cells; Molecular Structure; Neoplasms; Phosphorylation; Topoisomerase Inhibitors | 2013 |
Formulation design and evaluation of quantum dot-loaded nanostructured lipid carriers for integrating bioimaging and anticancer therapy.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Diagnostic Imaging; Drug Carriers; Humans; Lipids; Nanostructures; Neoplasms; Polyethylene Glycols; Quantum Dots | 2013 |
Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line; Cell Line, Tumor; Cell Survival; Drug Carriers; Endocytosis; Humans; Lipids; Mice; Mice, Inbred ICR; Nanoparticles; Neoplasms; Octreotide; Polyethylene Glycols; Receptors, Somatostatin; Surface Properties; Tumor Burden | 2013 |
Enhanced tumor targeting and antitumor efficacy via hydroxycamptothecin-encapsulated folate-modified N-succinyl-N'-octyl chitosan micelles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Delivery Systems; Folic Acid; Humans; Mice; Mice, Nude; Micelles; Neoplasms; Rats | 2013 |
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Chi-Square Distribution; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Neoplasms; Tissue Distribution | 2002 |
Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.
Topics: Blotting, Western; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cytosol; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Humans; Immunohistochemistry; Irinotecan; Kinetics; Liver; Microsomes, Liver; Neoplasms; Protein Isoforms; Tumor Cells, Cultured | 2002 |
St. John's Wort: more implications for cancer patients.
Topics: Antidepressive Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Induction; Enzyme Inhibitors; Humans; Hypericum; Irinotecan; Mixed Function Oxygenases; Neoplasms | 2002 |
Pharmacokinetics of irinotecan and its metabolites.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Irinotecan; Isotonic Solutions; Light; Neoplasms; Research Design; Sodium Chloride | 2002 |
Transcription-dependent degradation of topoisomerase I-DNA covalent complexes.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cricetinae; DNA; DNA Repair; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Haplorhini; Humans; Lung; Lymphocytes; Macromolecular Substances; Mice; Mice, Nude; Neoplasms; Nucleic Acid Synthesis Inhibitors; Peptide Hydrolases; Proteasome Endopeptidase Complex; Protein Subunits; RNA Polymerase II; Signal Transduction; Small Ubiquitin-Related Modifier Proteins; Topoisomerase I Inhibitors; Topotecan; Transcription, Genetic; Xenograft Model Antitumor Assays | 2003 |
Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Asparagine; Aspartic Acid; Camptothecin; COS Cells; Exons; Genetic Variation; Glucuronates; Glucuronic Acid; Glucuronosyltransferase; Humans; Irinotecan; Japan; Mutation; Neoplasms; Polymorphism, Single Nucleotide; Transfection; UDP-Glucuronosyltransferase 1A9 | 2003 |
[A symphony for the camptothecins].
Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan | 2003 |
Clinical Trials in Cancer-SMi Conference. 11-12 June 2003, London, UK.
Topics: Antineoplastic Agents; Camptothecin; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Humans; Molecular Structure; Neoplasms; Quinazolines; Treatment Outcome | 2003 |
Quantitative determination of DRF-1042 in human plasma by HPLC: validation and application in clinical pharmacokinetics.
Topics: Antineoplastic Agents; Calibration; Camptothecin; Chromatography, High Pressure Liquid; Humans; Neoplasms; Reproducibility of Results; Sensitivity and Specificity | 2003 |
Pharmacogenomics: road to anticancer therapeutics nirvana?
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; DNA Repair; Drug Design; Humans; Irinotecan; Neoplasms; Pharmacogenetics; Thymidylate Synthase | 2003 |
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured | 2003 |
Enzyme-prodrug systems: carboxylesterase/CPT-11.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Genes, Transgenic, Suicide; Genetic Therapy; Humans; Irinotecan; Liver; Molecular Sequence Data; Neoplasms; Prodrugs; Rabbits; Sequence Alignment; Sequence Homology, Amino Acid | 2004 |
Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin.
Topics: Animals; Annexin A5; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Body Weight; Camptothecin; Cell Line, Tumor; Cisplatin; Coloring Agents; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Heme Oxygenase (Decyclizing); Humans; Hydrogen Peroxide; Male; Metalloporphyrins; Mice; Mitomycin; Neoplasms; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxygen; Polyethylene Glycols; Proline; Reactive Oxygen Species; Tetrazolium Salts; Thiazoles | 2004 |
Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells.
Topics: Animals; Antineoplastic Agents; Bombesin; Camptothecin; Cell Death; Drug Delivery Systems; Drug Design; Mice; Neoplasms; Protein Binding; Receptors, Bombesin | 2004 |
Modeling antitumor activity by using a non-linear mixed-effects model.
Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Computer Simulation; Dacarbazine; Data Interpretation, Statistical; Humans; Irinotecan; Mice; Neoplasms; Nonlinear Dynamics; Rhabdomyosarcoma; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2004 |
Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Colonic Neoplasms; Cysteine; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Organoselenium Compounds; Radiation-Sensitizing Agents; Selenium; Selenocysteine; Selenomethionine; Time Factors | 2004 |
UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer.
Topics: Aged; Bilirubin; Camptothecin; Female; Genetic Linkage; Glucuronides; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Japan; Male; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide | 2004 |
[Management of chemotherapy induced diarrhea].
Topics: Antidiarrheals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Loperamide; Neoplasms; Octreotide; Patient Care Management; Practice Guidelines as Topic | 2004 |
Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Body Surface Area; Camptothecin; Dose-Response Relationship, Drug; Female; Glucuronates; Humans; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Models, Statistical; Neoplasms | 2004 |
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Female; Gene Frequency; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasms; Polymorphism, Genetic; UDP-Glucuronosyltransferase 1A9 | 2004 |
ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Black People; Camptothecin; Drug Resistance, Multiple; Female; Gene Frequency; Genotype; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; White People | 2004 |
Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
Topics: Animals; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Antiviral Agents; Camptotheca; Camptothecin; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Humans; Neoplasms; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors | 2004 |
In vivo efficacy of HSV-TK transcriptionally targeted to the tumour vasculature is augmented by combination with cytotoxic chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aorta; Camptothecin; Cell Line, Tumor; Cisplatin; Drug Therapy, Combination; Endothelial Cells; Genes, Reporter; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Neoplasms; Retroviridae; Simplexvirus; Survival Rate; Swine; Thymidine Kinase; Transcription, Genetic; Treatment Outcome | 2005 |
[Molecular biology methods in cancer medicine: options beyond steel instrument, ray and chemotherapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Immunotherapy; Irinotecan; Male; Mutation; Neoplasms; Prostatic Neoplasms; Research; Simplexvirus; Trastuzumab; Vascular Endothelial Growth Factor A | 2004 |
The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons.
Topics: Antineoplastic Agents, Phytogenic; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Cycle Proteins; Cell Line; Checkpoint Kinase 1; Checkpoint Kinase 2; DNA Topoisomerases, Type I; Gene Deletion; Genes, cdc; HSP90 Heat-Shock Proteins; Humans; Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases; RNA, Small Interfering; Topoisomerase I Inhibitors | 2005 |
topors, a p53 and topoisomerase I-binding RING finger protein, is a coactivator of p53 in growth suppression induced by DNA damage.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Camptothecin; Carrier Proteins; Cell Cycle; Cisplatin; DNA Damage; DNA Topoisomerases, Type I; DNA-Binding Proteins; Gene Expression Regulation; Genes, Tumor Suppressor; Humans; Mice; Molecular Sequence Data; Neoplasm Proteins; Neoplasms; Nuclear Proteins; Osteosarcoma; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; Zinc Fingers | 2005 |
Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; Cytosine; Disease Models, Animal; Drug Screening Assays, Antitumor; Female; Fluorouracil; Green Fluorescent Proteins; Humans; Immunotherapy; Interferons; Liposomes; Liver; Liver Neoplasms; Luminescent Proteins; Lung Neoplasms; Male; Metalloproteases; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Oligonucleotides, Antisense; Pancreatic Neoplasms; Prostatic Neoplasms; Red Fluorescent Protein | 2005 |
SCAN1 mutant Tdp1 accumulates the enzyme--DNA intermediate and causes camptothecin hypersensitivity.
Topics: Amino Acid Substitution; Camptothecin; Enzyme Inhibitors; Flow Cytometry; Humans; Mutation; Neoplasms; Phosphoric Diester Hydrolases; S Phase | 2005 |
Radiosynthesis of carbon-11-labeled camptothecin derivatives as potential positron emission tomography tracers for imaging of topoisomerase I in cancers.
Topics: Camptothecin; Carbon Radioisotopes; DNA Topoisomerases, Type I; Humans; Neoplasms; Positron-Emission Tomography; Radionuclide Imaging; Radiopharmaceuticals; Structure-Activity Relationship | 2005 |
Cancer cell adaptation to chemotherapy.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Camptothecin; Cell Line, Tumor; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Neoplasms; Paclitaxel; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topotecan; Treatment Outcome; Up-Regulation | 2005 |
Clinical trial designs for prospective validation of biomarkers.
Topics: Biomarkers, Tumor; Camptothecin; Clinical Trials as Topic; Genotype; Humans; Inactivation, Metabolic; Irinotecan; Neoplasms; Outcome Assessment, Health Care; Predictive Value of Tests; Reproducibility of Results; Research Design | 2005 |
Iridoids as DNA topoisomerase I poisons.
Topics: Camptothecin; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Enzyme Inhibitors; Glucosides; Humans; Iridoid Glucosides; Iridoids; Neoplasms; Pyrans; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2005 |
Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Carcinoma; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Synergism; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Plant Extracts; Silybum marianum; Time Factors | 2005 |
[Management of chemotherapy-induced mucositis and diarrhea].
Topics: Allopurinol; Antineoplastic Agents; Camptothecin; Diarrhea; Free Radical Scavengers; Histamine H2 Antagonists; Humans; Irinotecan; Neoplasms; Proton Pump Inhibitors; Quality of Life; Stomatitis | 2006 |
UGT1A1 genotyping in patients undergoing treatment with irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic; Predictive Value of Tests; Prospective Studies; Retrospective Studies | 2005 |
Expression of drug pathway proteins is independent of tumour type.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Lymphoma; Male; Melanoma; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Tissue Array Analysis | 2006 |
Identification of a small topoisomerase I-binding peptide that has synergistic antitumor activity with 9-aminocamptothecin.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Synergism; Humans; Mice; Mice, Nude; Molecular Sequence Data; Neoplasms; Oligonucleotides; Peptide Library; Peptides; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2006 |
Novel single nucleotide polymorphism of UGT1A7 gene in Japanese.
Topics: Alleles; Amino Acid Substitution; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; DNA; Exons; Female; Gene Frequency; Glucuronosyltransferase; Humans; Irinotecan; Japan; Male; Molecular Sequence Data; Neoplasms; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Novel single nucleotide polymorphism of UGT1A9 gene in Japanese.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; DNA, Neoplasm; Exons; Gene Frequency; Glucuronosyltransferase; Humans; Introns; Irinotecan; Japan; Molecular Sequence Data; Mutation; Neoplasms; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction; UDP-Glucuronosyltransferase 1A9 | 2006 |
Irinogenetics: what is the right star?
Topics: Alleles; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Carcinoma, Non-Small-Cell Lung; DNA Topoisomerases, Type I; Drug-Related Side Effects and Adverse Reactions; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Topoisomerase I Inhibitors | 2006 |
Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Celecoxib; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasms; NF-kappa B; Pyrazoles; Sulfonamides; Thalidomide; Tumor Necrosis Factor-alpha | 2007 |
Sensitization of cancer cells to DNA damaging agents by imidazolines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cisplatin; DNA Damage; Gene Expression Regulation, Neoplastic; Humans; Imidazolines; Models, Molecular; Molecular Structure; Neoplasms; Structure-Activity Relationship | 2006 |
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cisplatin; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Floxuridine; Humans; Irinotecan; Liposomes; Mice; Neoplasms; Xenograft Model Antitumor Assays | 2006 |
Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
Topics: Antineoplastic Agents; Camptothecin; cdc25 Phosphatases; Cell Cycle; Checkpoint Kinase 1; Checkpoint Kinase 2; DNA Damage; Doxorubicin; Female; Fluorouracil; HeLa Cells; Histones; Humans; Intracellular Signaling Peptides and Proteins; Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases; RNA, Small Interfering; Tumor Cells, Cultured | 2006 |
Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Clinical Trials as Topic; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Pharmacogenetics; Polymerase Chain Reaction; Polymorphism, Genetic; Promoter Regions, Genetic; Prospective Studies; Risk Factors; Topoisomerase I Inhibitors | 2006 |
Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
Topics: Antibodies; Blotting, Western; Camptothecin; Caspases; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; HeLa Cells; Humans; Molecular Structure; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; RNA, Small Interfering; Time Factors; Tumor Suppressor Protein p53; Urea | 2006 |
KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dactinomycin; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Combinations; Gamma Rays; Humans; Neoplasms; Proto-Oncogene Proteins c-mdm2; Repressor Proteins; Signal Transduction; Tripartite Motif-Containing Protein 28; Tumor Suppressor Protein p53 | 2006 |
[What happened during these 12 years since CPT-11 was launched in Japan ?].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Drug Approval; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2006 |
Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
Topics: Administration, Oral; Animals; Bone Marrow; Camptothecin; Cysteine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Irinotecan; Kidney; Kinetics; Liver; Mice; Mice, Nude; Neoplasms; Organoselenium Compounds; Plasma; Selenium; Selenocysteine | 2007 |
A generalised age- and phase-structured model of human tumour cell populations both unperturbed and exposed to a range of cancer therapies.
Topics: Algorithms; Camptothecin; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Kinetics; Models, Biological; Neoplasms; Paclitaxel; Time Factors | 2007 |
Hypoxia-targeted over-expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT-11).
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Hypoxia; Cell Line; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Irinotecan; Neoplasms; Rabbits; Transplantation, Heterologous | 2007 |
10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Humans; Mice; Mice, Inbred ICR; Nanoparticles; Neoplasms; Xenograft Model Antitumor Assays | 2007 |
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cannabinoids; Cytochrome P-450 CYP3A; Docetaxel; Drug Interactions; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Statistics, Nonparametric; Taxoids | 2007 |
Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Camptothecin; Female; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Japan; Linkage Disequilibrium; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; UDP-Glucuronosyltransferase 1A9 | 2007 |
[Our outpatient cases for home anti-cancer chemotherapy using a CV port and a portable pump system].
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Home Care Services, Hospital-Based; Home Infusion Therapy; Humans; Infusion Pumps; Infusion Pumps, Implantable; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Outpatients; Quality of Life | 2006 |
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Exons; Female; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Japan; Male; Middle Aged; Multivariate Analysis; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prodrugs | 2007 |
Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Crystallization; Diffusion; Drug Carriers; Humans; Hydrophobic and Hydrophilic Interactions; Macromolecular Substances; Materials Testing; Molecular Conformation; Nanostructures; Nanotechnology; Neoplasms; Particle Size; Porosity; Silicon Dioxide; Surface Properties | 2007 |
UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Chi-Square Distribution; Child; Child, Preschool; Clinical Trials as Topic; DNA, Neoplasm; Female; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasms; Promoter Regions, Genetic; Risk Factors | 2007 |
Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients.
Topics: Adult; Aged; Asian People; Camptothecin; Female; Glucuronides; Glucuronosyltransferase; Haplotypes; Humans; Introns; Irinotecan; Liver; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; UDP-Glucuronosyltransferase 1A9 | 2008 |
Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; Dose-Response Relationship, Drug; Drug Antagonism; Drug Combinations; Drug Compounding; Drug Evaluation, Preclinical; Drug Synergism; Female; Floxuridine; Humans; Injections, Intravenous; Irinotecan; Liposomes; Mice; Neoplasms; Pharmaceutical Vehicles; Survival Rate; Tissue Distribution; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2007 |
Efficacy of camptothecin and polymer-conjugated camptothecin in tumor spheroids and solid tumors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Collagen; Collagenases; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Neoplasms; Polyethylene Glycols; Polymers; Rats; Rats, Inbred F344; Solubility; Spheroids, Cellular; Tumor Cells, Cultured | 2007 |
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cytochrome P-450 CYP3A; Female; Haplotypes; Humans; Irinotecan; Japan; Male; Metabolic Clearance Rate; Middle Aged; Multivariate Analysis; Neoplasms; Polymorphism, Genetic; Prodrugs; Sex Factors | 2008 |
AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 1.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle Proteins; Clinical Trials as Topic; Humans; Irinotecan; Janus Kinase 2; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase C; Protein Serine-Threonine Kinases | 2007 |
Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cathepsins; Cell Line, Tumor; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Humans; Hydrolysis; Liver; Mice; Neoplasm Transplantation; Neoplasms; Prodrugs; Tissue Distribution; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2007 |
Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asian People; Bilirubin; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Incidence; Irinotecan; Japan; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; Retrospective Studies | 2008 |
Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
Topics: Adolescent; Adult; Antineoplastic Agents; Area Under Curve; Bilirubin; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Computer Simulation; Cytochrome P-450 CYP3A; Female; Glucuronates; Glucuronosyltransferase; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Metabolic Clearance Rate; Models, Biological; Multicenter Studies as Topic; Neoplasms | 2008 |
Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.
Topics: Camptothecin; Cell Cycle; Cell Proliferation; Checkpoint Kinase 1; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; G2 Phase; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; S Phase; Signal Transduction; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2008 |
[CPT-11 (Irinotecan)].
Topics: Antineoplastic Agents; Camptothecin; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic | 2008 |
Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy.
Topics: Antibodies, Neoplasm; Antineoplastic Agents; Binding, Competitive; Camptothecin; Catalysis; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Escherichia coli; Glucuronidase; Glucuronides; Humans; Kinetics; Models, Molecular; Molecular Structure; Neoplasms; Phenyl Ethers; Prodrugs; Structure-Activity Relationship | 2008 |
Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Chitosan; Drug Carriers; Drug Stability; Humans; Hydrolysis; Hydrophobic and Hydrophilic Interactions; Lactones; Mice; Mice, Nude; Nanoparticles; Neoplasms; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays | 2008 |
Triggering senescence programs suppresses Chk1 kinase and sensitizes cells to genotoxic stresses.
Topics: Aneuploidy; Camptothecin; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Checkpoint Kinase 1; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; DNA Repair; Down-Regulation; Enzyme Activation; HCT116 Cells; HeLa Cells; HSP72 Heat-Shock Proteins; Humans; Neoplasms; Protein Kinases; Signal Transduction; Tumor Suppressor Protein p53; Ultraviolet Rays | 2008 |
Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mice; Mice, Nude; Models, Biological; Neoplasms; Pancreatic Neoplasms; Polyethylene Glycols; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Enhancing ultrasound-mediated cell membrane permeabilisation (sonoporation) using a high frequency pulse regime and implications for ultrasound-aided cancer chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Membrane Permeability; Combined Modality Therapy; Dextrans; Fluorescein-5-isothiocyanate; Fluorescent Dyes; HeLa Cells; Humans; Neoplasms; Ultrasonics | 2008 |
Protein arginine (N)-methyl transferase 7 (PRMT7) as a potential target for the sensitization of tumor cells to camptothecins.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cricetinae; Down-Regulation; Drug Resistance, Neoplasm; HeLa Cells; Humans; Isoenzymes; Methyltransferases; Neoplasms; Oligonucleotides, Antisense; Protein-Arginine N-Methyltransferases | 2008 |
In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Benzoates; Camptothecin; Drug Stability; Female; Humans; Liposomes; Male; Mice; Mice, Inbred Strains; Neoplasms; Serum Albumin; Tissue Distribution; Tumor Burden | 2008 |
Pharmacogenetic pathway analysis of irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Enterohepatic Circulation; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Multidrug Resistance-Associated Protein 2; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prodrugs | 2008 |
Activity of camptothecin, harringtonin, cantharidin and curcumae in the human tumor stem cell assay.
Topics: Alkaloids; Antineoplastic Agents; Camptothecin; Cantharidin; Catechols; Cell Survival; Colony-Forming Units Assay; Curcumin; Dose-Response Relationship, Drug; Harringtonines; Humans; Neoplasms | 1983 |
Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity.
Topics: Aphidicolin; Camptothecin; Cell Line; Colony-Forming Units Assay; Cycloheximide; DNA Adducts; DNA Damage; DNA Topoisomerases, Type I; Down-Regulation; Drug Resistance; Humans; Neoplasms; RNA; Topoisomerase I Inhibitors | 1995 |
A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Camptothecin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Solubility; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured; Water | 1995 |
Efficient sampling strategies for forecasting pharmacokinetic parameters of irinotecan (CPT-11): implication for area under the concentration-time curve monitoring.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bayes Theorem; Camptothecin; Drug Monitoring; Humans; Irinotecan; Neoplasms | 1995 |
Clinical trials referral resource. Trials of topotecan.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Female; Humans; Male; Neoplasms; Topotecan | 1995 |
Topoisomerase I inhibition: a new target or new missiles?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Drug Design; Drug Synergism; Humans; Irinotecan; Neoplasm Proteins; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1995 |
Enhanced expression of the DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells.
Topics: Camptothecin; DNA Topoisomerases, Type II; Etoposide; Gene Expression; Hot Temperature; Humans; Irinotecan; KB Cells; Neoplasms; RNA, Messenger; Teniposide | 1993 |
Clinical trials referral resource. Clinical trials with topotecan.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Humans; Neoplasms; Topotecan | 1993 |
Cytogenetic effects of CPT-11 and its active metabolite, SN-38 on human lymphocytes.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromosome Aberrations; Dose-Response Relationship, Drug; Humans; Irinotecan; Lymphocytes; Mutagens; Neoplasms; Sister Chromatid Exchange; Time Factors | 1993 |
Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation.
Topics: Antineoplastic Agents; Camptothecin; Cell Survival; Combined Modality Therapy; Fibroblasts; Humans; Melanoma; Neoplasms; Radiation Dosage; Radiation Tolerance; Time Factors; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1996 |
Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cyclophosphamide; DNA Fragmentation; DNA, Neoplasm; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Topotecan | 1997 |
Factors affecting topotecan-induced programmed cell death: adhesion protects cells from apoptosis and impairs cleavage of poly(ADP-ribose)polymerase.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Camptothecin; Cell Adhesion; Chromatin; Fibronectins; HeLa Cells; Humans; Methacrylates; Neoplasms; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Topotecan; Tumor Cells, Cultured | 1997 |
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
Topics: Antineoplastic Agents; Area Under Curve; Camptothecin; Female; Humans; Irinotecan; Male; Neoplasms; Phenotype; Racial Groups; Severity of Illness Index; Sex Characteristics; Topoisomerase I Inhibitors | 1997 |
Camptothecin and taxol: from discovery to clinic.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Chemistry, Analytic; Chemistry, Pharmaceutical; Clinical Trials as Topic; Countercurrent Distribution; Enzyme Inhibitors; History, 20th Century; Humans; Molecular Structure; Neoplasms; Paclitaxel; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tubulin Modulators; United States | 1996 |
Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.
Topics: Camptothecin; Cell Cycle; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunohistochemistry; Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1997 |
Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection.
Topics: Antineoplastic Agents; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Humans; Hydrogen-Ion Concentration; Lactones; Neoplasms; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 1997 |
Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1997 |
Comparative disposition of the antineoplastic agent 9-nitrocampotothecin and the inactive isomer 12-nitro camptothecin in CASE-bearing nude mice: effect of route of administration on tissue distribution.
Topics: Animals; Antineoplastic Agents, Phytogenic; Autoradiography; Camptothecin; Infusions, Intravenous; Injections, Intramuscular; Isomerism; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Tissue Distribution; Tritium | 1997 |
In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Prodrugs; Tumor Cells, Cultured | 1998 |
[New cancer therapies: balancing risk and benefit].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Neoplasms; Risk | 1998 |
A risk-benefit assessment of irinotecan in solid tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Etoposide; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Risk Assessment | 1998 |
Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Humans; Irinotecan; Kidney Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Stomach Neoplasms; Subrenal Capsule Assay; Tumor Cells, Cultured | 1998 |
[NB 506].
Topics: Animals; Antineoplastic Agents; Camptothecin; Carbazoles; Clinical Trials, Phase I as Topic; Drug Resistance; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Glucosides; Humans; Neoplasms; Topoisomerase I Inhibitors | 1999 |
Continual reassessment methods in phase I trials of the combination of two drugs in oncology.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Camptothecin; Clinical Trials, Phase I as Topic; Computer Simulation; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Humans; Irinotecan; Likelihood Functions; Neoplasms; Neutropenia; Paclitaxel; Retrospective Studies; Taxoids | 1999 |
Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice.
Topics: Animals; Antineoplastic Agents; Camptothecin; Drug Carriers; Humans; Liposomes; Mice; Mice, Nude; Microscopy, Electron; Neoplasm Transplantation; Neoplasms; Particle Size | 1999 |
Sensitive determination of irinotecan (CPT-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry.
Topics: Acetonitriles; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Chemical Precipitation; Chromatography, High Pressure Liquid; Humans; Irinotecan; Male; Mass Spectrometry; Neoplasms; Reproducibility of Results; Sensitivity and Specificity | 1999 |
[Current problems of early phase clinical trials for new anticancer agents in Japan].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Japan; Medical Oncology; Neoplasms; Workforce | 2000 |
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colonic Neoplasms; Doxorubicin; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.
Topics: Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluorometry; Humans; Irinotecan; Neoplasms; Topotecan; Tumor Cells, Cultured | 2000 |
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bacterial Infections; Camptothecin; Cell Line; Cell Survival; Female; Fluorouracil; Glucagon-Like Peptide 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Intestines; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Peptides; Rats; Receptors, Glucagon; Survival Rate; Time Factors; Transfection; Tumor Cells, Cultured | 2001 |
Why drugs fail: of mice and men revisited.
Topics: Animals; Antineoplastic Agents; Biological Availability; Camptothecin; Enzyme Inhibitors; Humans; Mice; Neoplasms; Tissue Distribution; Topoisomerase I Inhibitors | 2001 |
Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Humans; Lactones; Mice; Mice, Inbred CBA; Neoplasms; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Humans; Liposomes; Mice; Mice, Nude; Neoplasms; Tissue Distribution | 2001 |
Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Body Mass Index; Camptothecin; Enzyme Inhibitors; Female; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Neoplasms; Sex Factors | 2001 |
Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Nuclear Proteins; Oligonucleotides, Antisense; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Topoisomerase I Inhibitors; Treatment Outcome | 2001 |
Highlights of the Eighth European Cancer Conference.
Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasms; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Taxoids; Vinblastine; Vinorelbine | 1995 |
Thrombogenic role of cells undergoing apoptosis.
Topics: Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Neoplasms; Phosphatidylserines; Thrombin; Thromboplastin; Tumor Cells, Cultured | 2001 |
Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies.
Topics: Blotting, Northern; Blotting, Western; Camptothecin; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cisplatin; Cyclin A; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Fluorouracil; Folic Acid Antagonists; Gene Expression Regulation, Enzymologic; Humans; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Protein Serine-Threonine Kinases; Quinazolines; RNA, Messenger; Tetracycline; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 2001 |
O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Drug Evaluation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glutathione; Humans; Irinotecan; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Plasmids; RNA, Messenger; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Future treatment options with capecitabine in solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Forecasting; Humans; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Taxoids | 2002 |
Enhanced phagemid particle gene transfer in camptothecin-treated carcinoma cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteriophages; Camptothecin; Carcinoma; Combined Modality Therapy; Enzyme Inhibitors; Epidermal Growth Factor; Genetic Therapy; Genetic Vectors; Humans; Male; Mice; Mice, Nude; Neoplasms; Plasmids; Transduction, Genetic; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
[Globalization of anti-cancer therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms | 2002 |
Combined chemotherapy trials require combined pharmacogenetic approaches.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasms; Oxidoreductases Acting on CH-NH Group Donors; Polymorphism, Genetic; Quinazolines; Thiophenes | 2002 |
Third Wave, Daiichi to develop personalized cancer treatment.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Polymorphism, Single Nucleotide | 2002 |
Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Carcinoma; Caspases; Cell Cycle; Cells, Cultured; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Synergism; Humans; Irinotecan; Kinetics; Membrane Glycoproteins; Neoplasms; Receptors, Tumor Necrosis Factor; RNA, Neoplasm; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients.
Topics: Adult; Aged; Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasms; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length | 2002 |
Overview of early and investigational chemotherapeutic agents in solid tumors.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Aziridines; Azo Compounds; Camptothecin; Cycloleucine; Etoposide; Floxuridine; Humans; Neoplasms; Nitrogen Mustard Compounds; Picolinic Acids; Platinum; Porfiromycin; Streptonigrin; Teniposide; Thiotepa; Tubercidin | 1976 |
Isolation and chemical characterization of antitumor agents from plants.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carubicin; Chemical Fractionation; Chemical Phenomena; Chemistry; Chromatography; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Countercurrent Distribution; Humans; Leukemia L1210; Leukemia, Experimental; Longevity; Mice; Neoplasms; Plant Extracts; Spectrum Analysis | 1976 |
Chemotherapy: topoisomerases as targets.
Topics: Camptothecin; Cell Line; Cell Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Forecasting; Humans; Neoplasms | 1990 |
Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin.
Topics: Animals; Camptothecin; Drug Administration Schedule; Drug Screening Assays, Antitumor; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Tumor Cells, Cultured | 1991 |
Ribosomes and cancer.
Topics: Aflatoxins; Animals; Camptothecin; Cell Transformation, Neoplastic; Cells, Cultured; Dactinomycin; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Humans; Molecular Conformation; Neoplasms; Plant Proteins; Protein Biosynthesis; Proteins; Ribosomes; Ricin; RNA, Ribosomal; Transcription, Genetic; Vinca Alkaloids | 1974 |
Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity.
Topics: Camptothecin; Chromatography, Gel; Chromatography, Thin Layer; Filtration; Humans; Neoplasms; Protein Binding; Serum Albumin; Spectrometry, Fluorescence; Time Factors; Uremia | 1972 |
Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.
Topics: Camptothecin; Cystitis; Humans; Leukocyte Count; Leukopenia; Neoplasms; Thrombocytopenia | 1972 |